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I N T R O D U C T I O N
THE WAR ON CANCER
Cancer is the leading cause of death in the Netherlands (1), and amongst the leading 
causes of death in the world (2). Now 45 years ago, the importance of performing cancer 
research in a collective and collaborative way to beat cancer was first recognized. In 
1971, President Nixon of the United States of America signed the National Cancer Act, 
allocating more funds towards cancer research, which was dubbed as the start of “the war 
on cancer”. Since then numerous success stories in the treatment of cancer have been 
described, for example in the cure of acute lymphocytic leukemia and other childhood 
cancers, Hodgkin’s lymphoma, and testicular cancer. Meaningful improvements have 
also been achieved by the early detection and adjuvant therapy for a variety of cancers. 
These success stories have led to significant improvements in 5-year overall survival for 
patients with cancer (3, 4). However, despite all these improvements and an enormous 
progress of our understanding of cancer, cancer remains to be a major cause of death.
LESSONS LEARNED
Our increased understanding of cancer has led to important observations that explain 
why it is so difficult to adequately treat cancer. First of all, it is important to realize that 
cancer mortality is generally not caused by the primary tumor, but by the formation of 
distant metastases. Current treatment of patients with metastatic cancer is generally 
driven by the characteristics of the primary tumor. However, an important lesson was that 
tumors are plastic: their characteristics change over time and under treatment pressure. 
This is for example reflected by comparing clinically actionable targets in breast cancer 
such as ER and HER2 between the primary tumor and the metastases. These targets for 
treatment differ between the primary tumor and metastases in 10-20% of the patients, 
leading to a change in patient management (5, 6). Another example of tumor plasticity 
is the fact that tumor cells acquire resistance against anti-tumor agents, for example 
due to resistance mutations. This was for example demonstrated in patients with lung 
cancer progressing on first-line tyrosine kinase inhibitors, in whom a mutation in the 
EGFR gene (T790M mutation) contributes to resistance to these therapies (7). These 
observations underlined that it is of utmost importance to evaluate the tumor cells, 
not only at diagnosis or before treatment, but also during treatment and at treatment 
progression. 
Another important lesson we learned was that tumors are highly heterogeneous, 
even down to the single cell level (8-13). This implies that targeting cancer cells with 
a specific “magic bullet” (targeted agents, such as trastuzumab and vemurafinib) is 
unlikely to eradicate all the tumor cells. Indeed, this is what is generally observed in 
clinical practice: in the best case scenarios, an initial response is observed in a large 
portion of the patients treated with targeted agent, however, resistance to therapy will 
eventually almost always arise. An example is the use of vemurafinib in patients with 
BRAF V600E-mutated metastatic melanoma, for which in the first study a spectacular 
objective response rate (ORR) of 48% was seen (14), compared to 5% ORR in patients 
treated with traditional chemotherapy. However, after 9 months of treatment virtually all 
patients in this study had progressed on vemurafinib.    
13
All these data stress that there is an urgent need for markers to improve diagnosis, 
prognostication, and prediction for patients with cancer, and these markers should 
preferentially be available sequentially under therapy. An obvious way to gain insight 
into the problem of plasticity of tumor cells in patients with metastatic cancer could 
be to obtain biopsies from metastatic tumor tissue. However, not only is this often a 
cumbersome and patient-unfriendly procedure and impossible in some patients due 
to inaccessible metastatic lesions, it is also a procedure that cannot realistically be 
performed sequentially during therapy. In addition, intra-tumor and inter-metastatic 
heterogeneity may be missed by performing single biopsies, as elegantly demonstrated 
by recent next-generation sequencing efforts (8, 13, 15-17). If tumor heterogeneity and 
plasticity could be assessed in a minimally invasive way, during the course of treatment, 
this could prove to be a huge step forward in oncology. The use of liquid biopsies 
sampled from the blood of patients with cancer is therefore a promising way to evaluate 
tumor characteristics and response to therapy repeatedly during therapy.     
L I Q U I D  B I O P S I E S  O F  C A N C E R
Several types of liquid biopsies of solid tumors have been described in the past 
decades. All of them have distinct characteristics, and they may be used alone or in 
combination. The purpose of these liquid biopsies generally are to sample the tumor 
cells themselves, however also endothelial cells that surround the tumor cells can be 
shed into the circulation and sampled. This thesis will focus on three important kinds of 
liquid biopsies: circulating tumor cells (CTCs), circulating endothelial cells (CECs) and 
circulating tumor DNA (ctDNA). While these liquid biopsies can all be measured in the 
blood, CTCs and ctDNA may be measured in other bodily fluids as well, such as pleural 
effusions, ascites or cerebrospinal fluid. Of note is that there are other liquid biopsies 
that are used in oncology, for example circulating exosomes, tumor-educated blood 
platelets and serum-derived biomarkers (such as CEA, CA15.3, etcetera), but these 
biomarkers will be not be discussed in this thesis. The liquid biopsies discussed in this 
thesis are presented in Figure 1, and explained in more depth below. 
Circulating tumor cell (CTC)
intact cell from tumor tissue
Circulating endothelial cell (CEC)
(near-)apoptotic but intact vascular cell
Circulating tumor DNA (ctDNA)
cell-free DNA mainly from apoptotic or necrotic tumor cells
Blood stream
Vascular endothelial cells
Tumor tissue 
(primary tumor or metastasis)
FIGURE 1. LIQUID BIOPSIES DISCUSSED IN THIS THESIS
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CIRCULATING TUMOR CELLS (CTCS)
CTCs are tumor cells derived from solid tumors detectable in the peripheral blood of 
cancer patients. It is thought that in patients with metastatic disease, CTCs represent 
characteristics of the metastases (18, 19). While a plethora of assays are currently 
commercially available to isolate CTCs (as reviewed by my colleagues (20, 21)), the 
CellSearch system (Janssen Diagnostics, Raritan, NJ, USA) is the only system that is 
approved by the Food and Drug Administration (FDA) for diagnostic purposes in breast 
cancer, prostate cancer and colorectal cancer. This system relies on the enrichment 
of EpCAM-positive tumor cells by using magnetic beads coupled to an anti-EpCAM 
antibody. Using the CellSearch system, the enumeration of CTCs before the start 
of treatment has robust prognostic value as has been demonstrated for numerous 
tumor types in the non-metastatic and the metastatic setting (22-25). Also changes 
during treatment, especially in the metastatic setting, have strong prognostic value 
(22-25). However, prognostic value and clinical validity of CTC enumeration do not 
necessarily translate into clinical utility. This is also reflected by the fact that the use 
of CTC enumeration is currently not advised in any of the ASCO or ESMO guidelines 
for any clinical decision in any tumor type. However, counting of CTCs only touches 
upon the surface of the possibilities with CTCs, as CTCs are bona fide tumor cells 
and thus express proteins and contain DNA and RNA. Therefore, CTCs have great 
promise to be used as a tool to characterize (metastatic) tumor cells multidimensionally 
during the course of treatment. While this is an attractive premise, characterization of 
CTCs is however hampered by the rarity of CTCs (median of 5 cells in patients with 
metastatic breast cancer) and the lack of purity of CTCs caused by the high background 
of leukocytes after using CellSearch-based enrichment (ratio of CTCs to leukocytes 
approximately 1:1000 (26)). Our group has previously demonstrated that regardless of 
these limitations, characterization of CTCs is feasible at the RNA (26-29) and DNA level 
(30). While CTC characterization is considered to be of huge interest to characterize 
tumor cells sequentially under therapy, its clinical relevance as a prognostic, predictive 
or response marker is currently still limited to the androgen receptor (AR) splice variant 
V7 (31-34).
CIRCULATING TUMOR DNA (CTDNA)
Tumor cells undergoing apoptosis release DNA fragments, while viable tumor cells may 
actively secrete DNA fragments. This DNA can then be detected in the blood stream as 
cell-free DNA (cfDNA). Cell-free DNA circulates in the blood stream and can be acquired 
by isolating DNA from plasma or serum. Subsequently, downstream analyses are 
needed to detect ctDNA. Nowadays, next generation sequencing(NGS)-based methods 
and digital PCR(dPCR)-based methods are most frequently used to detect ctDNA in a 
background of wildtype DNA. While CTCs have the great advantage of multidimensional 
characterization (protein, DNA, RNA level), the advantage of ctDNA over CTCs is the 
ease of collection and processing of blood for analysis, in addition to better options for 
high-throughput analysis (35). Also ctDNA seems to be more frequently present than 
CTCs in blood (36). This is also reflected by results obtained with techniques based 
on dPCR; these techniques are able to detect mutant ctDNA in about 47-69% of the 
patients with stage I-III cancers, while mutant ctDNA can be detected in about 82% 
of the patients with metastatic stage IV cancer (37). The capture frequency for CTCs 
across all tumor types is typically much lower. While the first years of ctDNA research 
have yielded highly promising results, standardization of pre-analytical conditions, the 
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choice of the optimal test to answer specific research questions, the exact diagnostic, 
prognostic or predictive value and optimal clinical utility of ctDNA are important matters 
that have not been crystallized as of yet.
CIRCULATING ENDOTHELIAL CELLS (CECS)
CECs are cells that are present in peripheral blood and are thought to originate from 
the vessel wall, reflecting the extent of angiogenesis or endothelial damage. CEC 
levels are increased in patients with different types of malignancies as opposed to 
healthy donors (38) and are thought to reflect damage coming from normal as well as 
tumor vasculature (38, 39). As CECs only possess endothelial characteristics (and not 
tumor characteristics, even if they originate from tumor vasculature), they cannot be 
used to assess tumor plasticity or heterogeneity. However, they may be an interesting 
surrogate marker for tumor response to therapy, especially in patients with tumors that 
are highly vascularized, or in patients receiving drugs with anti-angiogenic activities 
(e.g. bevacizumab, sunitinib, everolimus). In addition, they may be a compelling marker 
for vascular damage in general, also outside of the field of oncology, for example in 
cardiology or transplantation medicine. Because CECs in patients with cancer are 
derived from two compartments (the normal endothelium and tumor endothelium 
compartment), interpretation of CEC enumeration before treatment and changes during 
treatment is hampered by a lack of information on how these compartments change 
relative to each other. Recently, we identified a CEC marker (CD276) that is able to 
detect CECs that are shed from the tumor vasculature in a number of human tumors 
(40). The use of this marker has great potential to increase the specificity of the CEC 
test to identify true tumor-associated CECs. However, clinical data on the true clinical 
relevance of CD276-positive CECs is currently lacking.
CHALLENGES WITH LIQUID BIOPSIES
For liquid biopsies to be truly used to personalize treatment of cancer patients, what 
is needed are technically sound assays to measure these biomarkers with acceptable 
sensitivity and specificity, and these assays should at least have the potential to improve 
clinical decision-making. The three liquid biopsies as discussed in this thesis are all in 
different stages of development and implementation, meaning that various research 
questions emerge in this thesis. CTC enumeration is as of now the most developed 
biomarker: enumeration of CTCs has high reproducibility (41), high inter-reader agreement 
(42) and clear prognostic value and clinical validity (25). However, the exact clinical utility 
of enumerating CTCs remains to be established. CTC characterization has been shown 
to be feasible, but its clinical relevance is still limited to AR-V7 (31-34). For CECs, reports 
on their prognostic value have been inconsistent, probably due to different assays used 
to detect CECs (38) and presence of CECs from non-tumorous vasculature. Data on 
tumor-specific CEC markers have not been published as of yet. Therefore, prospective 
trials evaluating CECs and tumor-associated CECs using a robust assay are of utmost 
importance to further evaluate the role of CECs as a prognostic marker in oncology. 
Circulating tumor DNA is the marker that has most recently been widely introduced, 
yielding exiting data but still a lot of unanswered questions are present regarding the 
validity of ctDNA tests, their optimal use, clinical relevance and clinical utility.             
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F O C U S  O F  T H I S  T H E S I S
This thesis focusses on several technical and clinical aspects of liquid biopsies, all with 
the ultimate aim to allow personalized medicine based on these liquid biopsies that are 
able to markedly improve the clinical outcome of cancer patients.
In Chapter 2, current evidence on the clinical validity of CTC enumeration using 
CellSearch in primary and metastatic breast cancer is reviewed, and recommendations 
for the use of CTCs are provided. 
These CTCs enumerated by the CellSearch system can be directly analyzed for clinically 
relevant markers such as HER2. Metastatic breast cancer patients who have a HER2-
positive primary tumor, have poorer outcome on endocrine therapy. In Chapter 3, the 
prognostic relevance of HER2-positive CTCs in patients with an HER2-negative primary 
tumor is investigated, with a special interest in those patients receiving endocrine 
therapy. In addition, CTC characterization on the mRNA level is performed to assess the 
ER status of the CTCs and to explore its clinical relevance. 
Beyond classical predictive factors in breast cancer such as HER2 and ER, recently the 
occurrence of resistance mutations in the gene coding for the estrogen receptor, ESR1, 
has sparked a lot of interest. Chapter 4 reviews data on ESR1 mutations in metastatic 
breast cancer patients, with a particular interest in the techniques to detect them, their 
functional role and clinical relevance. 
Chapter 5 further examines the role of ESR1 mutations in patients with metastatic breast 
cancer. The concept of CTC characterization is taken a step further, with molecular 
characterization of CTCs not only at the mRNA level, but also at the DNA level. ESR1 
mutations are assessed in CTCs and cfDNA in a cohort of patients starting first-line 
endocrine therapy and in a cohort of patients progressing on endocrine therapy. Also 
ESR1 splice variants are assessed in both cohorts. 
ESR1 mutations can be assessed in cfDNA. But before large prospective multicenter 
studies can be initiated on the predictive value of ESR1 mutations using cfDNA, it is of 
utmost importance to determine the right pre-analytical conditions under which cfDNA 
is collected. In Chapter 6, different time intervals to plasma collection and different 
blood tubes are tested to optimize and standardize blood collection for cfDNA analysis. 
When cfDNA is optimally collected, assessing mutations in cfDNA can provide information 
on primary and acquired resistance to therapies. However, several techniques to assess 
these mutations in ctDNA have been described, all with their own specific pros and cons. 
In Chapter 7, three targeted techniques to assess mutations in ctDNA are described 
and compared in colorectal cancer patients undergoing a resection of liver metastases. 
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Malignant pleural mesothelioma is a highly treatment-resistant malignancy, leading to a 
very poor prognosis. Its diagnosis is challenging, and prognostic markers are lacking. 
In Chapter 8, efforts are undertaken to improve the diagnosis of mesothelioma by 
using an alternative (MCAM-based) approach to enumerate CTCs. In addition, MCAM-
positive CTCs and CECs are explored as novel biomarkers to improve prognostication 
of patients with mesothelioma. 
In Chapter 9, another treatment-resistant malignancy, malignant glioblastoma, is 
investigated. As glioblastomas are highly vascularized, and anti-angiogenic treatments 
are given in patients with glioblastoma, the enumeration of CECs as a prognostic or 
response marker is evaluated in this chapter.
In Chapter 10, an application of CECs outside of the field of oncology is explored. 
As vascular damage may be related to complications after allogeneic stem cell 
transplantation, the use of CECs as a marker for these complications was evaluated. 
Finally, Chapter 11 discusses on current state and future of liquid biopsies and provides 
a summary of the thesis. 
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A B S T R A C T
Circulating tumor cells (CTCs) are cancer cells that are present in the blood of patients 
with solid cancers and are shed from existing tumor lesions into the blood stream. 
The enumeration of CTCs has long been considered to hold great promise in guiding 
treatment decision-making in breast cancer patients. However, guidelines on how to use 
CTC enumeration in clinical decision-making in primary breast cancer and metastatic 
breast cancer are lacking. Here, we set out to review the most relevant literature to date, 
to ultimately come to general recommendations regarding the use of CTC enumeration 
in primary breast cancer and metastatic breast cancer. 
02
26
I N T R O D U C T I O N
Breast cancer (BC) is the most commonly diagnosed malignancy in women and the 
leading cause of cancer deaths in the world (1). Evidently, almost all BC-related deaths 
are caused by distant metastases and not by the primary breast tumor itself. Treatment 
strategies in primary BC are focused on preventing recurrence and preventing the 
development of distant metastatic disease. However, once BC has metastasized the 
treatment aims are to relieve or delay cancer related symptoms, thereby improving overall 
survival (OS) and quality of life. Multiple clinical and pathological features currently guide 
treatment decision making in BC. But disappointingly, the lack of reliable prognostic 
and predictive factors and imperfect tools to evaluate treatment success both in the 
primary and metastatic setting still results in serious overtreatment of patients. Novel 
strategies for determining prognosis and adequately monitoring treatment success in 
both primary and metastatic BC are therefore urgently needed.  
Circulating tumor cells (CTCs) are tumor cells that circulate in the peripheral blood of 
patients with solid malignancies and are shed from an existing primary tumor or from 
metastatic lesions into the blood stream. Since its first description, CTC enumeration was 
envisioned to establish prognosis, to evaluate treatment success and to guide treatment 
decision making in BC. However, although CTC enumeration is increasingly used by 
some medical oncologists, clear guidelines as to the optimal use of CTC enumeration 
are still lacking. Here, we will review the most relevant published literature to date and 
discuss the current possibilities for clinicians to use CTC enumeration into daily clinical 
practice, at different stages of BC treatment. Additionally, we make  recommendations 
regarding the use of CTC enumeration in primary and metastatic BC. Since most of the 
non-interventional studies have used CellSearch for CTC enumeration, the only FDA 
approved CTC enumeration method to be used for clinical purposes, only publications 
in which CellSearch enumeration was employed will be discussed.
CELLSEARCH ASSAY FOR CTC ENUMERATION
The CellSearch method (Figure 1) relies on the automatized immunomagnetic 
enrichment of epithelial tumor cells expressing EpCAM by adding magnetic ferrofluids 
coupled to anti-EpCAM antibodies to 7.5 mL of whole blood. The enriched sample 
is subsequently immunocytochemically stained for nucleated (DAPI positive) cells 
expressing cytokeratin 8/18/19, while contaminating leukocytes are excluded by using 
the pan-leukocyte marker CD45. Finally, a trained user identifies and counts all cells 
meeting the criteria for CTCs according to consensus guidelines (2) using an automatized 
fluorescence microscope. 
The CellSearch method has been demonstrated to be highly specific and its performance 
is still robust at CTC counts as low as 1 CTC/7.5 mL of blood when made sure there is 
minimal inter-reader variability (3, 4). Consequently, minimal inter-(2) and intra-reader (5) 
variability were demonstrated using this system. If blood is collected in a CellSave tube 
which contains a mild fixative, CTCs are stabilized for up to 96 hours following blood 
draw and can be shipped by room temperature, which renders it feasible to ship a blood 
sample to remote locations. 
In contrast to these clear advantages, also several disadvantages are associated with 
the use of CellSearch. Since the system relies on EpCAM-enrichment, tumor cells not 
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expressing EpCAM, in particular breast tumor cells exhibiting stem cell features (6), go 
uncaptured by using CellSearch. In addition, tumor cells may undergo epithelial-to-
mesenchymal transition, which might lead to a decrease or loss of EpCAM expression 
(7). Consequently, these “mesenchymal CTCs” are probably also not captured by 
CellSearch based isolation of CTCs. CTCs lacking cytokeratin 8/18/19 expression may 
also go uncaptured when using the CellSearch system (8).         
C T C S  I N  P R I M A R Y  B R E A S T  C A N C E R
Additionally to local treatment for the primary tumor, management of an individual 
primary BC patient is determined by the risk of distant metastases. Patients with 
primary BC who harbor a high risk for developing distant metastases are treated with 
neo-adjuvant or adjuvant systemic treatment. The risk estimate for developing distant 
metastases is currently based on multiple classical clinicopathological factors including 
patient characteristics such as younger age; as well as primary tumor characteristics 
such as large tumor size, high Bloom-Richardson differentiation grade and the 
presence of lymph node metastases. Additionally, predictive factors determined on 
the primary tumor like the presence of estrogen receptor (ER) expression and HER2 
amplification are of key importance. In those patients with BC expressing the ER and 
HER2 receptor adjuvant treatment  with endocrine treatment and anti-HER2 treatment, 
respectively, have been demonstrated to decrease BC recurrence rates substantially (9-
11). However, following adjuvant therapies the absolute improvement in 15-year breast 
cancer mortality is relatively modest at 3-10% (9). These findings illustrate that many 
patients have to be treated to benefit a few and that many are unnecessarily exposed 
to significant toxicity impairing quality of life both in the short and long-term. These 
observations clearly stress the high need for robust prognostic factors in primary BC to 
prevent overtreatment.
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Over the last years, commercially available molecular tests on primary breast tumor 
material determining the prognosis  have become available and have been implemented 
in daily clinical practice to advice about the usefulness of adjuvant chemotherapy 
treatment (12, 13). CTC enumeration also has the potential to guide treatment decision 
making in primary BC. In primary BC, potential applications for CTC enumeration 
may include the identification of patients with a low probability of developing distant 
metastases in whom adjuvant systemic therapy may be omitted or patients with high 
probability of developing distant metastases in whom peri-operative systemic therapy 
may be intensified. In addition, CTC count changes could be used  to evaluate treatment 
response, thereby possibly identifying non-responding patients at an early stage who 
could switch to non-cross-resistant treatment options.
 
NEOADJUVANT TREATMENT
Next to reducing BC recurrences, neoadjuvant chemotherapy is considered in patients 
who are diagnosed with primary BC in whom the goal is to shrink the tumor, enabling 
breast conserving surgery instead of a mastectomy or enabling a mastectomy in case 
of a large tumor (14). In addition, in patients in whom the indication to receive adjuvant 
chemotherapy is already present before surgery, neoadjuvant chemotherapy can be 
considered and is increasingly becoming the standard of care. 
The clinical validity of CTC enumeration in neoadjuvant chemotherapy for BC was 
assessed by three studies. The REMAGUS02 trial (15) investigated 118 patients in whom 
CTCs were enumerated before and after neoadjuvant chemotherapy. At least one CTC 
was detected in 23% of all patients before treatment, and in 17% of all patients after 
treatment. While the occurrence of CTCs before and/or after chemotherapy was not 
associated with pathological complete response (pCR), tumor size, nodal status and 
tumor grade, patients without CTCs before and after treatment had a relative higher 
chance of 4.15 (95% CI 1.29-13.3, p=0.017) to maintain free from distant metastases in 
multivariate analysis, compared to patients in whom CTCs were present before and/or 
after treatment. Recently, a 70 month follow-up of the REMAGUS02 trial was published 
(16) demonstrating that the presence of CTCs before treatment was only borderline 
associated with OS (HR 3.0, 95% CI 1.0-9.5, p=0.05). Since the observed hazard ratios 
in this study decreased over time, it was suggested that the prognostic impact of CTC 
before treatment in the neoadjuvant setting seems to be limited to the first 3-4 years 
after treatment, limiting its potential clinical utility. It should however be noted that the 
REMAGUS02 analysis should be interpreted as purely exploratory since only 95 patients 
were analyzed and the occurrence of relapses and deaths were thus relatively rare (17% 
and 12%, respectively). After 70 months of follow-up CTC counts after neoadjuvant 
treatment were not associated with distant metastases-free survival or OS.
The GeparQuattro trial (17) comprised 213 patients with HER2-positive primary BC 
undergoing neoadjuvant chemotherapy. At least one CTC was present in 22% patients 
before treatment and in 11% of patients after treatment. In accordance with the 
REMAGUS02 trial was the absence of a correlation between CTC counts and pCR. 
However, in contrast to the REMAGUS02 study, the GeparQuattro trial did not observe 
any correlations between CTC counts and early relapse or OS. An explanation for the 
lack of correlation between CTC counts and clinical outcome could be that only patients 
with a HER2-positive tumor were included in this study. CTC enumeration might have 
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less prognostic value in patients with HER2-positive disease receiving trastuzumab 
(18-20). The HER2-positive subtype is however relatively rare compared to other BC 
subtypes and therefore all studies evaluating the prognostic value of HER2-positive 
disease suffer from subgroup analyses on small numbers. 
The BEVERLY-2 study evaluated 52 patients with HER2-positive inflammatory breast 
cancer starting a bevacizumab-based neoadjuvant regimen (21). At baseline, 35% of 
patients had at least one detectable CTC , while at least one CTC was present in 13% 
of patients during treatment. As in the other neoadjuvant studies, CTC count was not 
correlated with pCR. A recent abstract including three-year follow-up data however 
revealed that the presence of CTCs at baseline was an independent prognostic factor 
for poor disease-free survival (DFS) (22) (p-value or HR not reported).    
     
In conclusion, current literature in the neoadjuvant setting of BC regarding the prognostic 
power of CTC enumeration before or after neoadjuvant chemotherapy is not convincing. 
Although the REMAGUS02 study suggested that the presence of CTC might be a 
prognostic factor for a worse OS and unpublished data of the BEVERLY-2 suggested the 
same for worse DFS in patients with HER2-positive inflammatory breast cancer, large, 
appropriately powered studies with a longer follow-up are needed to further explore 
whether such an association is indeed present; and if so, whether it holds clinical value 
and should be implemented in treatment decision-making. Also it may be worthwhile 
for such studies to explore the use of other markers than EpCAM, for example MCAM, 
which has been reported to improve CTC capture rate in the neoadjuvant setting when 
used together with EpCAM (23). In conclusion, at this point there does not seem to be a 
role for CTC enumeration in the neoadjuvant setting. 
ADJUVANT TREATMENT
Multiple, relatively small studies investigated the occurrence and prognostic power of 
CTCs before or after surgery for primary BC, all suggesting that the occurrence of CTCs 
before surgery is associated with early relapse or decreased OS (24-28). By far the 
largest study is the SUCCESS study that accrued 2026 patients and which assessed 
the prognostic value of CTC before and after adjuvant treatment (29). In this study, 
since CTCs were expected to be present at a low frequency, 30 mL instead of 7.5 
mL of peripheral blood was drawn and following Ficoll cell separation processed on 
CellSearch. After the resection of the primary tumor and before the start of adjuvant 
chemotherapy, CTCs were detected in 435 of 2026 patients (21.5%) in 30 mL of blood. 
In the SUCCESS trial, the occurrence of at least one CTC before starting adjuvant 
chemotherapy was associated with poor DFS (HR 2.11, 95% CI 1.49-2.99) and impaired 
OS (HR 2.18, 95% CI 1.32-3.59). Patients who had lymph node metastases were more 
frequently CTC positive. Looking at subgroups, the presence of CTCs before adjuvant 
treatment was not prognostic for DFS in node-negative patients, a finding which was 
in contrast to node-positive patients, in whom the occurrence of CTCs was associated 
with poor prognosis. After receiving adjuvant chemotherapy, CTCs were detected in 
330 of 1493 patients (22.1%). Patients in whom no CTCs were detected before and after 
chemotherapy had a good 3-year DFS of 94.2% and 3-year OS of 97.6%. The persistence 
of CTCs after chemotherapy was associated with shorter 3-year DFS (85.9%), however, 
only a trend towards reduced OS (HR 1.16, 95% CI 0.99-1.37) was observed when 
comparing this group to other subgroups in which CTC were not present before and/
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or after chemotherapy. Of note was that in 17% of patients in this study CTCs switched 
from absent prior to chemotherapy to present after chemotherapy. In these patients a 
3-year DFS rate of 94.9% was demonstrated which was similar to patients who were 
stable negative, which suggests that a switch towards the presence of CTCs after 
chemotherapy was not associated with worse outcome. Disappointingly, patients in 
whom CTCs switched from present before chemotherapy to absent after chemotherapy 
had a worse 3-year DFS (91.1%) than the group who switched from absent before to 
present after chemotherapy (3-year DFS 94.9%).
The SUCCESS study certainly provided valuable data regarding the prognostic value 
of CTCs in the adjuvant setting. However, at this point we can only speculate how this 
prognostic value may be relevant for the clinic. Since the presence of ≥1  CTC before 
and after adjuvant chemotherapy was associated with poor DFS and a trend towards 
poor OS, one might consider studies to explore additional treatments in this subset 
of patients. Since this study had a relatively short follow-up of 3 years it will certainly 
be interesting to see some more mature data regarding these patients with seemingly 
resistant tumor cells. 
Disappointing was that the switch of CTCs from absent before treatment and present 
after treatment and vice versa did not seem to render particular prognostic effects in 
this study, raising doubts on the value of CTC enumeration as a marker for response in 
this setting.  Importantly, the use of 30 mL of blood and an additional Ficoll separation 
to allow CellSearch enumeration may have led to reduced reproducibility, which might 
have been caused by variation in CTC recovery following Ficoll separation. While the 
use of 30 mL of blood probably had an statistical background, meaning that the use of 
more blood would simply improve the chances of catching a CTC (30), we are not aware 
of any studies evaluating the occurrence of CTCs in BC in 7.5 mL of blood versus 30 mL 
of blood. Of note is that the CTC capture rate in the SUCCESS study was comparable 
with studies in the neoadjuvant setting and peri-operative setting using only 7.5 mL of 
blood for CTC enumeration, rendering CTC capture rates of 22 to 24% (15, 17, 26). Since 
conclusions are drawn based on the occurrence of only one CTC in an individual’s 
blood sample, matters regarding reproducibility should be evaluated before any firm 
conclusions about the true clinical value and place of CTC enumeration in the adjuvant 
setting can be established. In addition, if true clinical prognostic value exists, it still has 
to be investigated how CTC enumeration compares to and/or adds to other already 
available methods  such as Mammaprint (31) or Oncotype DX (32) in stratifying primary 
BC patients into good and poor prognosis groups.
PROGNOSTIC VALUE OF CTCS IN METASTATIC BREAST CANCER
In 2004, Cristofanilli and colleagues published their landmark paper on CTC enumeration 
in metastatic breast cancer (MBC) patients starting a new line of therapy for MBC (33). 
In 61% of all patients, at least 2 CTCs were observed. Thresholds between 1 and 10000 
CTCs prior to a new line of treatment for MBC were systematically correlated with 
progression free survival in a training set of 102 patients, to find the optimal cut-off to 
identify patients with poor prognosis. Following this correlation, a cut-off of ≥5 CTCs for 
poor prognosis was established, which was subsequently prospectively validated in a 
validation set of 75 patients. In patients who had ≥5 CTCs before starting a new line of 
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therapy, progression occurred after a median of 2.7 months, while this was 7 months in 
patients who had <5 CTS. Patients who had ≥5 CTCs also had a shorter median OS than 
patients who had <5 CTCs (10.1 months versus >18 months, respectively).
Ever since this study has demonstrated that a subset of patients with poor prognosis 
could be identified using CTC enumeration, the robustness and clinical validity of CTC 
enumeration in MBC have been important subjects of investigation. Especially the 
monitoring of CTC changes during treatment was considered to have great promise 
as an early response marker. Other clinical consequences of stratifying MBC patients 
according to CTC counts that can be thought of are treating patients with a good 
prognosis with less intensive treatment regimens (for example endocrine therapy) than 
patients with a poor prognosis.
Ten years after the landmark paper of Cristofanilli and colleagues, the first pooled 
analysis of individual patient data evaluating the clinical validity of CTC enumeration 
at baseline and during treatment was recently performed by Bidard et al. (34). This 
analysis involved patients with MBC starting a new line of therapy, for whom at least 
a CTC baseline value and follow-up regarding progression-free survival (PFS) and 
OS was available. 17 centers in Europe provided patient data from 1944 patients with 
a median follow-up of 23 months. This study confirmed the findings of the study by 
Cristofanilli and colleagues. Patients who had ≥5 CTCs at baseline had a significantly 
shorter median PFS (6.5 vs 11.4 months, respectively) and OS (15.5 vs 37.1 months, 
respectively). In addition to baseline CTC counts, also changes in CTC counts after 
3-5 weeks of treatment were evaluated as a potential marker for treatment response. 
Patients with <5 CTCs at baseline and in whom CTCs were stable (i.e., <5 CTCs) 
during treatment demonstrated the best prognosis with a median OS of 41.5 months. 
Importantly, patients who had ≥5 CTCs prior to treatment while CTCs decreased <5 
during treatment, demonstrated much better OS than the patients in whom CTCs did 
not decrease <5 during treatment (13.1 months vs 27.0 months, respectively). Notably, 
only in 2.5% of patients CTCs increased from <5 to ≥5 CTCs during treatment. This last 
observation suggests that is not worthwhile to investigate CTC changes in patients with 
<5 CTCs at baseline. 
In conclusion, level A clinical evidence for the clinical validity of CTC enumeration as a 
prognostic marker in each treatment line of MBC was presented by this large analysis. 
CTCS VERSUS SERUM BIOMARKERS
Besides the focus on the prognostic impact of CTCs, a lot of work has been performed 
to further evaluate and establish the role of CTC enumeration as opposed to other 
frequently used methods to monitor tumor burden and treatment efficiency, like 
radiographic imaging studies and serum biomarkers. Serum biomarkers are frequently 
used by medical oncologists to monitor tumor burden and treatment success in MBC 
patients. The 2007 ASCO guideline recommendations (35) and 2013 ESO guidelines 
(36) advocate to only use the serum biomarkers cancer antigen 15-3 (CA 15-3), 
carcinoembryonic antigen (CEA) and cancer antigen 27.29 (CA 27.29) in conjunction with 
imaging and patient characteristics to contribute to clinical decision making regarding 
MBC therapy. The use of these biomarkers as the sole parameter to alter therapy for 
MBC is only recommended in case metastatic disease is not adequately measurable, 
for example in those patients who have bone metastases only. 
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As a side-study of their large pooled CTC data analysis, Bidard and colleagues (34) 
compared the clinical value of serum biomarkers CEA and CA15-3 with the clinical 
value of CTC enumeration. It was demonstrated that a model with clinicopathological 
parameters harboring primary tumor characteristics, previous treatments, metastases 
free-interval, metastatic sites, age and performance status combined with the CTC 
count before the start of MBC treatment was the strongest model associated with OS. 
A model of these clinicopathological parameters combined with either baseline CEA or 
CA15-3 without CTC count was also associated with OS, albeit less strongly than the 
model including CTC count. Remarkably, the addition of CEA or CA15-3 changes to 
the strongest baseline model did not result in a significantly better prognostic model 
for OS, while the addition of CTC changes during changes to the model did contribute 
to a significantly better prognostic model for OS. These results clearly suggest that 
the use of CTC enumeration prior to and during treatment in MBC is superior to serum 
biomarker assessment. Since serum biomarkers are now the clinical standard to 
evaluate treatment success in patients with poorly evaluable metastatic disease, for 
example those with bone metastasis only, the monitoring of CTC changes instead of 
serum biomarkers should be considered especially in these patients.  
CTCS VERSUS IMAGING
Radiographic response evaluation is one of the cornerstones of measuring treatment 
success in MBC patients. In addition, response evaluation using the RECIST (37) is 
a commonly used endpoint in clinical trials. However, the absence of progression as 
assessed by RECIST does not necessarily translate into clinical benefit for an individual 
patient (38). 
Budd et al. (39) compared CTC enumeration in MBC patients to CT-scan with respect 
to its association with OS. CTCs were enumerated at baseline and following 4 weeks 
of therapy, while radiographic response evaluation was performed every 9 to 12 weeks 
during therapy. CTC counts were always reviewed at a local laboratory and a central 
laboratory and two radiologists centrally reviewed all radiologic responses. There 
was excellent inter-reader agreement for CTC counts for which 0.7% variability was 
demonstrated, while radiologic responses showed 15.2% inter-reader variability. 
Patients with <5 CTCs after four weeks of treatment and who had stable disease or 
partial response on radiographic response evaluation demonstrated the best median 
OS at 26.9 months. Strikingly, patients who had radiographic progressive disease 
(PD) had largely differing prognoses according to their CTC counts at first follow-up: 
for patients who had radiographic PD and <5 CTCs a median OS of 19.9 months was 
demonstrated, while for patients who had radiographic PD and ≥5 CTCs an abysmal 
OS of 6.4 months was reported. A study performed in MBC patients comparing CTCs 
with 18F-fluorodeoxyglucose positron emission tomography combined with computed 
tomography (FDG-PET/CT ) for radiographic response evaluation demonstrated similar 
results as Budd et al. (40). CTC counts at mid-therapy in this study were demonstrated 
to be the strongest factor associated with OS in this study, independent of mid-
therapy FDG-PET/CT response. These studies indicate that CTCs can be used as an 
early endpoint for clinical response evaluation instead of, or in addition to radiographic 
evaluations. In addition, these studies suggest that it might be better to switch treatment 
based on CTC enumeration rather than imaging.
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TREATMENT SWITCH BASED ON CTC CHANGES
While it is appreciated that CTC changes following therapy for MBC have prognostic 
relevance, it was unknown whether a therapy switch in patients in whom the CTC count 
did not decrease <5 during treatment, thus suggesting treatment failure, would be 
beneficial. In 2014 the first interventional trial using CTC enumeration and addressing 
this question was published by Smerage et al. (41). The primary objective of this SWOG 
S0500 study was to demonstrate an OS benefit in CTC non-responding patients switching 
from first-line therapy to second-line therapy for MBC, as opposed to patients in whom 
first-line therapy was maintained and switched at the time of progression as shown by 
conventional means such as CT-scanning. The study was powered to demonstrate a 
70% increase in median OS in the patients in whom therapy was switched early on the 
basis of a lack of CTC response compared to patients in whom therapy was maintained. 
Following an initial screening of 595 patients, 288 MBC patients who had ≥5 CTCs 
starting treatment were evaluated after 3 weeks of first-line chemotherapeutic treatment. 
A total of 123 patients who had persistently ≥5 CTCs were then randomized between 
arm C1, in which first-line therapy was maintained, and arm C2, in which therapy was 
switched. Disappointingly, no benefit in PFS or OS was demonstrated between the 
randomized arms, with median OS being a poor 10.7 months in arm C1 and 12.5 months 
in arm C2. Although this study did not have sufficient power to demonstrate smaller 
differences between the two randomization arms that can be considered clinically 
relevant, while furthermore OS benefits can be diluted in the first line setting due to 
subsequent salvage treatments, the least we can conclude is that a therapy switch in 
these poor prognosis patients does not seem to yield large benefits. At this point, it 
can only be speculated why a therapy switch in these poor prognosis patients did not 
lead to significantly improved outcomes. Perhaps the presence of some sort of general 
chemo-resistance or cross-resistance between commonly used first- and second-line 
therapies for MBC might be present and future research should further unravel the 
potential underlying mechanism.      
C O N C L U S I O N S  A N D  R E C O M M E N D AT I O N S
Ever since the landmark paper by Cristofanilli and colleagues in 2004 (33), CTC 
enumeration by using the CellSearch machine has been considered to have great 
promise as a tool to individualize BC treatment. Over the past ten years, lots of efforts 
have been made to further validate and incorporate the findings of the original seminal 
paper, which has further added to the robustness of CTC enumeration. At this point, 
CTC enumeration in primary BC has not yet proved to hold true clinical value in today’s 
clinical oncology practice. In contrast, the recent milestone paper with a large pooled 
CTC data analysis by Bidard et al. (34) has provided level A evidence for the clinical 
validity of CTC enumeration in MBC. However, it has become clear that the presence of 
clinical validity in this case does not necessarily translate into clinical utility. The SWOG 
S0500 trial demonstrated that a therapy switch in MBC patients who had a persistence 
of ≥5 CTC during treatment did not result in better clinical outcome. Importantly, 
although this study was powered to reveal a 70% increase in median OS, which would 
be huge in a first-line setting, switching treatment early on the basis of CTC changes is 
unlikely to results in a much better outcome. For the group of patients with persistence 
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of ≥5 CTC during treatment, supposedly not responding to traditional first- and second 
line chemotherapeutics, alternative treatment options, preferably guided by other 
individualized treatment approached will have to be explored in the near future. 
The results of the SWOG interventional trial were undeniably disappointing. However, it 
is not all bad news. There is robust evidence to recommend the use of CTC enumeration 
in two clinical situations (Table 1). First, there is a superiority of CTCs over serum 
biomarkers in MBC, clearly suggesting that CTCs should be used more often to monitor 
tumor aggressiveness and response to treatment in patients who have poorly evaluable 
disease such as those with bone metastases only. Second, CTC enumeration is a robust 
way to evaluate treatment response in MBC and early changes in CTC counts, already 
4 to 6 weeks after start of treatment, are strongly correlated with clinically relevant 
endpoints including PFS and OS. Therefore, the use of CTCs as an early response 
marker in early clinical trials such as phase I or II studies can be advocated instead of or 
in addition to radiographic response evaluation.
In addition to already available clinical uses of CTC enumeration, promising interventional 
studies using CTC enumeration to guide treatment decision making using different angles 
than the SWOG0500 trial are ongoing (42). For example, in the STIC CTC METABREAST 
study, therapy-naive first-line hormone-receptor positive MBC patients are randomized 
between a clinicians choice arm and a CTC count-driven choice to guide the choice 
of endocrine therapy versus chemotherapy (43). In the CTC-count driven arm patients 
who have less than 5 CTCs, who have a relatively good prognosis and therefore a more 
indolent tumor, will receive endocrine therapy, while patients who have ≥5 CTC and a 
more aggressive tumor will receive chemotherapy. 
Another interesting trial with a similar design as the SWOG S0500 study is the CirCe01 
trial, which evaluates a therapy switch in the third- and subsequent lines of MBC 
treatments until a CTC response <5 is achieved (44). Since the SWOG S0500 study 
suggested that the metastases in patients in whom CTCs were persistently increased ≥5 
harbored some sort of general chemo-resistance, the repeated use of CTC enumeration 
to evaluate treatment response might be suitable to identify the right drug for the right 
patient. Besides OS, a co-primary endpoint involves a medico-economic study to 
Table 1. Recommendations on the use of CTC CellSearch enumeration in breast cancer
Stage of disease Recommendation
Primary breast cancer 
(neoadjuvant and adjuvant 
setting)
Present data is insufficient to recommend the use of CTC enumeration for risk 
stratification and treatment response evaluation
Metastatic breast cancer - In patients with poorly evaluable disease, for example those with bone 
metastases only, CTC enumeration should be used over serum biomarkers 
when the clinician wishes to evaluate tumor aggressiveness and response to 
treatment
- CTC enumeration may be used as an early response marker in clinical trials to 
allow shorter follow-up
- Present data is insufficient to recommend the use of CTC enumeration to 
perform early switches based on CTC counts
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evaluate whether CTC-based early treatment switches used in this study are able to 
minimize toxicity and costs of inefficient treatments. We believe that this may prove to 
be another important and valid use of CTC enumeration, which might ultimately benefit 
patients and health care in general.
Set aside these current clinical applications and the ongoing promising studies for CTC 
enumeration, one could argue that just enumerating CTCs is merely a one-dimensional 
use of these cells. Fortunately, despite lots of technical challenges, for example the 
presence of leukocyte contamination after CTC isolation (45), other strategies using 
information on CTCs on a molecular level are on the way (Figure 2). For example, 
the molecular characterization of CTCs to identify patients suitable for a certain drug 
treatment is promising and a clinical trial evaluating a gene profile determined on 
CTCs, tentatively able to predict sensitivity for cisplatin chemotherapy, has recently 
started (46). In addition, HER2 immunocytochemical characterization, which can be 
performed directly in the CellSearch machine, identifies patients with a HER2-negative 
primary tumor but HER2-positive CTCs who may benefit from trastuzumab treatment, 
which is now tested in several clinical trials (42). Particularly interesting is that in one 
of the trials investigating this, subsequent to CellSearch isolation also multiplex in situ 
characterization of phosphorylated HER2, ER and mutations in PIK3CA is performed, 
possibly allowing even better identification of subsets of patients responding to 
trastuzumab treatment (47). Finally, CTCs were recently isolated out of peripheral blood 
and cultured ex vivo, allowing drug sensitivity screening on cultured CTCs (48). All these 
relatively new techniques are exciting and we believe that in addition to CTC enumeration, 
great potential is present for CTC molecular characterization to eventually make it to 
the clinic which may then prove to be the next step towards more individualized BC 
treatment. 
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FIGURE 2. POSSIBILITIES FOR MOLECULAR CHARACTERIZATION OF CTCS
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A B S T R A C T
BACKGROUND Preclinical and clinical studies have reported that human epidermal 
growth factor receptor 2 (HER2) overexpression yields resistance to endocrine 
therapies. Here the prevalence and prognostic impact of HER2-positive circulating 
tumor cells (CTCs) was investigated retrospectively in metastatic breast cancer (MBC) 
patients with a HER2-negative primary tumor receiving endocrine therapy. Additionally, 
the prevalence and prognostic significance of HER2-positive CTCs was explored in a 
chemotherapy cohort, as well as the prognostic impact of the ER (estrogen receptor)-
CTC status in both cohorts. 
METHODS  Included were MBC patients with a HER2-negative primary tumor, with 
≥1 detectable CTC, starting a new line of treatment. CTCs were enumerated using the 
CellSearch system, characterized for HER2 with the CellSearch anti-HER2 phenotyping 
reagent, and characterized for ER mRNA expression. Primary endpoint was progression-
free-rate after 6 months (PFR6months) of endocrine treatment in HER2-positive versus 
HER2-negative CTC patients. 
RESULTS  HER2-positive CTCs were present in 29% of all patients. In the endocrine 
cohort (n=72) the PFR6months was 53% for HER2-positive, versus 68% for HER2-
negative CTC patients (P=0.23). In the chemotherapy cohort (n=82) no prognostic 
value of HER2-positive CTCs on PFR6months was observed either. Discordances in ER 
status between the primary tumor and CTCs occurred in 25% of all patients, but had no 
prognostic value in exploratory survival analyses. 
CONCLUSION Discordances regarding HER2 status and ER status between CTCs and 
the primary tumor occurred frequently, but had no prognostic impact in our MBC patient 
cohorts.
03
46
I N T R O D U C T I O N
Treatment of metastatic breast cancer (MBC) is currently mainly driven by the 
characteristics of the primary tumor (PT). However, clinically relevant discordances 
between the PT and the metastases with respect to the estrogen receptor (ER)-status 
and the human epidermal growth factor receptor 2 (HER2)-status occur and influence 
systemic therapy choices and patient management (1). As a result, both European and 
American guidelines (2, 3) recommend to perform biopsies of metastatic lesions to 
assess their receptor status and decide on subsequent systemic therapy. Biopsies of 
metastases are, however, often not performed since this is regarded a cumbersome 
procedure for patients, and it is sometimes even impossible due to inaccessibility of 
the metastases. Another limitation of taking single metastatic biopsies is that intra-
tumor and inter-metastatic heterogeneity is missed. To assess the characteristics of 
metastatic tumor cells in a minimally invasive way, it is attractive to obtain circulating 
tumor cells (CTCs) as a liquid biopsy from peripheral blood. Discrepancies between the 
ER-status and the HER2-status of the PT and the CTCs in MBC have been demonstrated 
by numerous groups (4-18). Some of these groups have also reported on the prognostic 
value of receptor discrepancies between PTs and CTCs, but such reports have been 
scarce (17, 18). Further, previous studies have been performed in rather small and 
heterogeneous groups of patients, making it difficult to draw firm conclusions on the 
exact clinical relevance of ER and HER2 expression in CTCs.
It has been suggested that the HER2-status of the tumor impacts response to endocrine 
therapy. Several pre-clinical studies demonstrated that the introduction of the HER2 
transcript in ER-positive breast cancer cell lines confers endocrine resistance (19-21). 
In addition, a meta-analysis in 2,379 MBC patients demonstrated that patients with 
a HER2-positive PT were less sensitive to endocrine treatment than patients with a 
HER2-negative PT (22). In the current study we investigated whether or not MBC 
patients with a HER2-negative PT, but HER2-positive CTCs, have a worse outcome 
to endocrine treatment compared to patients with HER2-negative CTCs. In addition, 
a separate control group of MBC patients with a HER2-negative PT receiving first-line 
chemotherapy was included in which the prognostic impact of HER2-positive CTCs 
was explored. Also explored in both cohorts were the clinical impact of switches in ER 
expression between the PT and CTCs.
M E T H O D S
PATIENTS AND TREATMENT
MBC patients with a HER2-negative PT and the presence of at least one detectable 
CTC by the CellSearch system (see below), who started a new line of systemic treatment 
for MBC, were eligible for this study. We used data from our CTC studies with patients 
starting first line chemotherapy (study 06-248 (9, 17, 23)) or starting a new line of 
endocrine therapy (study 09-405 (24)) for MBC. All patients had been included between 
February 2008 and March 2015 in six centers the Netherlands and Belgium. From all 
patients 2 x 7.5 mL of blood was drawn for CTC enumeration and CTC characterization. 
The local institutional review board of each participating center approved the study 
protocols (Erasmus MC ID MEC-06-248 & MEC-09-405). All patients provided written 
informed consent.
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ENUMERATION OF CTCS AND HER2 STAINING
Before the start of a new line of systemic treatment for MBC, 7.5 mL of blood was drawn 
in CellSave tubes (Janssen Diagnostics, Raritan, NJ, USA). CTC enumerations were 
performed within 96 hours of the blood draw using the CellSearch system (Janssen 
Diagnostics). CTCs were characterized for HER2 expression directly in the CellSearch 
system using the anti-HER2 antibody as described by the manufacturer (CellSearch 
tumor phenotyping reagent HER2, Janssen Diagnostics). We used the cut-off for 
HER2-positivity in CTCs as described by Riethdorf and colleagues (25), a gallery of 
representative images for scoring is presented in Supplementary Figure 1. When 
at least one CTC immunofluorescently stained 2+ or 3+ for HER2, the patient was 
considered as having HER2-positive CTCs. The results of the enumeration were always 
checked by a second certified reviewer. The results of the HER2 staining were reviewed 
in a HER2 consensus meeting involving 2 investigators (NB & JK). 
CTC ER ASSAY
Simultaneously with the blood draw for CTC enumeration, 7.5 mL of blood was drawn in 
EDTA tubes and enriched for CTCs using the CellSearch profile kit (Janssen Diagnostics). 
Samples were processed within 24 hours and subsequently frozen at -80 °C for RNA 
isolation and analysis. Larger than 200 bp RNA was isolated using the AllPrep DNA/RNA 
Micro Kit (Qiagen, Germantown, MD, USA). Generation of cDNA, pre-amplification and 
reverse transcription quantitative polymerase chain reaction (RT-qPCR) to quantify the 
expression of ESR1 were performed as described in detail before, using a validated ESR1 
Taqman assay (Hs00174860 m1, Applied Biosystems, San Francisco, CA, USA) (9). ER-
positivity in CTCs was defined as an ESR1 mRNA ∆Cq level higher than -3.89 corrected 
for background healthy donor blood signal, which we previously demonstrated to be a 
reliable cut-off for ESR1 with excellent sensitivity and specificity (17). 
STATISTICAL CONSIDERATIONS
The primary endpoint of this study was the progression-free rate after six months of 
treatment (PFR6months) in patients receiving endocrine therapy. A small survey amongst 
medical oncologists revealed that a PFR6months of 20% for endocrine therapy alone 
in MBC patients with HER2-positive CTCs, would be convincing enough for medical 
oncologist not to treat a MBC patient with an ER-positive PT with endocrine therapy 
alone. Given that the expected PFR6months for endocrine therapy in unselected MBC 
patients is around 70% (and certainly not lower than 50%), and the prevalence of HER2-
positive CTCs was expected to be around 25%, we calculated that 60 patients would 
render 15 patients with HER2-positive CTCs to detect a PFR6months of 20% with a 95% 
confidence interval (CI) not higher than 50% (4-48%), with a type I error probability (α) of 
0.05 & a type II error probability (β) of 0.2. 
Secondary objectives were 1) to explore the association between the HER2-status of 
CTCs and the PFR6months on chemotherapy (as a control cohort), 2) to establish the 
incidence of ER-positive CTCs in the endocrine and chemotherapy cohort, 3) to establish 
discrepancy rates of the ER and HER2 status in CTCs compared to PT characteristics 
in both cohorts, and 4) to explore whether an ER-status switch between the primary 
breast tumor and the CTCs was associated with outcome in both cohorts. The date of 
progression was established by the treating physician and was defined as radiological 
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progression according to RECIST version 1.1 (26). In case of poorly evaluable disease, 
the treating physician was allowed to use other techniques considered to be appropriate 
(e.g. bone scan, serum biomarkers, CTC counts) to assess progressive disease. Data on 
the HER2 and ER-status (including HercepTest (Dako, Glostrup, Denmark) scoring and 
the percentage of ER-positive tumor cells) of the PT were collected from the pathology 
report. A HER2-negative PT was defined as having 0 or 1+ scoring according to the 
HercepTest (scored according to the manufacturer’s instructions) on the PT, or 2+ scoring 
in combination with negative HER2 in situ hybridization. An ER-negative PT was defined 
as having <10% of the primary tumor cells staining for ER using immunohistochemistry. 
Differences in the PFR6months between patients with HER2-positive versus HER2-
negative CTCs were analyzed using the chi-square test. Univariate Cox regression 
was used to evaluate whether the presence of at least one HER2-positive CTC (as a 
dichotomous variable) was associated with progression-free survival (PFS) or overall 
survival (OS). The HER2/CTC ratio was calculated by dividing the number of HER2-
positive CTCs by the total number of CTCs. No statistics were performed in the ER-
CTC-related analyses, as this study was not appropriately powered to evaluate the 
prognostic power of the ER-CTC status. Instead Kaplan-Meier curves were constructed 
to explore the potential prognostic power of the ER-CTC status. Associations between 
the HercepTest score and the HER2-CTC status were investigated with the chi-square 
test, while associations between the percentage of ER-positive tumor cells in the PT 
and ER-switches were compared with the Kruskall-Wallis test. Reported P-values are 
two-sided, and a significance level α = 0.05 was used. REMARK criteria (27) were taken 
into account for this report. Analyses were done using Stata/SE version 12 (StataCorp 
LP, College Station, TX, USA).  
R E S U LT S
PATIENT CHARACTERISTICS 
A total of 154 MBC patients were included in the current analysis (Table 1); 72 patients 
were treated with endocrine therapy, and 82 patients with first-line chemotherapy for 
MBC. Patients treated with endocrine therapy mainly started this as first-line therapy 
(69%) for MBC, and mostly received an aromatase inhibitor (64%). The patients in the 
chemotherapy cohort predominantly received taxane-based (48%) or anthracycline-
based chemotherapy (35%). No patients in either cohort received targeted therapies 
such as trastuzumab or everolimus. Median follow-up of all patients was 15 months.57%, 
P=0.48). In patients in whom HER2-positive CTCs were present, the median HER2 to 
CTC ratio (total number of HER2-positive CTCs divided by total number of CTCs) was 
0.08 (Q1 0.03 – Q3 0.22).
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TABLE 1. Baseline characteristics
Endocrine therapy (n=72) Chemotherapy (n=82)
Age at inclusion, median (range) 67 (37-88) 61 (33-85)
Primary tumor ER-positive 72 (100%) 57 (70%)
Previous chemotherapy lines for MBC
          0 68 (94%) 82 (100%)
          1 4 (6%)
Previous endocrine therapy lines for MBC
          0 50 (69%) 78 (96%)
          1 17 (24%) 2 (2%)
          2 5 (7%) 2 (2%)
Chemotherapy regimen received after inclusion
          Taxane-based 39 (48%)
          Anthracycline-based 29 (35%)
          Other 14 (17%)
Endocrine therapy regimen received after inclusion
          AI-based 46 (64%)
          Tamoxifen-based 17 (24%)
          Other 9 (12%)
CTC count at baseline
          1-4 CTCs/7.5 mL 30 (42%) 24 (29%)
          ≥5 CTCs/7.5 mL 42 (58%) 58 (71%)
Follow-up, median days (range) 511 (30 - 1436) 406 (8 - 1430)
TABLE 2. Prevalence and PRF6 months in relation to the HER2-CTC status
Endocrine therapy 
(n=72)
Chemotherapy 
(n=82)
HER2-positive CTCs (2+ or 3+ HER2 staining) present 19 (26%) 26 (32%)
HER2-positive CTCs (3+ HER2 staining) present 6 (8%) 9 (11%)
PFR 6 months
          Absent HER2-positive CTCs (2+ or 3+ HER2 staining) 68% 57%
          ≥1 HER2-positive CTCs (2+ or 3+ HER2 staining) present 53% 65%
          Chi-square PFR 6 months P-value (absent vs present) 0.23 0.48
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FIGURE 1. PFS AND OS ACCORDING TO HER2-CTC STATUS. Panel A and C show PFS and OS, respectively, 
for the endocrine therapy cohort, Panel B and D show PFS and OS, respectively, for chemotherapy cohort.
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Because we had ample follow-up time for the included patients, we also explored 
whether the presence of HER2-positive CTCs was associated with PFS or OS in a 
univariate Cox regression model. The presence of at least one HER2-positive CTC in the 
endocrine therapy cohort was not associated with a difference in PFS (HR 1.17, 95% CI 
0.65-2.09) or OS (1.72, 95% CI 0.73-4.03) (Figure 1 A&C). Similarly, in the chemotherapy 
cohort no association of HER2-positive CTCs with change in PFS (HR 1.09, 95% CI 0.67-
1.78) or OS (HR 0.93, 95% CI 0.53-1.63) was observed (Figure 1 B&D).
When the cut-off for HER2-positivity was shifted to only the CTCs that had a 3+ 
immunofluorescent staining, HER2-positive-3+ CTCs were observed in 6 patients (8%) 
in the endocrine therapy cohort and in 9 patients (11%) in the chemotherapy cohort. 
As the number of patients with HER2-positive-3+ CTCs was very limited, we did not 
perform formal statistics on differences in PFR6months. 
INCIDENCE AND PROGNOSTIC VALUE OF SWITCHES IN ER
STATUS BETWEEN PT AND CTCS
The ER-status of CTCs was assessed on the mRNA level and determined using our 
pre-defined cut-off for ESR1-positivity as described before (17). We compared the ER-
status of the CTCs with the ER-status of the PT as reported by the pathologist. The 
ER-CTC status could not be determined in 38 patients (25%): in 9 patients no sample 
for mRNA analysis was available, in 29 patients the mRNA was of poor quality or the 
epithelial mRNA signal was too low, the latter being indicative of a CTC count too low for 
a reliable mRNA analysis. We were thus able to determine the ER-status on CTCs in 116 
patients (75%) (Table 3). In the endocrine therapy cohort, consisting solely of patients 
with ER-positive PTs, 10 patients (14%) had ER-negative CTCs. In the chemotherapy 
cohort, 31% of the patients had a discordant ER-status between the PT and the CTCs. 
Interestingly, out of 19 patients who had an ER-negative PT, 13 patients (68%) had ER-
positive CTCs. In addition, in 7 out of 46 patients (15%) with an ER-positive PT, the CTCs 
were negative for ER. 
TABLE 3. Discordances between primary tumor and CTC regarding the ER status
ESR1 status CTCs negative ESR1 status CTCs positive Total
ENDOCRINE THERAPY
   ER status primary tumor
          Positive 10 41 51
CHEMOTHERAPY 
   ER status primary tumor
         Negative 6 13 19
         Positive 7 39 46
         Total 13 52 65
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FIGURE 2. PFS AND OS ACCORDING TO ER-CTC STATUS. Panel A and C show PFS and OS, respectively, 
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Exploratory Kaplan-Meier curves for the prognostic impact of ER-switches between 
the PT and the CTCs were constructed as planned. As depicted in Figure 2, no clear 
prognostic impact of ER-switch appeared to be present in either the endocrine therapy 
cohort or the chemotherapy cohort.
ASSOCIATIONS BETWEEN HER2 AND ER-STATUS OF CTCS AND THE PT 
We explored whether HER2-positive CTCs were related to the HER2 HercepTest score 
as assessed on the PT by the pathologist in the context of standard clinical care. For 
42 patients, no data on the PT HercepTest score was available. In the remaining 112 
patients, the HercepTest score (0, 1+ or 2+) was not found to be associated with the 
presence or absence of HER2-positive CTCs (p=0.24, Supplementary Table 1). We 
also explored whether switches in patients with an ER-positive PT to ER-negative CTCs 
were associated with the percentage of ER-positive tumor cells in the PT. Patients who 
had an ER-positive PT, but ER-negative CTCs, had lower percentages of ER-positive 
tumor cells in the PT than patients with an ER-positive PT in whom the CTCs remained 
ER-positive (p=0.03; Supplementary Figure 2). No data on the percentage of ER-
positive tumor cells was available for patients with an ER-negative PT.
D I S C U S S I O N
CTCs are an attractive alternative to solid biopsies, and may give insight into intra-
tumor and inter-metastatic heterogeneity (28, 29). Previous studies demonstrated 
discrepancies in the HER2 and ER status between the PT and the metastases, as well as 
discordances of these markers between the PT and the CTCs. However, appropriately 
powered studies evaluating the prognostic impact of HER2-positive CTCs have been 
scarce. We set out to evaluate the prevalence and prognostic value of HER2-positive 
CTCs in MBC patients with HER2-negative PTs. We hypothesized that MBC patients 
with HER2-positive CTCs would have a lower PFS after six months of endocrine therapy 
compared to patients with HER2-negative CTCs. While discordance in the HER2-status 
between the PT and CTCs was frequently present, no prognostic value of HER2-positive 
CTCs was observed in MBC patients treated with endocrine therapy.
Our findings that HER2-positive CTCs occur in a relatively large subset of HER2-negative 
MBC patients (45/154 patients, 29%) is in accordance with previous reports. Wallwiener 
and colleagues (18) used the same method as we did to score HER2-positive CTCs, 
and found HER2-positive CTCs in 30% of their 107 MBC patients with ≥5 CTCs and 
HER2-negative PTs. In contrast to our results, this study observed that patients with ≥5 
CTCs and HER2-positive CTCs had a longer PFS than patients with ≥5 CTCs without 
HER2-positive CTCs. However, since also patients with HER2-positive PTs who were 
treated with HER2-targeted treatments were included in that study, the results cannot 
directly be compared with our results. Slightly higher numbers of HER2-positive CTCs 
than in our study were observed by Fehm et al. (30), whom used an immunofluorescent 
staining on CellSearch for HER2 of 3+, and observed HER2-positive CTCs in 25 of 76 
(33%) MBC patients with HER2-negative PTs. Although other studies have investigated 
the prognostic impact of HER2-CTC status in MBC (4, 8, 12), these studies did either not 
use a FDA-cleared method to enumerate CTCs followed by characterization for HER2 
expression, or they did not sufficiently describe their technique to score HER2-positive 
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CTCs. For these reasons, direct comparison of the results from these studies with our 
study is not possible. 
While HER2-positive CTCs were frequently present in our MBC patients, their presence 
was not of prognostic value. Our study was powered to detect a 20% PFR6months in 
patients with HER2-positive CTCs receiving endocrine therapy versus 70% PFR6months 
in patients with HER2-negative CTCs, which was a difference considered clinically 
relevant after a small survey amongst medical oncologists. We believe it is justified to 
have powered this study for these sorts of large differences in PFR, because only such 
large differences will have a clear clinical impact and affect clinical decision making. 
Our data at least suggests that the presence of HER2-positive CTCs in patients with 
HER2-negative PTs does not have a major impact on their prognosis. There are several 
explanations for the lack of prognostic value of HER2-positive CTCs. First, it is possible 
that there is indeed no association between HER2 overexpression in CTCs of MBC 
patients and outcome to endocrine treatment. Second, specificity issues may have 
occurred when using the CellSearch Tumor Phenotyping reagent HER2. We found a 
moderate but significant correlation between the number of CTCs and the number of 
HER2-positive CTCs (Spearman r= 0.31, P<0.001). This suggests that when a higher 
number of CTCs would be present, there would be larger chance of finding at least 
one HER2-positive CTC. This may be in line with the observed heterogeneity for HER2 
expression in CTCs as seen in the median HER2 to CTC ratio, or indicate specificity 
issues. Third, a limitation of our study is that we did not perform FISH analysis on CTCs 
to confirm amplification of HER2, which may have further improved the specificity of 
the HER2-CTC-assay. Fourth, a subset of patients in the endocrine therapy cohort had 
already received prior endocrine therapy for MBC, which may have impacted the analyses 
regarding PFS in this cohort. However, in a subgroup analysis of patients receiving first-
line endocrine therapy which also met our power calculation, no prognostic value of 
HER2-positive CTCs was observed either. Fifth, the fact that HER2 is overexpressed, 
does not necessarily mean that it is also an active driver of tumor growth in that particular 
patient. The determination of phosphorylated HER2 or markers downstream of HER2 in 
CTCs may provide better insight into the activity of the HER2-signaling pathway in CTCs 
(31). Lastly, there is currently no consensus on the optimal cut-off for HER2-positivity. 
We chose CTCs immunofluorescently staining 2+ or 3+ as HER2-positive, given that 
this was the cut-off used in the CellSearch/Veridex inter-reader variability study (32), 
and good agreement for this cut-off was demonstrated between academic readers and 
Veridex consensus. However, other cut-offs for HER2 positivity on CTCs might yield 
different results regarding the prognostic impact of HER2-positive CTCs. Consensus 
on the optimal cut-off for HER2-positive CTCs is needed, and should be driven by the 
prognostic power and clinical utility of such a cut-off (for example for response to anti-
HER2 targeted agents).
With regard to ER-status, we found discordance between the PT and CTCs in 26% of 
our patients, which is in line with our previous reports (9, 17) and reports by others (6, 13, 
33-35), describing heterogeneity of CTCs for ER and discordances in ER-status in 24-
45% of the MBC cases. Especially of interest is that ER-positive CTCs were observed 
in 68% of the patients with an ER-negative PT, which might indicate that a subset of 
patients with an ER-negative PT might benefit from endocrine therapy. Also worth noting 
is the finding that patients in whom the PT was ER-positive, but the CTCs ER-negative, 
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the number of ER-positive tumor cells in the primary was significantly lower than in 
patients in whom the CTCs remained ER-positive. This suggests that heterogeneity in 
ER expression in the PT may give a higher chance of clonal evolution of an ER-negative 
clone. While heterogeneity and discordances between PTs and CTCs for ER expression 
have frequently been described, little is known about the prognostic impact of the ER-
CTC status. We previously explored the prognostic value of the ER-CTC status and 
found patients with ER-negative PTs but ER-positive CTCs to have a longer time-to-
treatment-switch than patients who remained ER-negative (17). However, in the present 
study (comprising 30 of the patients who were also included in our previous report), we 
were unable to confirm these findings. This could be due to the facts that our previous 
cohort was smaller (n=62), and that included patients were treated with either endocrine 
therapy or chemotherapy. In addition, the applied cut-off for ER-positivity of CTCs in 
our previous study was based on ESR1 mRNA levels in the PTs. Although this cut-off 
was demonstrated to have excellent sensitivity and specificity (17), it was not feasible 
to validate that cut-off value for the current study since the PT tissue was not available 
for all patients. The exploratory analyses here indicating lack of prognostic value should 
however be interpreted with caution, as the number of patients who had a switch in ER 
status was limited. Larger studies are required to evaluate the prognostic value of ER 
discordances between the PT and CTCs, preferably also evaluating ER-expression in 
CTCs at the single cell level to enable the evaluation of heterogeneity in ER expression 
between single CTCs. We have recently started a study in which we are evaluating 
heterogeneity of ER-positive-CTCs and their prognostic impact using a proximity-
ligation-assay technique (CareMore-Trastuzumab study & CareMore-AI study; NTR5121 
(36, 37)), while others have reported on immunofluorescent ER staining directly in the 
CellSearch machine, similar to HER2 in this study (35). 
In conclusion, a lack of prognostic value was observed for HER2-positive CTCs and 
ER-positive CTCs with respect to outcome to endocrine therapy or chemotherapy in 
MBC patients. Future research should focus on ER characterization of CTCs in a larger 
patient cohort, but may also focus on looking beyond classical predictive factors (such 
as HER2 and ER expression) that are related to endocrine resistance. This could for 
example be done by determining resistant mutations in ESR1 (34) or measuring gene 
expression panels associated with resistance to anti-tumor therapy (23, 24). Such 
characterization of several prognostic and predictive markers on CTCs correlated with 
resistance to either endocrine therapy or chemotherapy may eventually lead to improved 
prognostication and prediction of therapeutic response in MBC patients.   
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3+ score 
(HER2 staining, no background)
2+ score 
(HER2 staining, little background)
1+ score 
(HER2 staining, lot of background)
0 score 
(no HER2 staining)
S U P P L E M E N TA R Y  D ATA
SUPPLEMENTARY TABLE 1. HercepTest score in the primary tumor and association with HER2-positive CTCs
HER2 status of primary tumor No HER2-positive CTCs (n=76) HER2-positive CTCs (n=36)
          HercepTest score 0 34 12
          HercepTest score 1+ 29 13
          HercepTest score 2+ 13 11
 Chi-square P-value = 0.24
SUPPLEMENTARY FIGURE 1. HER2 scoring in CTCs. According to the Riethdorf criteria (Clinical Cancer 
Research 2010)
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A B S T R A C T
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been 
associated with acquired endocrine resistance in patients with ER-positive metastatic 
breast cancer (MBC). Functional studies revealed that these ESR1 mutations lead to 
constitutive activity of the ER, meaning that the receptor is active in absence of its 
ligand estrogen, conferring resistance against several endocrine agents. While recent 
clinical studies reported that the occurrence of ESR1 mutations is rare in primary breast 
cancer tumors, these mutations are more frequently observed in metastatic tissue and 
circulating cell-free DNA of MBC patients pretreated with endocrine therapy. Given the 
assumed impact that the presence of ESR1 mutations has on outcome to endocrine 
therapy, assessing ESR1 mutations in MBC patients is likely to be of significant interest 
to further individualize treatment for MBC patients. Here, ESR1 mutation detection 
methods and the most relevant pre-clinical and clinical studies on ESR1 mutations 
regarding endocrine resistance are reviewed, with particular interest in the ultimate goal 
of guiding treatment decision-making based on ESR1 mutations. 
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I N T R O D U C T I O N
Endocrine therapy with selective estrogen receptor modulators/downregulators 
(SERMs/SERDs) or by estrogen deprivation using aromatase inhibitors (AIs), is the most 
important treatment modality for estrogen receptor (ER)-positive metastatic breast 
cancer (MBC) patients (1). Unfortunately, 40% of patients do not benefit from first-line 
endocrine therapy due to intrinsic resistance, and the remainder of patients initially 
responding will eventually develop resistance during therapy (1). Several mechanisms 
have been linked to endocrine resistance, however, no marker for resistance has 
reached wide clinical use yet (2-4). Recently, mutations in the gene encoding ERα, 
ESR1, have attracted particular interest as a mechanism for endocrine resistance in 
MBC. Large-scale next-generation sequencing (NGS) efforts on MBC tissues revealed 
that these mutations are enriched in MBC patients treated with endocrine agents while 
these variants are not or only at very low frequencies present in primary tumor tissue (5, 
6). Importantly, this implies that their presence has to be assessed in metastatic lesions, 
or in “liquid biopsies” such as circulating cell-free DNA (cfDNA) as a representative of 
metastatic tumor cells. Here we review the pros and cons of current detection methods 
for ESR1 mutations, the pre-clinical and clinical studies investigating ESR1 mutations 
and highlight its potential role in treatment decision-making in MBC patients.
F U N C T I O N A L  S T U D I E S  O N  E S R 1  M U TAT I O N S
 
The ER belongs to the nuclear hormone receptor superfamily (7) and consists of two 
activation function (AF)-1/2 domains, DNA binding and hinge domains, and a ligand 
binding domain (LBD) (Figure 1). The ER functions as a ligand-dependent transcription 
factor. Binding of estradiol to the LBD leads to a conformational change of helix 12, 
resulting in recruitment of coregulatory proteins (8). This eventually yields transcription 
of genes important in normal physiological processes but also for breast tumorigenesis 
and breast cancer (BC) progression (9). 
Recent NGS efforts revealed that somatic ESR1 mutations in the LBD were more 
frequently present in metastatic lesions than previously thought. In preclinical models 
to evaluate the role of ESR1 mutations in endocrine resistance, it was demonstrated 
that cell lines transfected with a D538G, Y537S, L536Q, Y537N, Y537C, S463P or 
E380Q ESR1 mutation exert activity in the absence of estrogen (6, 10-15) (Figure 1). 
This constitutive activity suggests that estrogen-depriving therapies such as AIs are not 
or less effective in patients with activating ESR1 mutations. Cell lines transfected with 
mutant ESR1 variants were however still responsive to treatment with tamoxifen and 
fulvestrant, though sensitivity to these drugs was relatively impaired compared to ESR1 
wildtype transfected cell lines (5, 6, 12, 13). Similar observations were recently made for 
novel SERM/SERD hybrid endocrine therapies pipendoxifene and bazedoxifene (16). 
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T E C H N I Q U E S  T O  D E T E C T  E S R 1  M U TAT I O N S
Several techniques can be used to assess ESR1 mutations in tissue or cfDNA (Figure 
2), all having their own advantages and disadvantages. Importantly, these techniques 
widely vary in their sensitivity. NGS can be performed either in the context of whole 
genome sequencing, as part of a whole exome panel, or as part of a targeted ESR1 
panel. While NGS is an established and widely used approach for mutation detection in 
tumor tissue, mutation detection in cfDNA is more challenging, as the relative number of 
mutant to wildtype DNA alleles has to be taken into account. Frequencies of circulating 
tumor DNA (ctDNA) vary largely between patients, frequently being below 1% of the total 
cfDNA (17), which is beyond the sensitivity of conventional NGS. Therefore, techniques 
based on digital PCR (dPCR) have been introduced enabling the detection of ctDNA in 
frequencies as low as 0.001% (18, 19). In dPCR-based techniques, each individual DNA 
molecule, within its own partition, is able to react with a specific probe for wildtype ESR1 
and another probe for a specific ESR1 mutant. There are several commercially available 
dPCR-based assays (e.g. digital PCR, droplet digital PCR (ddPCR), BEAMing), differing 
in used reagents and sample readouts, but generally having similar sensitivity (17, 20). In 
a study comparing conventional targeted NGS with dPCR to detect mutations in cfDNA, 
threefold more D538G ESR1 mutations in cfDNA were observed using dPCR than with 
NGS (21). One disadvantage of dPCR assays is however that only a subset of hotspot 
mutations can be evaluated. Other assays, using some sort of target-enrichment prior 
to analysis, can be used to detect multiple hotspot mutations (OnTarget assay (22, 23)) 
or multiple frequently mutated genes (e.g. SafeSeqS (24), CAPP-Seq (25)), however to 
date these assays have not yet been reported to be used to detect ESR1 mutations. 
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N
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53
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T A T G G C C T G 
AF-1 DBD H LBD
D538G mutation (A>G)
FIGURE 1. SCHEMATIC OVERVIEW OF THE DIFFERENT DOMAINS OF THE ER.  Activation function (AF) 
domain-1 present at the N-terminus acts in a ligand-independent manner, whereas, the AF-2 within the ligand 
binding domain (LBD) is dependent on estradiol for its activation (53). The DNA binding domain encodes two 
zinc finger molecules, playing an important role in receptor dimerization and binding of the ER to specific 
DNA sequences: the estrogen response element (ERE) (54). H=hinge region. ESR1 mutations, some hotspot 
mutations shown as vertical red lines, mainly occur in the C-terminal domain of the receptor encoding for the 
LBD of the ER. 
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CLINICAL STUDIES ON THE SIGNIFICANCE OF ESR1 MUTATIONS
ESR1 MUTATIONS IN PRIMARY AND METASTATIC TUMOR TISSUE 
Although already described anecdotally in the 90s (11, 26, 27), ESR1 mutations were 
thought to be rare in BC. They occur only in up to 3% of primary tumors using NGS 
(Supplementary table 1) (5, 6, 12, 13). Using more sensitive dPCR-based techniques, 
the ESR1 mutation rate in primary BC tumors may mildly increase (28, 29), however, only 
at very low variant allele frequencies (VAF; 0.07-0.2%) (29). 
In contrast to mutation rates in primary BC, the landmark papers of Toy et al. (6) and 
Robinson et al. (13) showed much higher ESR1 mutation rates in metastatic lesions 
(Supplementary table 2). Toy and colleagues (6) found ESR1 mutations (predominantly 
D538G and Y537S) in metastatic tissues in 9/36 ER-positive MBC patients who had 
received at least 3 months of endocrine therapy. All patients with an ESR1 mutation 
were at least treated with two lines of endocrine therapy; all containing an AI. In an 
independent cohort of 44 metastatic tumors from patients pretreated with endocrine 
therapy, 5 metastases (11%) harbored an ESR1 mutation.
Likewise, Robinson et al. (13) demonstrated ESR1 mutations in 6/11 (55%) evaluated 
metastatic biopsies of ER-positive MBC patients. All patients with an ESR1 mutation 
were pretreated with AIs and SERMs or SERDs. None of three available matched primary 
tumors of patients with a metastatic ESR1 mutation harbored an ESR1 mutation. Based 
on these findings and the accompanied functional studies, both groups hypothesized 
that ESR1 mutations are a common mechanism underlying endocrine resistance, 
developing during estrogen deprivation, especially in the context of AI treatment.
Prompted by these findings, several studies investigated ESR1 mutations in metastatic 
tissue of MBC patients. In 5/13 (38%) ER-positive MBC patients, who failed on multiple 
lines of endocrine treatment, a D538G ESR1 mutation was reported (12). Furthermore, 
Jeselsohn et al. (5) detected in 9/76 (12%) ER-positive metastatic tumors ESR1 mutations 
(Y537N/C/S and D538G) using NGS, whereas none of the 115 ER-negative tumors they 
Whole-genome sequencing
Whole-exome sequencing
ESR1 targeted 
  sequencing
dPCR
FIGURE 2. VARIOUS TECHNIQUES FOR ESR1 MUTATION 
DETECTION. The pyramid represents the range in which the 
genome is investigated. ESR1 mutations can be detected by 
large-scale NGS efforts such as whole-genome sequencing 
or whole-exome sequencing, or by more targeted methods 
as targeted sequencing of the ESR1 gene only, or by the 
interrogation of individual mutations in ESR1 by digital PCR. 
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assessed had such mutations. In both studies no ESR1 mutations in matched primary 
tumors were detected (5, 12). 
In a study using dPCR, an ESR1 mutation was revealed in metastatic tissue of 11/55 ER-
positive MBC patients (28). Notably, polyclonal ESR1 mutations (multiple ESR1 mutations 
in one sample) were observed in 4/11 (36%) patients. Also of particular interest was that 
two patients with ESR1 mutations were not pretreated with any therapies at all and 
4/11 only received prior treatment with tamoxifen, supporting a previous observation 
(5) that ESR1 mutations are not exclusively found following AI treatment. In another 
study (29) applying dPCR, ESR1 mutations were found in 3/43 primary tumors, 1/12 
bone metastasis tissues and 3/38 brain metastasis tissues in ER-positive MBC patients. 
The prevalence of ESR1 mutations and their VAF were higher in bone (1.4% VAF) and 
especially in brain metastases (34.3-44.9% VAF) compared to primary tumors (0.07-
0.2% VAF), suggesting an enrichment of ESR1-mutant subclones in metastatic tissue.
All these tissue-based studies provided important insights into the prevalence of ESR1 
mutations and the population of patients in which they occur. However, the biggest 
disadvantage of these studies is that they concerned mostly small, heterogeneously 
treated, and retrospectively selected patient cohorts. Furthermore, of note is that 
biopsies were usually taken at various time points and therefore the evidence at which 
moment ESR1 mutations emerge, which is suggested to be mainly after AI treatment, is 
indirect. The majority of the above mentioned drawbacks are mainly driven by the fact 
that taking metastatic biopsies is a cumbersome procedure and even impossible in some 
patients, not easily allowing the assessment of ESR1 mutations over time. In addition, 
taking metastatic biopsies may lead to sample bias due to tumor heterogeneity (30). 
Therefore, recent studies have focused on ESR1 mutation detection in “liquid biopsies” 
as a patient-friendly alternative to taking biopsies from metastatic lesions.
ESR1 MUTATIONS IN ‘LIQUID BIOPSIES’
Circulating blood biomarkers such as circulating tumor cells (CTCs) and cfDNA are 
increasingly used as non-invasive surrogate “liquid biopsies”, and are thought to 
represent the most important metastatic tumor sites (31, 32). Both these types of liquid 
biopsies can be measured in peripheral blood, with CTCs being intact tumor cells and 
cfDNA being DNA mainly derived from apoptotic tumor cells. Recently, several studies 
investigating the presence of ESR1 mutations in liquid biopsies, particularly in cfDNA, 
have been published (Table 1). 
To evaluate NGS and dPCR techniques to detect ESR1 mutations in plasma, Guttery 
et al. examined cfDNA of 48 ER-positive MBC patients (21). In 3/48 patients (6%), they 
observed an ESR1 mutation in cfDNA using NGS. In one patient with a D538G mutation 
also CTCs, isolated by the CellSearch system, were sequenced, and the same mutation 
was detected in CTCs. When dPCR was performed in the same cohort for the D538G 
mutation only, the D538G mutation was found in 6 additional patients (15%) at VAF 
below 1%, underlining the limited sensitivity of NGS to detect low frequent mutations. 
In eleven patients, serial plasma samples were available. Interestingly, in one patient an 
ESR1 mutation was present at baseline and was further enriched (0.4% VAF to 13.6% 3 
months later) while treated with chemotherapy (docetaxel/vinorelbine). 
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To further explore whether ESR1 mutations present in metastases are also represented 
in the cfDNA, Chu et al. (33) assessed ESR1 mutations in plasma cfDNA in 11 ER-
positive MBC patients in whom the ESR1 mutation status in a metastatic lesion was 
assessed by NGS. All ESR1 mutations (8/8) observed in the metastatic lesions were also 
observed in the cfDNA using dPCR. In one patient with an ESR1 wildtype metastatic 
lesion, a low frequency ESR1 mutation was observed in the cfDNA. It should however 
be noted that the cfDNA was obtained two months after the biopsy, meaning that 
changes in ESR1 mutation status could also be due to therapy-related effects emerging 
after the initial biopsy. In an independent cohort consisting of 8 ER-positive patients, 
dPCR was once more demonstrated to be able to detect ESR1 mutations in cfDNA, 
and in two more patients an ESR1 mutation was observed in the cfDNA but not in the 
metastatic lesion. This study further underscored that dPCR is able to readily detect 
ESR1 mutations in the cfDNA and that cfDNA seems to represent ESR1 mutations in the 
metastatic lesions. Also, strikingly, ESR1 mutations were detected in cfDNA but not in 
metastatic lesions, which may be indicative of heterogeneity within the metastatic lesion 
or between multiple metastases. 
Another study only used dPCR to detect ESR1 mutations (29), and ESR1 mutations were 
detected in 7/29 MBC patients (24%), with one patient having polyclonal ESR1 mutations. 
All patients with an ESR1 mutation in cfDNA received at least one line of endocrine 
treatment, mainly AIs or tamoxifen. In this series, also an ESR1 mutation was seen in 
a patient who had only received prior treatment with fulvestrant. Of particular interest 
were the serial blood draws in the patient with the polyclonal ESR1 mutations, which 
revealed that two mutations were enriched during AI treatment and chemotherapy, while 
one mutation was absent after treatment. This may suggest that different mutations 
react differently to different treatments.
Schiavon and colleagues (34) were the first to present a study in which ESR1 mutations 
were assessed in a relatively large cohort of MBC patients. With dPCR to examine cfDNA 
from MBC patients at the time of progression under endocrine therapy, ESR1 mutations 
were observed in 18/128 patients (14%), with D538G mutations comprising 56% of all 
observed ESR1 mutations. Polyclonality of ESR1 mutations was observed in 21% of 
the patients. All patients in whom ESR1 mutations were observed had received prior AI 
treatment, while no ESR1 mutations were observed in a subset of 22 patients who had 
only received tamoxifen treatment. Interestingly, ESR1 mutations were mainly detected 
in patients who received AIs only in the metastatic setting (36%), and not in patients who 
received AIs only in the adjuvant setting (4%) or in the adjuvant and metastatic setting 
(8%). In accordance were observations in two relatively small independent cohorts, in 
which no ESR1 mutations were observed in 32 BC biopsies taken at recurrence after 
adjuvant AI treatment or in 7 cfDNA samples of MBC patients who received adjuvant 
AI treatment only. Regarding the outcome of patients with ESR1 mutations, subgroup 
analyses in ESR1 mutant versus wildtype patients revealed a significantly poorer 
progression-free survival (PFS) on subsequent AI treatment in patients harboring an 
ESR1 mutation, although these analyses should be seen as exploratory given the small 
number of patients eligible for such analyses. 
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The observations by Schiavon et al. suggests that AI treatment in the metastatic setting, 
but not in adjuvant setting, causes ESR1 mutations. This may suggest selection of 
subclones already present in the primary tumor, or in the metastases when the tumor 
load is increased and the probability of acquiring mutations increases (35). This first 
observation could be in line with the previously mentioned findings by Wang et al. whom 
found ESR1 mutations at extremely low VAF in primary tumors of MBC patients with 
ESR1 mutations. While the study by Schiavon and colleagues also provided evidence 
for an impaired response to AI treatment, larger studies were needed to confirm these 
findings and to examine whether MBC patients with ESR1 mutations will have improved 
responses on alternative therapie
 
ESR1 MUTATIONS AND OUTCOME ON ENDOCRINE THERAPIES 
In the randomized phase II FERGI trial, baseline plasma samples of patients failing to 
AI treatment randomized either to fulvestrant combined with the pan-PI3K inhibitor 
pictilisib or to the combination of fulvestrant and placebo, were examined for ESR1 
and PIK3CA mutations in tissue and cfDNA using BEAMing (36). They detected ESR1 
mutations in cfDNA in 57/153 (37%) of patients at baseline; 13 patients (23%) harbored 
polyclonal mutations. Surprisingly, the prevalence of the E380Q mutation was rather 
high (26%), while this mutation was previously not often observed. No ESR1 mutations 
were detected in 42 matched primary tumors of patients with ESR1 mutations in 
cfDNA. PIK3CA mutations were observed in the cfDNA of 40% of the patients and 
were generally concordant with findings in matched metastatic tissue. For the ESR1 
mutations, discordances between the cfDNA and metastatic biopsies occurred more 
frequently and cfDNA sometimes harbored more ESR1 mutations than the metastatic 
biopsies. These analyses were however limited by the fact that metastatic tissue and 
cfDNA were generally not collected on the same day. Of note was that the median VAF of 
PIK3CA mutations was markedly higher than for ESR1 mutations (3.6% versus 0.45%). 
The higher VAFs and concordance with tissue probably reflect that PIK3CA mutations 
usually occur in earlier stages of BC (37), in contrast to ESR1 mutations. Similar to 
Wang and colleagues (29), it was observed in multiple longitudinal samples in patients 
with polyclonal ESR1 mutations that different ESR1 mutations reacted differently under 
treatment. 
The clinical analyses in the fulvestrant/placebo arm of the FERGI study revealed that 
patients with an ESR1 mutation in ctDNA had no impaired PFS on fulvestrant compared 
to ESR1 wildtype. When the analyses were further restricted to those patients with 
polyclonal ESR1 mutations or ESR1 mutation with VAF above the median, also no effect 
on PFS was observed. Also no differences in PFS were observed in patients with and 
without ESR1 mutations receiving fulvestrant and pictilisib.
The data from the FERGI study suggested that fulvestrant does not have reduced 
activity in patients with ESR1 mutations. However, data on the impact of ESR1 mutations 
on outcome to fulvestrant versus AI treatment and the addition of other agents to 
fulvestrant treatment were still missing. These gaps were filled by data from two phase 
III randomized trials, reported by Fribbens et al. whom assessed ESR1 mutations in 
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cfDNA by dPCR (38). In the SoFEA study, patients who had previously benefited from 
a non-steroidal AI were randomly assigned to fulvestrant combined with anastrozole, 
fulvestrant with placebo, or exemestane alone. Mutations were detected at baseline 
in 63/161 (39%) patients; 27/55 (49%) patients evaluable for polyclonal mutations had 
such mutations. Patients with an ESR1 mutation had an improved PFS after taking a 
fulvestrant-containing regimen versus exemestane (median PFS fulvestrant-containing 
5.7 versus exemestane 2.6 months, P=0.02), in contrast to ESR1 wildtype patients in 
whom a similar PFS was found (5.4 months versus 8.0 months, P=0.77). Within the 
exemestane-treated patients, patients with ESR1 mutations (n=18) had a worse PFS 
compared to patients having an ESR1 wildtype (n=39), (median PFS 2.6 versus 8.0 
months P=0.01).
In the PALOMA3 study, patients who failed on prior endocrine therapy were randomized 
to fulvestrant in combination with the CDK4/6-inhibitor palbociclib or to fulvestrant 
and placebo. In 91/360 patients (25%), ESR1 mutations were detected with polyclonal 
mutations observed in 26/91 (29%). The main study revealed a significant PFS benefit 
in patients receiving fulvestrant/palbociclib versus patients receiving fulvestrant alone 
(median 9.5 versus 4.6 months, P=0.0001) (39). This PFS benefit was maintained in 
patients with ESR1 mutations (median 9.4 versus 3.6 months, P=0.002), while no PFS 
difference was observed between ESR1 mutants and wildtype in patients treated with 
fulvestrant/palbociclib (median 9.4 versus 9.5 months, respectively). Although PFS 
seemed to be slightly worse in the ESR1 mutated patients treated with fulvestrant alone 
(3.6 months 95% CI, 2.0-5.5) compared to ESR1 wildtype (5.4 months 95% CI 3.5-7.4), 
this was not statistically significant, which is in line with the results of the FERGI study 
(36).
So far, the only large study providing overall survival (OS) data with respect to ESR1 
mutations is the phase III BOLERO-2 study (40). In this study, postmenopausal 
women who progressed on an AI were randomized to the AI exemestane combined 
with everolimus, or exemestane and placebo. Overall, 156/541 (28.8%) of evaluable 
patients had either a D583G and/or Y537S ESR1 mutation detected in their cfDNA, 
with double-mutations detected in 30/541 (5.5%) patients. ESR1 mutations were more 
prevalent in patients who had previously received AI treatment for metastatic disease 
(33%) than in patients who had received AIs as adjuvant therapy (11%), supporting 
previous data from Schiavon et al (34). The results of the main study revealed that 
PFS was significantly improved in patients treated with everolimus and exemestane 
compared to exemestane and placebo (7.8 months versus 3.2 months), though the 
combination therapy did not result in improved OS (41, 42). In the ESR1 mutation-
driven subgroup analyses for PFS in the exemestane arm, patients with a mutation in 
D538G had a shorter PFS than ESR1 wildtype patients (2.7 versus 3.9 months), which 
is in accordance with the findings of the SoFEA study (40, 43). When the analysis was 
restricted to patients with an Y537S mutation only, this association was not observed, 
which may be related to the limited sample size for these subgroup analyses. Of note 
is that the PFS of ESR1 wildtype patients was 3.9 months in this study, while in the 
SoFEA study this was 8 months. This discrepancy in PFS might be due to differences 
in selection criteria of both studies. In the SoFEA trial only patients who received a 
non-steroidal AI as adjuvant therapy or as first-line therapy for MBC were included 
whereas patients in the BOLERO-2 trial were also included after receiving more lines of 
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therapy for MBC representing a more advanced disease stage. When everolimus was 
added to exemestane this resulted in an improved PFS in both D538G mutated (5.8 
months; HR 0.34, 95% CI 0.02-0.6) and wildtype patients (8.5 months; HR 0.4, 95% CI 
0.3-0.5), suggesting that ESR1 mutated patients could still benefit from the addition of 
everolimus. Of note is that benefit of the addition of everolimus was not demonstrated 
for patients with an Y537S mutation alone (4.2 months; HR 0.98, 95% CI 0.5-1.9), or with 
both an Y537S and D538G mutation (5.4 months; HR 0.53, 95% CI 0.2-1.3). Again, one 
should keep in mind that these analyses may have suffered from the limited sample size 
of patients with only an Y537S mutation or a polyclonal ESR1 mutation. If larger future 
studies confirm that patients with an Y537S indeed do not benefit from the addition of 
everolimus, this mutation might be used to select for patients who should be treated 
with other treatment modalities. Overall, the absolute median PFS interval seemed to 
be shorter in patients with an ESR1 mutation than in ESR1 wildtype patients, however, 
no formal analyses on these potential differences were observed. In this context, it was 
intriguing that OS analyses according to ESR1 mutation status showed that patients 
with an ESR1 mutation had a worse OS compared to wildtype patients (median OS 22 
versus 32 months). Noteworthy, the type of individual mutations was also suggested 
to influence OS, with a median OS of 26 months for patients with a D538G mutation 
only and 20 months for the Y537S mutation alone. In patients harboring both mutations 
the OS was even worse with a median OS of 15 months. Overall, these results may 
indicate that ESR1 mutations are associated with more aggressive disease biology. 
D I S C U S S I O N
The putative role of ESR1 mutations in endocrine resistance has sparked a wide interest 
in techniques enabling their detection, the conditions under which they appear, and 
whether their detection can ultimately assist treatment decision-making in MBC patients.
Regarding the best substrate for ESR1 mutation detection, data from multiple studies 
suggests that the cfDNA compartment sometimes provides additional mutations 
compared to matched metastatic tumor material. This may indicate that cfDNA is more 
representative of the whole somatic tumor landscape. Another obvious advantage 
of cfDNA over metastatic biopsies is that it can easily be obtained repeatedly during 
treatment. Therefore, future studies on the clinical relevance of ESR1 mutations should 
preferably be performed using cfDNA, measuring mutations not only at baseline but 
also sequentially during treatment. Of note, ESR1 mutations can also be detected in 
CTCs (21, 44, 45), but at this point it is unclear how ESR1 mutation detection in CTCs 
relates to ESR1 mutation detection in cfDNA, and if this adds anything to ESR1 mutation 
analyses in cfDNA.
Assessing ESR1 mutations in tissue and cfDNA provided clues as to how these ESR1 
mutations are enriched in MBC patients. Very strong indirect evidence exists for the 
enrichment of these ESR1 mutations during treatment with AIs in the metastatic setting. 
However, to date no direct evidence for the enrichment of ESR1 mutations under AI 
treatment has been presented yet. In this context it is also of note that several studies 
observed ESR1 mutations in metastases or cfDNA from patients treated with SERMs or 
SERDs only, or from patients not treated with endocrine therapy at all (5, 21, 28, 29). This 
further underlines that the understanding on how ESR1 mutations exactly occur is still 
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limited. ESR1 mutations are present at very low frequencies in primary BC tumors using 
dPCR (29), supporting the hypothesis that ESR1 mutations may already be subclonally 
present in the primary tumor, and because of growth advantages, become the more 
prominent clone under treatment pressure (34). ESR1 mutations might also occur as 
a result of mutational processes such as initiated by the APOBEC enzymes, however 
the mutational pattern of the hotspot ESR1 mutations (T>A/C/G) does not follow an 
APOBEC pattern or the pattern of any other mutational signature known to date (46, 47).
While the exact mechanism behind the enrichment of ESR1 mutations in MBC is still 
unknown, the clinical relevance of ESR1 mutations being present in cfDNA becomes 
evident. PFS after treatment with the AI exemestane was impaired in the patients 
harboring an ESR1 mutation (38, 40), while fulvestrant had similar efficacy in patients 
with an ESR1 mutation versus patients without an ESR1 mutation. Given these results 
with fulvestrant, efficacy of tamoxifen may also be unaffected in patients harboring ESR1 
mutations, however, no clinical data on this is present as of yet. For the addition of other 
agents to endocrine treatment, for example palbociclib or everolimus, the question 
remains whether the presence of ESR1 mutations is of any predictive significance for 
the efficacy of these agents. While the ESR1 mutation status did not seem to impact 
median PFS in patients receiving fulvestrant and palbociclib, the presence of an ESR1 
mutation in patients treated with exemestane and everolimus might be associated with 
decreased PFS compared to ESR1 wildtype patients.
Since a raise in ESR1 mutation ratio during the course of treatment may be indicative 
of progressive disease (48) and ESR1 mutations in general are associated with poor 
outcome (40), it will be of particular interest to see whether certain treatments (for 
example fulvestrant combined with palbociclib or specific chemotherapeutic regimen) 
are able to select against ESR1 mutant subclones. Recently, it was shown that upon the 
discontinuation of anti-epidermal growth factor receptor (EGFR) antibodies, resistant 
KRAS mutant clones decay, allowing re-challenges with anti-EGFR antibodies in 
particular patients (49). If ESR1 mutations are lost with certain treatment regimen, this 
could potentially allow re-challenges with AIs in a subset of patients. 
Also currently unknown is whether the different ESR1 mutations result in distinctive 
phenotypes. Functional studies on ESR1 mutations did not specifically focus on 
differences between various ESR1 mutations, and for some ESR1 mutations that have 
been measured in clinical studies (e.g. K303R, V524E, P535H, L536H/P/R), very little 
functional evaluation of its constitutive activity and potential role in endocrine resistance 
has been performed at all. In addition, clinical studies to date have generally been 
underpowered for subgroup analyses evaluating differential effects of different ESR1 
mutations. Even further complicating such analyses is the described polyclonality of 
ESR1 mutations. Multiple studies with anecdotal longitudinal sampling data suggested 
that in patients with polyclonal ESR1 mutations there are differential effects of therapy 
on different ESR1 mutations. This suggests that ESR1 mutations are present in different 
subclones, and not in the same cell. Theoretically, this may mean that patients with 
polyclonal mutations are more difficult to treat given the wider repertoire of resistance 
mutations. However, in rather small analyzed groups of patients with polyclonal ESR1 
mutations treated with fulvestrant such effects were not observed. Given that some ESR1 
mutations are rarer than others, the most pragmatic way to evaluate the prognostic value 
of these rare ESR1 mutations will likely be in the form of a meta-analysis in due time, 
as it is virtually impossible to evaluate the prognostic value of these mutations in single 
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studies. In addition, functional studies evaluating all LBD ESR1 mutations described in 
patients to date, validating their constitutive activity and exploring potential differential 
effects of different ESR1 mutations are of interest. 
The current evidence on ESR1 mutations warrants prospective studies in which patients 
are randomized and treated according to the ESR1 mutation status in cfDNA. Therefore, 
standardized methods to process plasma, to isolate cfDNA and to prepare and analyze 
the dPCR chips are needed. A lot of the recent ESR1 mutation research was performed 
on cfDNA samples that were suboptimally collected. For example, in the SoFEA trial, 
plasma was collected in EDTA tubes and processed up to 9 days after sample collection 
which may have consequences for the sensitivity to detect ESR1 mutations, especially 
in the context of longitudinal sampling (50, 51). Recently, it was demonstrated that blood 
collected in CellSave or BCT blood tubes assures optimal quality of cfDNA for dPCR or 
NGS analyses for up to 96 hours after the blood draw (50-52), providing opportunities 
to send blood samples to remote locations for plasma isolation. In addition, it is of 
utmost importance to assess variables such as intra-assay, inter-assay, inter-lab and 
inter-observer variability when using dPCR, which are currently not only poorly studied 
for ESR1 mutations, but also for cfDNA analyses in general. 
In conclusion, the presence of ESR1 mutations in patients with ER-positive MBC has 
high potential for clinical validity and utility. Prospective studies in which the exact 
role of how ESR1 mutations can be used to guide treatment decision-making have to 
be initiated, but firstly standardization of protocols to assess these mutations will be 
necessary to eventually allow clinical implementation.
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Supplementary Table 1. Overview of ESR1 mutation analysis in primary breast cancer 
Patients Method ESR1 mutation No. ESR1 mutations  Ref 
183 pts with ER-positive MBC 
participating in BOLERO-2 NGS ESR1 exome 6/183 (3%) (6) 
390 ER-positive tumors resected 
before endocrine therapy (TCGA 
sequenced tumors)
NGS 0/390 (13)
80 ER-negative tumors   0/80  
134 pts with ER-positive/HER2-
negative BC NGS ESR1 exome 0/58 (5)
104 pts with ER-negative BC   0/115  
270 pts with ER-positive BC ddPCR ESR1 D538G, Y537S/N 7/270 (0.03%) (28)
43 ER-positive primary tumors ddPCR
D538G, Y537S/
N/C, S463P, 
K303R
3/43 (7%) (29)
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A B S T R A C T 
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield 
endocrine resistance in metastatic breast cancer (MBC) patients. This research aimed to 
determine if these putative resistance mechanisms occur more frequently in circulating 
tumor cells (CTCs) of MBC patients progressing on endocrine treatment and in matched 
cell-free DNA (cfDNA). Two MBC cohorts were evaluated: 1) patients starting first-line 
endocrine therapy (n=43, baseline cohort) and 2) patients progressing on endocrine 
therapy (n=40, progressing cohort). ESR1 splice variants and ESR1 hotspot mutations 
were evaluated in CTC-enriched fractions and for ESR1 mutations compared with 
matched cfDNA (n=18 baseline cohort; n=26 progressing cohort). Only the ∆5 splice 
variant was CTC-specific expressed, but not enriched in the progressing cohort. 
Sensitivity for detecting ESR1 mutations in CTC-enriched fractions was markedly lower 
than for cfDNA. ESR1 mutations detected in the cfDNA were enriched upon progression, 
suggesting a role in conferring endocrine resistance in MBC.
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I N T R O D U C T I O N
Endocrine therapy is the mainstay of treatment for estrogen receptor (ER)-positive 
metastatic breast cancer (MBC) patients. However, 40% of these patients obtain no 
clinical benefit from first-line endocrine therapy, and virtually all of the patients in whom 
the tumor initially responds will eventually develop resistance (1). Several mechanisms 
have been linked to endocrine resistance (2), but none of these have been implemented 
in daily clinical practice because their clinical value could not be confirmed, or was 
not strong enough. One recently revealed mechanism for acquired resistance is the 
emergence of mutations in the gene coding for ER, ESR1, yielding a constitutively 
activated ER. Functional studies have suggested that tumor cells with these mutations 
are less responsive to estrogen deprivation as induced by aromatase-inhibitors (AIs) (3, 
4), but may still experience growth inhibition by ER blocking agents such as tamoxifen 
and fulvestrant (3-5). This was recently supported in a retrospective clinical analysis, in 
which a modest progression-free survival benefit was observed for MBC patients with an 
ESR1 mutation who were treated with fulvestrant, when compared to the AI exemestane 
(6). These results have further emphasized the potential for the determination of ESR1 
mutations to guide treatment-decision making in ER-positive MBC.
Another mechanism that potentially contributes to acquired endocrine therapy 
resistance is the occurrence of ESR1 mRNA splice variants. ESR1 splice variants have 
been described as having various effects on the transcriptional activity of the ER (7), 
and are heterogeneously expressed in primary breast cancers (8). The ERα∆5 splice 
variant is of particular interest, since preclinical experiments have reported that this 
variant exerts constitutional transcriptional activity (9, 10). However, to date, the putative 
role of ESR1 splice variants with regard to endocrine resistance in MBC has not been 
assessed.
ESR1 mutations and mRNA splice variants are likely to emerge during treatment, and 
can therefore only be observed in tumor cells obtained during or after treatment. Thus, 
these investigations require metastatic tumor tissue obtained through biopsies, which 
can be technically challenging, or even impossible. 
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are alternative and 
minimally-invasive means for assessing the characteristics of metastatic cancer cells. 
Theoretically, each are different substrates for DNA, with DNA from CTCs coming 
from intact cancer cells, and ctDNA (which is part of the total cell-free DNA (cfDNA)) 
is thought to originate mainly from apoptotic tumor cells (11). The introduction of very 
sensitive digital polymerase chain reaction (dPCR) assays has opened new avenues 
to determine the presence of mutations in ctDNA and in CTC-derived DNA of cancer 
patients. Although promising results have been achieved with the detection of ESR1 
mutations in cfDNA using dPCR (6, 12-17), the important advantage of using CTCs over 
cfDNA is that multiple parameters in multiple dimensions (DNA, RNA and protein) can 
be measured in the same sample, and can be associated with, for example, endocrine 
resistance. This implies that besides assessing mutations in CTC-derived DNA, the 
characterization of RNA from CTCs permits the assessment of splice variants. 
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The current study set out to evaluate ESR1 mutations and splice variants in CellSearch-
enriched CTCs of MBC patients before the start of first-line endocrine therapy, and 
during progression under any line of endocrine therapy. The main objective was to 
determine whether these putative mechanisms for endocrine resistance are enriched 
in patients progressing on endocrine therapy. To this end, a cohort of MBC patients 
before the beginning of first-line endocrine therapy for MBC was defined, as well as a 
cohort of MBC patients progressing under any line of endocrine therapy. Additionally, 
in a subgroup of these patients, the ESR1 mutation status in CTCs was compared with 
patient-matched cfDNA. 
M E T H O D S
PATIENTS AND TREATMENT
The patients evaluated in this study were selected from two CTC studies comprised of 
patients receiving endocrine therapy (study 06-248 (18-20) and study 09-405 (21)). Six 
centers in the Netherlands and Belgium participated in these studies from February 
2008 through March 2015. The patients were included in these studies if they had MBC, 
and a new line of endocrine therapy was begun. Blood was sampled before the start of 
endocrine therapy and/or at the time of progression to palliative endocrine treatment. At 
both of these time points, 10 mL of blood was drawn for CTC enumeration, and another 
10 mL of blood was drawn for CTC characterization. In each participating center, the 
institutional board approved the study protocols (Erasmus MC ID MEC-06-248 & MEC-
09-405). All patients provided written informed consent.
Two cohorts of patients were defined for the current study: a cohort starting first-
line endocrine therapy for MBC, and a separate cohort progressing under any line of 
palliative endocrine therapy. Further eligibility criteria required that the patient had ≥5 
CTCs/7.5 mL of blood at the time of the blood draw, to allow for the characterization of 
CTCs. 
ENUMERATION AND ISOLATION OF DNA AND RNA FROM CTCS AND 
CFDNA AND ESR1 MUTATION DETERMINATION
Details regarding the CTC enumeration and isolation of DNA/RNA from CTCs have 
been reported previously (18-21). Briefly, in each patient, 10 mL of blood was drawn 
in CellSave tubes (Janssen Diagnostics, Raritan, NJ, USA) for CTC enumeration, 
which was performed on 7.5 mL of blood within 96 hours of the blood draw using the 
CellSearch system (Janssen Diagnostics). Another 10 mL of blood was drawn in EDTA 
tubes for CTC characterization, and CTCs were isolated from 7.5 mL of blood within 24 
hours using the CellSearch system with the CellSearch profile kit (Janssen Diagnostics). 
Subsequently, DNA and RNA were isolated from enriched CTCs using the AllPrep DNA/
RNA Micro Kit (Qiagen, Germantown, MD, USA) (20). For cfDNA analyses, the remainder 
of the EDTA blood (maximum of 2.5 mL) was centrifuged to isolate plasma within 24 
hours after the blood draw. Cell-free DNA (cfDNA) was isolated from a total of 200 µL of 
plasma using the QIAamp circulating nucleic acid kit (Qiagen).
DNA from the CellSearch-enriched CTC fractions and cfDNA from plasma were 
quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, 
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Waltham, MA, USA). The DNA (0.1 to 1 ng/µL) was subjected to an ESR1 target-specific 
amplification of 15 cycles with TaqMan PreAmp Master Mix (Thermo Fisher Scientific), 
as recommended by the manufacturer, using the ESR1 PreAmp primer combination 
(Supplementary Table 1) at a final concentration of 400 nM each. The resulting pre-
amplified 136 base pair product covering the positions of all 4 ESR1 hotspot mutation 
sites (D538G and Y537S/C/N) was diluted 10-fold, and quantified via regular quantitative 
PCR (qPCR) for wild type (WT) ESR1 using the same primers. The resulting Cq value 
was used to control the number of WT copies to be loaded onto the chips for dPCR 
analyses. The variant allele frequencies (VAF) of the studied mutations for ESR1 were 
evaluated with mutation-specific TaqMan assays (the primer and probe sequences 
are given in Supplementary Table 1, and the reproducibility of these assessments 
in Supplementary Figure 1) via chip-based dPCR (QuantStudio 3D, Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Positive and negative control 
DNA was always included in each dPCR run, and all of the analyzed DNA samples (CTC 
and cfDNA) were evaluated in duplicate.
Digital PCR was performed for 4 ESR1 hotspot mutation sites (D538G and Y537S/
C/N). Ten healthy blood donors were used to specify the cut-offs for the presence of 
ESR1 mutations in CellSearch-enriched samples. Seven of them had sufficient plasma 
available, and these samples were used to specify the cut-offs for the presence of 
ESR1 mutations in cfDNA. The cut-off for the positivity for each individual assay was 
set at the highest VAF in the healthy blood donors plus 2.58 standard deviations (SD) 
(99% confidence interval) (Supplementary Figure 2 & 3). The cut-offs were: D538G 
= 0.6% (CTCs) and 1.0% (cfDNA), Y537S = 0.3% (for both CTCs and cfDNA), Y537N = 
0.3% (CTCs) and 1.65% (cfDNA), Y537C = 0.5% (CTCs) and 0.65% (cfDNA). Both of the 
duplicate ESR1 mutation measurements had to be above the cut-offs for a sample to be 
considered positive for a specific ESR1 mutation.
SHORT TANDEM REPEAT ANALYSIS ON PATIENT-MATCHED
CTC-DNA AND CFDNA
In a subset of samples, a short tandem repeat (STR) analysis was performed to confirm 
that the CellSearch-enriched DNA and cfDNA were indeed from the same donor. The 
PowerPlex 16 System (Promega, Madison, WI, USA) in combination with an ABI PRISM 
3130xl Genetic Analyzer (Thermo Fisher Scientific) and GeneMarker v1.91 software 
(Softgenetics LLC, State College, PA, USA)), was used to genotype the DNA, as 
recommended by the manufacturer’s instructions. 
ESR1 SPLICE VARIANTS AND EXPRESSION IN RNA FROM ENRICHED CTCS
The measured “splice variant gene panel” consisted of full-length (FL) ESR1 and ESR1 
splice variants ∆5, ∆7, 36KD and 46KD. In addition, reference genes and epithelial 
genes were evaluated. Two µL of complementary DNA was pre-amplified in 15 cycles 
with TaqMan assays and TaqMan PreAmp Master Mix (Thermo Fisher Scientific), 
as recommended by the manufacturer, using the gene panel combination given in 
Supplementary Table 1. After pre-amplification, each gene was individually measured 
via qPCR with the same TaqMan assay used in the pre-amplification. Positive and negative 
controls were included in each individual experiment to monitor the reproducibility of 
the measurements (for reproducibility, see also Supplementary Figure 4). 
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The splice variants were assessed in CellSearch-enriched fractions of 10 healthy blood 
donors to evaluate the possible leukocyte expression of FL ESR1 and splice variants. 
The splice variant gene panel was always evaluated in duplicate, and the averages of 
the duplicate measurements were used for further calculation. Only those samples with 
sufficient mRNA signal (reference genes average ∆Cq<26.5) and epithelial signal (KRT19/
EPCAM average ∆Cq<26.5), as described previously (20, 22, 23), were used for further 
evaluation of splice variants. The ∆Cq values for the splice variants were calculated 
relative to the FL ESR1. In those cases where no expression could be measured for both 
the splice variant and the FL ESR1, the sample was excluded from the analysis. 
STATISTICAL CONSIDERATIONS
The primary objective of this research was to investigate whether ESR1 mutations were 
more frequently observed in CTCs of MBC patients progressing on endocrine therapy, 
than in those patients starting first-line endocrine therapy. Based on data from the 
literature (3, 4), it was hypothesized that ESR1 mutations in CTCs would be detectable in 
30% of MBC patients experiencing progressive disease (PD) during palliative endocrine 
therapy, and that ESR1 mutations in CTCs would be present in 5% of those patients 
beginning palliative first-line endocrine therapy. In order to detect this difference (α=0.05 
and β=0.2), 44 MBC patients progressing on palliative endocrine therapy, and 44 MBC 
control patients initiating first-line endocrine therapy were needed. 
Secondary objectives included 1) an assessment of ESR1 mutations in cfDNA samples, 
and a comparison between the detection of ESR1 mutations in cfDNA versus CTC; 
2) an exploration of whether ESR1 mutations measured in cfDNA are enriched under 
endocrine therapy; 3) an exploration of whether ESR1 splice variants are more prevalent 
in those patients experiencing PD than in patients beginning first-line endocrine therapy 
for MBC; and 4) an exploration of whether certain clinical factors are associated with the 
presence of ESR1 mutations and/or splice variants.
Differences in the prevalence of ESR1 mutation and splice variants between the baseline 
cohort and the progressing cohort were calculated using Fisher’s exact test (2-sided), 
while those patients with matched samples in the baseline and the progressing 
cohort were excluded from this analysis. Correlations were tested using Kendall’s tau 
correlation coefficient, and the differences of splice variant ∆Cq values between groups 
were tested using the Kruskal-Wallis test. All of the analyses were performed using 
Stata/SE version 12 (StataCorp LP, College Station, TX, USA).   
R E S U LT S
PATIENT CHARACTERISTICS
For the baseline cohort, a total of 43 patient samples was included, while the progressing 
cohort contained a total of 40 patient samples (Table 1). Most of the patients in the 
baseline cohort were not treated with any adjuvant chemotherapy (79%); however, 
17 patients (40%) had been treated with adjuvant endocrine therapy. Samples in the 
progressing cohort originated mainly from patients progressing on first-line (55%) or 
second-line (30%) palliative endocrine therapy. Prior to the PD sample, 37 patients 
(93%) had received at least one line of AI treatment. Most patients (81%) in the baseline 
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TABLE 1. Baseline characteristics
Parameter Baseline cohort (n=43) PD cohort (n=40)
Age at sample draw
          Median age (range)     72 (37 - 83) 63 (35 - 88)
Adjuvant endocrine therapy 
          No 26 (60%) 26 (65%)
          Yes, tamoxifen only 10 (23%) 9 (23%)
          Yes, tamoxifen + AI 5 (12%) 4 (10%)
          Yes, AI only 2 (5%) 1 (2%)
Adjuvant chemotherapy 
          No 34 (79%) 28 (70%)
          Yes 9 (21%) 12 (30%)
Neoadjuvant therapies
         No 43 (100%) 40 (100%)
Number of previous lines endocrine therapy lines for MBC
          0 43 (100%)
          1 22 (55%)
          2 12 (30%)
          ≥3 6 (15%)
Endocrine therapy after start (BL cohort) or before PD (PD cohort)
          AI 30 (70%) 25 (63%)
          Tamoxifen 13 (30%) 7 (17%)
          Fulvestrant 8 (20%)
Previous endocrine therapy lines for MBC (in case of inclusion at 
PD on ≥2nd-line endocrine therapy)
          Yes, AI only 9 (23%)
          Yes, AI + tamoxifen 6 (15%)
          Yes, tamoxifen only 3 (7%)
Progression on the current line
          Yes 35 (81%) 40 (100%)
CTC count
          Median count (range) 81 (6 – 32492) 21 (5 – 2837)
95
cohort experienced PD on endocrine therapy during the time of follow-up. For 6 of 
these patients, matched samples from the baseline cohort and progressing cohort 
were available; however, for the other 29 patients, no PD sample was available, mainly 
because it was not collected. The median CTC count was higher in the baseline cohort 
(81 CTCs/7.5 mL) than in the progressing cohort (21 CTCs/7.5 mL).  
ESR1 MUTATIONS IN CTCS AND MATCHED CFDNA
In the 6 matched samples from the baseline and progressing cohorts, no ESR1 mutations 
were detected. ESR1 mutations were observed in the CTCs of 2 (5%) baseline cohort 
samples (2x Y537N), and 3 (8%) progressing cohort samples (2x D538G, 1x Y537S) 
(P=0.66) (Table 2). One of the patients in the baseline cohort with an ESR1 mutation 
had received prior adjuvant treatment with tamoxifen, while the other patient had not 
received any prior adjuvant therapy. Two of the ESR1 mutations in CTCs from patients 
in the progressing cohort, occurring after palliative first-line therapy, were observed in 
one patient who had been treated with an AI, and one patient who had been treated 
with tamoxifen. The third ESR1 mutation was observed in a patient progressing on 
fulvestrant as second-line palliative endocrine therapy, who had received an AI as her 
first-line treatment.      
Matched cfDNA and CTCs from the same time point were available from a subset of the 
patients in the baseline cohort (n=18) and the progressing cohort (n=26) (Supplementary 
Table 2). Two ESR1 mutations (1x D538G and 1x Y537S) (11%) were observed in cfDNA 
of the baseline cohort, and 12 ESR1 mutations were observed in 11 patients (42%) in 
cfDNA of the progressing cohort (8x D538G, 2x Y537S, 1x Y537N, 1x Y537C) (P=0.04) 
(Table 2). In the 4 matched cfDNA samples from the baseline and progressing cohorts, 
no ESR1 mutations were detected. Neither of the mutations found in cfDNA from the 
baseline cohort were observed in the CTCs (Table 2). In one of these patients, however, 
an Y537N mutation was observed in CTCs but not in cfDNA. Neither of the patients with 
ESR1 mutations in cfDNA from the baseline cohort had received any adjuvant therapy. 
When the mutations in cfDNA from the progressing cohort samples were compared with 
the mutation status of the CTCs, 3 out of 3 mutations observed in CTCs were confirmed 
in cfDNA. With one exception, variant allele frequencies (VAFs) of the mutations were 
much higher in cfDNA than in CTCs (Table 2). In addition, 9 mutations in 8 patients 
were observed in the cfDNA, but not in the CTCs. The mutations found in cfDNA of 
the progressing cohort occurred after first-line endocrine therapies (n=6) including AIs 
(n=5) and tamoxifen (n=1), and after second-line endocrine therapies (n=5) including 
fulvestrant (n=3) and tamoxifen (n=2). All of these latter patients had received an AI as 
first-line palliative endocrine treatment.  
From 4 patients with matched CTC-cfDNA samples and discordant CTC versus cfDNA 
ESR1 mutation results, unamplified DNA was available to perform STR analyses (Table 
2). These analyses showed that both of the DNA fractions originated from the same 
patient, and thus excluded sample swapping.
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ESR1 SPLICE VARIANTS IN CTCS
In order to assess the presence of ESR1 splice variants in CTCs, RNA was extracted from 
CellSearch-enriched CTCs, and analyzed for the expression of 4 ESR1 splice variants 
relative to full-length ESR1. In the baseline cohort, 10 of the 43 (23%) samples were 
excluded from further analysis, because of insufficient quality of mRNA (n=4) or lack of 
an epithelial signal (n=6). In the progressing cohort, 17 out of 40 (43%) samples had to 
be excluded because of insufficient quality of the mRNA (n=2), lack of an epithelial signal 
(n=6), or unavailable RNA (n=9). 
ESR1 splice variant ∆Cq values relative to full-length ESR1 were not correlated with 
CTC counts (Supplementary Figure 5). ∆Cq values of the ∆5 splice variant relative 
to full-length ESR1 were significantly higher in patients than in healthy blood donors 
(HBDs) (Figure 1A), but the ∆5 splice variant was not enriched in the progressing 
cohort, when compared to the baseline cohort (P=0.39). When 4 matched samples, 
taken from the baseline and progressing cohorts, were analyzed from patients receiving 
first-line AI treatment, the ∆5 splice variant was enriched at PD in two of the patients 
(Supplementary Figure 6). The ∆7 and 36KD splice variants were similarly expressed 
in patient samples and HBDs (Figure 1B-C). Nevertheless, for the 4 matched samples 
from the baseline and progressing cohorts, the ∆7 and 36kD splice variants were 
enriched at PD in 1 and 3 patients, respectively (Supplementary Figure 6). The 46KD 
splice variant was only observed in patient samples and not in HBDs; however, this did 
not reach statistical significance (Figure 1D).  
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D I S C U S S I O N
The current study evaluated whether ESR1 mutations and splice variants were enriched 
in CTCs from MBC patients progressing under endocrine therapy. No enrichment of 
any of these putative resistance mechanisms in CTCs was observed after endocrine 
therapy. However, cfDNA analyses did reveal an enrichment of ESR1 mutations at the 
time of progression on endocrine therapy, when compared to before the initiation of 
first-line endocrine treatment. 
FIGURE 1. OCCURRENCE OF SPLICE VARIANTS IN THE BASELINE COHORT, THE PROGRESSING 
COHORT AND HEALTHY BLOOD DONORS (HBDS). Boxes demonstrate median and IQR, lines represent 
adjacent values (1.5*IQR). Observations were binned at ∆Cq of 0.5. 
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The observation that ESR1 mutations were more frequently observed in cfDNA than 
in CTCs suggests that cfDNA is a more sensitive substrate for the analysis of ESR1 
mutations than CTCs enriched by the FDA-approved CellSearch system. This is also 
reflected by the VAFs in the CTCs, which were generally low (range: up to 3.8%), as 
opposed to the VAFs in the cfDNA, which were generally much higher (range: up to 
40%). One explanation for this difference could be the presence of contaminating 
leukocytes following the CellSearch enrichment of CTCs, which has been reported to 
be around 1,000 leukocytes (23), thereby decreasing the sensitivity for the detection of 
ESR1 mutations in CTCs. Although cfDNA analysis is also challenged by contamination 
of wildtype DNA, our results suggest that this is less of an issue in cfDNA than in CTCs. 
The stringency of the cut-offs for ESR1 mutations, now arbitrarily set at the highest VAF 
observed in HBDs plus 2.58xSD (representing the 99% confidence interval), could have 
played a role in the limited sensitivity of ESR1 mutation detection in CTCs. When less 
stringent cut-offs based on the highest VAF in HBDs were explored (data not shown), 
slightly more ESR1 mutations were observed in CTCs; however, the majority of these 
mutations were not observed in cfDNA, suggesting that relaxing the cut-offs for ESR1 
mutation positivity may lead to false-positive findings. This stresses the need to include 
HBDs, and to be stringent with setting the cut-off value for ESR1 mutation positivity. 
This also seems to apply to cfDNA: while most reports using dPCR have used the 
presence of at least 2 mutant signals as a cut-off for ESR1 mutation positivity in cfDNA, 
we observed that some HBDs harbor more than 2 mutant signals (Supplementary 
Figure 7). However, it should be noted that all studies to date have used the BioRad 
droplet dPCR system, whereas we used the Quantstudio 3D dPCR system. Interestingly, 
the current study observed one ESR1 mutation exclusively present in CTCs and not 
in cfDNA. This finding suggests that some ESR1 mutations may be missed by cfDNA 
analysis only, albeit this observation may be merely anecdotal. 
The current study is among the first to assess ESR1 mutations in a cohort of patients 
beginning first-line endocrine treatment for MBC. While it has already been recognized 
that primary breast cancers rarely harbor ESR1 mutations (3, 5), most studies thus far 
have evaluated patients who had been pre-treated with palliative endocrine therapy, 
suggesting that these mutations become enriched during treatment with AIs (14). Here, 
it has been confirmed that ESR1 mutations are not frequently present in MBC patients 
before first-line endocrine therapy, and are enriched in MBC patients progressing under 
endocrine therapy.
Most of the patients in this study having an ESR1 mutation progressed on AI treatment, 
or had previously been treated with an AI. In three of the patients, ESR1 mutations 
were observed after progression on fulvestrant, suggesting that although it has been 
reported that fulvestrant is more effective than AIs in ESR1 mutant patients (6, 24), 
mutant subclones can still be observed at PD on fulvestrant therapy. Of further note is 
the fact that in the current study the observed mutations in the baseline cohort occurred 
in those patients who were not pre-treated with AIs, or who received no pre-treatment 
with endocrine therapy at all. In addition, an ESR1 mutation was observed in CTCs and 
cfDNA of one patient progressing on first-line palliative tamoxifen therapy, but who had 
not received any AI treatment, also not in the adjuvant setting. These findings are in line 
with the observations of multiple groups (5, 12, 15), who reported ESR1 mutations in 
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metastatic biopsies or cfDNA of patients who had only received tamoxifen, or no pre-
treatment at all. This could also fit with the observations by Wang and colleagues (16), 
who reported that ESR1 mutations were sometimes present in primary breast cancers 
of patients at extremely low VAFs. 
In the current study the ESR1 splice variant ∆5 was expressed at higher levels in the 
CellSearch-enriched samples from MBC patients than in HBD samples; however, we 
found no enrichment of this splice variant during endocrine therapy for MBC. The ∆7, 
36KD and 46KD splice variants were not significantly more highly expressed in patients 
versus HBDs. The fact that full-length ESR1 and splice variants were also measured 
in a subset of HBDs suggests that leukocytes, which are known to express ESR1 (25), 
may also express these splice variants. This clearly complicates the analysis of ESR1 
splice variants measured in CellSearch-enriched CTC fractions, where one thousand-
fold of leukocytes is still present. In metastatic prostate cancer, the presence of the 
androgen receptor (AR) splice variant V7 in CTCs was previously demonstrated to be 
strongly associated with resistance to endocrine agents (26), but not to chemotherapy 
(22, 27, 28). It should, however, be noted that splice variants of ESR1 in breast cancer 
differ importantly from splice variants of the AR, since ESR1 splice variants are also 
expressed in healthy breast tissue (8), and full-length AR and splice variants are typically 
absent in CellSearch-enriched fractions of HBDs (22). It should also be kept in mind that, 
in the current study, only a limited number of samples could be evaluated for presence 
of splice variants. However, given that the ESR1 splice variant ∆5 has been linked to 
endocrine resistance (9, 10), is CTC-specific expressed, and that we found anecdotal 
evidence of enrichment of this splice variant in paired samples, further research of this 
splice variant in CTCs is warranted.
In conclusion, ESR1 mutations and splice variants in CellSearch-enriched CTCs 
were not enriched in MBC patients progressing on palliative endocrine therapy, but 
ESR1 mutations were enriched in those patients when they were assessed in cfDNA. 
Therefore, cfDNA appears to be a more sensitive and robust source for detecting ESR1 
mutations than DNA from CellSearch-enriched CTCs. However, the use of other CTC 
enrichment methods might yield better results (29). To improve the sensitivity and 
specificity of detecting mutations and splice variants, and to really exploit the potential 
power of CTCs, characterization of pure CTCs with single cell isolation systems is 
probably required (30). Until that has been proven feasible and superior to analysis of 
cfDNA, the detection of ESR1 mutations in cfDNA rather than CTCs is recommended. 
The increased incidence of ESR1 mutations in cfDNA at the time of progression on 
endocrine therapy further adds to the evidence that emergence of ESR1 mutations is 
involved in resistance to endocrine therapy in MBC.
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SUPPLEMENTARY FIGURE 1. REPRODUCIBILITY OF ESR1 MUTATION MEASUREMENTS IN CTCS 
AND CFDNA. Boxes demonstrate average VAF along with standard deviations (SDs) based on duplicate 
measurements.
SUPPLEMENTARY FIGURE 2. CUT-OFFS FOR ESR1 MUTATIONS IN CTCS. Each point represent one sample. 
Samples were ranked according to the VAF and cut-offs were set at the VAF in the highest HBD (depicted with red 
dot) + 2.58xSD. Stars indicate that the although the average VAF% was above the cut-off, duplicate experiments 
were not both above the cut-off.     
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SUPPLEMENTARY FIGURE 3. CUT-OFFS FOR ESR1 MUTATIONS IN CFDNA. Each point represent one 
sample. Samples were ranked according to the VAF and cut-offs were set at the VAF in the highest HBD 
(depicted with red dot) + 2.58xSD.  
SUPPLEMENTARY FIGURE 4. REPRODUCIBILITY OF SPLICE VARIANT MEASUREMENTS IN T47D CELL 
LINE WITH VARIOUS INPUTS OF RNA. Various inputs (10 ng, 2.5 ng, 0.62 ng and 0.16 ng) of RNA from cell 
line T47D were measured in the splice variant panel. Bars represent Cq values of reference genes for all inputs, 
and ∆Cq values (corrected for reference genes) for cytokeratin 19 (KRT19), EpCAM, ESR1-wildtype/full length 
and ESR1 splice variants.
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SUPPLEMENTARY FIGURE 5. CORRELATION BETWEEN ESR1 SPLICE VARIANT ∆CQ VALUES 
(RELATIVE TO ESR1 FULL-LENGTH) AND CTC COUNTS. CTC counts were log-normalized to compress the 
figure. Samples in which both the ESR1 splice variant and ESR1 full-length had no Cq were excluded. Samples 
in which only ESR1 full-length but no ESR1 splice variant was measured got a ∆Cq values (relative to ESR1 
full-length) of -15.
SUPPLEMENTARY FIGURE 6. DYNAMICS OF SPLICE VARIANTS IN 4 MATCHED SAMPLES AT BASELINE 
AND PD. All patients received first-line AI treatment.
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SUPPLEMENTARY FIGURE 7. POSITIVE SIGNALS FOR ESR1 MUTATION Y537N IN CFDNA FROM MALE 
HBD . Blue dots represent mutant signals, yellow dots represent unamplified signal, red dots represent wildtype 
signals, green dots represent double positive signals (wildtype+mutant).
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SUPPLEMENTARY TABLE 2. Characteristics of patients in cfDNA subgroup analysis
Parameter Baseline cohort (n=18) Progressing cohort (n=26)
Age at sample draw
          Median age (range) 68 (46 - 83) 64 (35 - 88)
Adjuvant endocrine therapy 
          No 11 (61%) 18 (69%)
          Yes, tamoxifen only 5 (28%) 4 (15%)
          Yes, tamoxifen + AI 2 (11%) 3 (12%)
          Yes, AI only 1 (4%)
Adjuvant chemotherapy 
          No 15 (83%) 18 (69%)
          Yes 3 (17%) 8 (31%)
Number of previous lines endocrine therapy lines 
for MBC
          0 18 (100%)
          1 16 (62%) 
          2 8 (31%)
          ≥3 2 (7%)
Endocrine therapy after start (baseline cohort) or 
before PD (progressing cohort)
          AI 11 (61%) 16 (62%)
          Tamoxifen 7 (39%) 3 (11%)
          Fulvestrant 7 (27%)
Previous endocrine therapy lines for MBC (in 
case of inclusion at PD on ≥2nd-line endocrine 
therapy)
          Yes, AI only 6 (23%)
          Yes, AI + tamoxifen 2 (8%)
          Yes, tamoxifen only 2 (8%)
Progression on the current line
          Yes 13 (77%) 26 (100%)
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CHAP TER  6
Application of circulating tumor DNA in prospective 
clinical oncology trials: standardization of 
pre-analytical conditions
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Maxime P. Look, Ronald de Wit, Stefan 
Sleijfer, Maurice P.H.M. Jansen, John 
W.M. Martens, Martijn P.J.K. Lolkema 
Mol Oncol. 2016 in press
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A B S T R A C T
BACKGROUND Circulating tumor DNA (ctDNA) has emerged as a potential new 
biomarker with diagnostic, predictive and prognostic applications for various solid 
tumor types. Before embarking large prospective clinical trials to prove the added value 
of utilizing ctDNA in clinical practice, it is essential to investigate the effects of various 
pre-analytical conditions on the quality of cell-free DNA (cfDNA) in general and of ctDNA 
in particular to optimize and standardize these conditions.
METHODS Whole blood samples were collected from patients with metastatic 
cancer bearing a known somatic variant. The following pre-analytical conditions were 
investigated: 1) different time intervals to plasma isolation (1 hour, 24 hours and 96 
hours); 2) different preservatives in blood collection tubes (EDTA, CellSave and BCT). 
Quality of cfDNA/ctDNA was assessed by DNA quantification, digital PCR (dPCR) for 
somatic variant detection and a β-actin fragmentation assay for DNA contamination 
from lysed leukocytes.
RESULTS In 11/16 (69%) of our patients we were able to detect the known somatic 
variant in ctDNA. We observed a time-dependent increase in cfDNA concentrations in 
EDTA tubes which was positively correlated with an increase in wild type copy numbers 
and large DNA fragments (> 420bp). Using different preservatives did not affect somatic 
variant detection ability, but did stabilize cfDNA concentrations over time. Variant allele 
frequency was affected by fluctuations in cfDNA concentration only in EDTA tubes at 
96 hours.
CONCLUSIONS Both CellSave and BCT tubes ensured optimal ctDNA quality in 
plasma processed within 96 hours after blood collection for downstream somatic 
variant detection by dPCR.
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I N T R O D U C T I O N
Circulating tumor DNA (ctDNA) has emerged as a potential new biomarker in the field of 
oncology. The quantification and characterization of ctDNA in plasma creates numerous 
potential applications, including detection of minimal residual disease, early evaluation 
of treatment response and stratification for targeted therapy according to specific 
genetic changes (1-7). 
The application of ctDNA-based diagnostic tests into the clinic still faces several 
technical difficulties. The biggest hurdle might be the detection limit: ctDNA may 
comprise less than 1.0% of the total cell-free DNA (cfDNA), making detection of the 
tumor-specific fraction challenging (1, 8, 9). The majority of cfDNA is derived from 
apoptotic tissue and hematological cells which release their DNA in the circulation (10, 
11). Thus, the absolute quantity of cfDNA (“the background”) determines our ability 
to detect ctDNA, and quantification of the tumor specific variant frequency depends 
both on the abundance of ctDNA molecules and the total amount of cfDNA. One of 
the most important factors impacting the total amount of cfDNA is the time to plasma 
processing after blood collection, which increases the release of wild type DNA from 
lysed hematological cells present in the blood collection tube (12, 13). To avoid this, 
plasma needs to be separated from the blood sample within hours after the blood draw, 
but the maximum time frame to do so, remains to be revealed. 
Due to logistical and practical reasons it is often not possible to process and store blood 
samples immediately after the blood draw to ensure optimal ctDNA quality. Especially 
in the context of large multi-center prospective clinical trials, which are essential to 
definitely establish ctDNA as a clinically relevant new biomarker, there is a need for 
standardization of pre-analytical conditions that allow longer processing time of blood 
samples. To overcome this problem specialized ‘cell-stabilizing’ blood collection tubes 
have been developed. These tubes should not only minimize contamination by wild type 
DNA from lysed hematological cells in the blood tube, they should also preserve the 
quality of ctDNA for reliable downstream analyses. 
Until today, a number of studies have tested the different available blood collection tubes 
to optimally preserve cfDNA/ctDNA (12, 14-16). They all demonstrate a time-dependent 
increase in cfDNA concentrations in EDTA tubes, while cfDNA concentrations remained 
stable in both BCT and CellSave tubes. Toro et al. (14) included the PAXgene blood 
DNA tube in their study, but this tube did not improve the results obtained with EDTA 
tubes. Yet, even though preservation methods have been compared (17), thorough 
direct comparisons between BCT and CellSave tubes at clinically relevant time frames 
are missing.  We set out to compare the available preservatives for their ability to allow 
easier implementation of ctDNA-based tests into larger clinical trials where processing 
of samples within 1 hour presents a major logistical challenge. The purpose of this 
study was to investigate the effect on the quality of cfDNA in general and of ctDNA in 
particular in metastatic cancer patients under the following pre-analytical conditions: 
1) different time intervals to plasma isolation (1 hour, 24 hours and 96 hours); and 2) 
different types of preservative in the blood collection tubes (EDTA, CellSave and BCT 
tubes). To this purpose the amount of cfDNA isolated from plasma was quantitated, its’ 
size determined and the fraction of ctDNA determined.
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M E T H O D S
PATIENT CHARACTERISTICS AND SOMATIC VARIANT STATUS OF TUMOR
Between October 2015 and January 2016 cancer patients within the Erasmus MC 
Cancer Institute in Rotterdam, the Netherlands were invited to contribute blood samples 
for this study by their treating physician. Patients were included if they had metastatic 
disease, were not currently receiving systemic treatment and if a validated dPCR assay 
was available for the known somatic variant in their primary and/or metastatic lesion. 
Somatic variant status and variant allele frequency (VAF) in tissue had been assessed as 
part of the standard of care by the molecular diagnostics laboratory of the department 
of pathology in the Rotterdam region. The calculation of VAF was performed through 
NGS analysis by calculating the coverage of the variant nucleotide relative to the total 
coverage on that position. For tissue samples (n=2) analyzed by Sanger sequencing the 
VAF was calculated by determining the ratio between the variant peak and the wildtype 
peak. All patients provided written informed consent, and the institutional review board 
approved the protocols (Erasmus MC ID MEC 15-616). 
PRE-ANALYTICAL CONDITIONS
After obtaining written informed consent, 9x10 mL of blood samples were collected 
within a single blood draw (See Supplemental figure 1). Matched blood samples were 
collected in sterile 3x 10 mL K2EDTA vacutainer® (BD, Franklin Lakes, NJ, USA), 
3x 10 mL Cell-Free DNA BCT® (Streck, Omaha, NE, USA) and 3x 10 mL CellSave 
Preservative (Janssen Diagnostics, Raritan, NJ, USA) blood collection tubes according 
to manufacturer instructions. The blood samples from one of each type of tube (EDTA, 
BCT and CellSave) were processed for plasma isolation at 3 different time points: within 
1 hour after blood draw, at 24 hours and at 96 hours after blood draw (See Supplemental 
figure 1). Plasma was isolated using 2 sequential centrifugation steps: 1) 1711g for 10 
minutes at room temperature; 2) 12,000g for 10 minutes at room temperature. Plasma 
was stored at -80°C in 1 ml aliquots immediately after centrifugation until further 
processing.
CFDNA ISOLATION AND QUANTIFICATION
For cfDNA isolation plasma samples were thawed at 4°C and 3 ml of plasma per sample 
was used. cfDNA was isolated using the QIAamp® Circulating Nucleic Acid kit (QIAGEN, 
Venlo, Limburg, The Netherlands) according to manufacturers instructions. cfDNA was 
eluted from the QIAGEN® Mini column using 50 µL buffer AVE which was applied 3 times 
to the column to obtain the highest cfDNA concentration possible. cfDNA was stored at 
-20°C. cfDNA concentrations were quantified using the Quant-iT dsDNA high-sensitivity 
assay (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to manufacturer’s 
instructions and the Qubit fluorometer (Invitrogen) was used as readout. 
DIGITAL PCR TAQMAN® SNP GENOTYPING AND Β-ACTIN
FRAGMENTATION ASSAY 
cfDNA samples were thawed at room temperature. Validated TaqMan® SNP genotyping 
assays (ThermoFisher Scientific, Waltham, MA USA) were used for somatic variant and 
wild type detection according to manufacturer’s instructions (Supplementary table 1). 
Accordingly, the limit of detection of this assay is 0.1% (2016). The maximum volume 
input of 7.8 µl of the final cfDNA eluate was used, unless the amount of cfDNA in this 
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volume exceeded the maximal input of 30 ng cfDNA, then 30 ng cfDNA was used. 
Depending on the obtained cfDNA concentration after plasma isolation, at least 2.57 ng 
cfDNA was analyzed, leading to a detection rate of 0.78% at the most.
The TaqMan® β-actin fragmentation assay was based on the assay developed by 
Norton et al. (Norton et al., 2013) to detect a small (136 bp) and long (420 bp) β-actin 
fragments. We adapted the assay so that both fragments were measured within a single 
experiment using the reported primers, but different probes for each fragment (See 
Supplemental table 2). For the β-actin fragmentation assay a standardized input of 2 ng 
cfDNA was used to minimize the change of having multiple DNA fragments in one well. 
All dPCR reactions were performed with the QuantStudio 3D Digital PCR System 
(ThermoFisher Scientific) according to the manufacturer’s protocol. In short, dPCR 
reaction mix was prepared containing 8.7 µL QuantStudio 3D Digital PCR Master Mix 
v2, 0.44 µL Taqman primer/probe mix, up to 7.8 µL of cfDNA and the total volume was 
completed with PCR grade H2O to a final volume of 17.4 µL. Using the QuantStudio 3D 
Digital PCR Chip Loader samples were partitioned on a 20,000 wells QuantStudio 3D 
Digital PCR Chip v2 followed by a PCR reaction on a ProFlex 2x Flat PCR System with 
the following program: 10 min at 96°C, 40x cycles of 2 min at 60°C, and followed by 
30 sec at 98°C, 2 min at 60°C and pause at 10°C. The dPCR data were then acquired 
with the QuantStudio 3D Digital PCR Instrument and the data was analyzed with the 
QuantStudio 3D Analysis Suite by one technician (JH) to account for inter-observer 
variability.
STATISTICAL ANALYSIS
The Wilcoxon signed rank test was used to compare the difference between matched 1 
hour and 24 hour samples relative to the difference between matched 1 hour and 96 hour 
samples. The Friedman test was used to test the order of the three 1 hour samples. To 
correct for multiple testing we adjusted the P value for significance using the Bonferroni 
correction. Significance was thus defined as P < 0.008 (0.05/6). Correlations were tested 
by Spearman’s rank correlation coefficient.
cfDNA concentrations determined by the Quant-iT dsDNA high-sensitivity assay were 
corrected for the plasma input and were converted from ng/ml plasma to copies/ml 
plasma by taking into consideration that 3.3 pg of human DNA contains 1 copy of a 
single gene. cfDNA concentrations were then log-transformed.
To correct for differences in plasma input used for cfDNA isolation and for differences 
in elution volume after cfDNA isolation, we expressed dPCR results as variant/wild type 
copy numbers per mL plasma. To calculate variant/wild type copy numbers per mL 
plasma the following equation as described by Lo et al. (18) was used: 
C = Q * (VDNA)/VPCR) * (1/Vext)
where C is variant/wild type copy numbers per mL plasma; Q is the total number of 
variant/wild type copy numbers determined by dPCR; VDNA is the total volume of cfDNA 
obtained after cfDNA isolation; VPCR is the volume of cfDNA solution used for the dPCR 
reaction; and Vext is the volume of plasma used for cfDNA isolation. 
To calculate VAF we divided the variant copy numbers per mL plasma by the sum 
of variant and wild type copy numbers per mL plasma. All statistical analyses were 
performed using STATA version 14.1. All figures were plotted using R version 3.2.3.
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TABLE 1. Tumor characteristics and somatic variant detection.
Patient 
ID (#)
Primary 
tumor
Site and 
number of 
metastases (x)
Interval 
tumor tissue 
and plasma 
analysis 
(months)
Known somatic variant  
(nucleotide change)
Variant allele 
frequency in 
plasma EDTA 
1h (%)
Cell-free DNA 
concentration 
in plasma EDTA 
1h (copies/ml 
plasma)
01
Cholangio-
carcinoma
Li (3), Lu (2), 
LN (1)
2 KRAS p.G12D (c.35G>A) 0.00 3655
02
Pancreatic 
cancer
Li (3), Lu (1) 
LN (6) 
9
KRAS p.G12V (c.35G>T) 0.00
4055
CRC
BRAF p.V600E 
(c.1799T>A)
0.97
PIK3CA p.H1047R 
(c.3140A>G)
1.86
03 Breast cancer LN (>2) -1*
PIK3CA p.H1047L 
(c.3140A>T)
0.00 2788
04 Melanoma Li (2), LN (5) 2 BRAF p.V600E 
(c.1799T>A)
1.44 1615
05 CRC Li (6), LN (2) 6 KRAS p.G13D (c.38G>A) 65.46 223130
06 CRC Li (3), Lu (4) 18 KRAS p.G12D (c.35G>A) 8.61 2215
07 Melanoma Brain (2), Abd 
(7)
8
NRAS p.Q61R 
(c.182A>G)
17.22 4245
08 Melanoma
LN (3), Lu (6), 
Li (>15), Spleen 
(1), Bone (4), 
Peritonitis 
carcinomatosa, 
pleuritis 
carcinomatosa
1
BRAF p.V600E 
(c.1799T>A)
37.21 22442
09 Melanoma LN (5) 1 BRAF p.V600E 
(c.1799T>A)
6.42 2739
R E S U LT S
SOMATIC VARIANT DETECTION RATE IN CTDNA OF RECRUITED PATIENTS
A total of 16 patients were included who all met the set criteria to investigate the effect 
of different pre-analytical conditions on the quality of ctDNA. Somatic variant status of 
the primary and/or metastatic lesion had been previously assessed, either by targeted 
next generation sequencing (14/16 patients) or by traditional Sanger sequencing (2/16 
patients). Table 1 lists the origin of the primary tumor, the site(s) of metastasis and the VAF 
in the tumor tissue. Using the specific TaqMan SNP genotyping assay (Supplementary 
table 1), we were able to detect in 11/16 (69%) of the patients the known somatic variant 
in ctDNA isolated within 1 hour from EDTA tubes. This corresponds to the detection of 
13/19 (68%) of the total number of somatic variants tested as some patients had multiple 
known somatic variants.
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TEMPORAL EFFECT OF STORAGE IN EDTA TUBES ON CFDNA QUALITY
To investigate the effect of different time intervals from the blood draw to plasma 
isolation on cfDNA quality, we measured cfDNA concentration isolated from plasma 
collected in EDTA tubes. We observed a significant increase in cfDNA concentrations in 
samples isolated after 96 hours compared to samples isolated within 1 hour (p<0.001; 
Figure 1). This increase in cfDNA concentration was significantly positively correlated 
to an increase in wild type copy numbers (rho=0.85; p<0.001; Figure 2A). If a somatic 
variant was detected in the 1 hour sample, the somatic variant could also be detected in 
24 and 96 hours samples. We also observed a significant positive correlation between 
variant copy numbers and cfDNA concentration, though this was less strong (rho=0.42; 
p<0.001; Figure 2B).
To investigate whether the increase in cfDNA concentrations and wild type copy 
numbers was due to the release of intact DNA from lysed leukocytes, we used the 
β-actin fragmentation assay (Figure 3A). In all pre-analytical conditions we detected 
low amounts of large fragments. We observed significantly more larger fragments in 
samples from 96 hours than in samples from 1 hour (420bp p<0.001; 2000bp p<0.001; 
Figure 3B). There was also a small but significant increase in fragmented DNA in 
samples from 96 hours compared to samples from 1 hour (136bp p=0.002; Figure 3B).
THE INTERACTION BETWEEN DIFFERENT PRESERVATIVES AND PLASMA 
ISOLATION TIME INTERVALS AND CFDNA QUALITY
Next, we investigated the effect of different preservatives in blood collection tubes on 
cfDNA quality. We compared cfDNA concentrations isolated from plasma collected in 
EDTA, BCT and CellSave tubes processed within 1 hour. cfDNA concentrations were 
10 CRC Brain (2), Li (1), 
Lu (8)
87 KRAS p.G13D (c.38G>A) 0.00 6030
11 CRC Lu (2) 5 KRAS p.G13D (c.38G>A) 0.84 4670
12 CRC Li (>20), LN (1) 3 KRAS p.Q61R (c.182A>G) 0.00 16136
13 NSCLC
Brain (8), 
Adrenal gland 
(1)
7
EGFR p.T790M 
(c.2369C>T)
1.18
5358
EGFR p.L858R 
(c.2573T>G)
2.62
14 Melanoma LN (7), Lu (5), 
adnexa
22
BRAF p.V600E 
(c.1799T>A)
5.37 3539
15 NSCLC Li (unknown) 1
EGFR p.T790M 
(c.2369C>T)
27.60 14085
16 Melanoma Brain (1) 38 BRAF p.V600E 
(c.1799T>A)
0.00 3012
CRC: colorectal cancer; NSCLC: non-small cell lung cancer; Li: liver; Lu: lung; LN: lymph node; Abd: abdomen
TABLE 1. Tumor characteristics and somatic variant detection.
Patient 
ID (#)
Primary 
tumor
Site and 
number of 
metastases (x)
Interval 
tumor tissue 
and plasma 
analysis 
(months)
Known somatic variant  
(nucleotide change)
Variant allele 
frequency in 
plasma EDTA 
1h (%)
Cell-free DNA 
concentration 
in plasma EDTA 
1h (copies/ml 
plasma)
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FIGURE 1. CFDNA CONCENTRATIONS FOR DIFFERENT PRE-ANALYTICAL CONDITIONS. Boxes 
(interquartile ranges (IQR)) and whiskers (1.5x IQR) are shown together with the median (black horizontal line) 
of the log cfDNA concentrations in ng/mL plasma of 16 patients for the different pre-analytical conditions. 
Outliers are displayed as black dots. The Wilcoxon signed rank test was used to compare the difference between 
matched 1 hour and 24 hour samples relative to the difference between matched 1 hour and 96 hour samples. 
*p<0.001.
FIGURE 2. CORRELATION BETWEEN WILD TYPE OR VARIANT COPY NUMBERS AND CFDNA 
CONCENTRATION. The log number of wild type copies (A) or variant copies (B) in copy numbers/mL plasma on 
the x-as is plotted against the log cfDNA concentrations in ng/mL plasma on the y-as. Data points correspond 
to single sample measurements from each time interval and each type of preservative. Correlations were tested 
by Spearman’s rank correlation coefficient. *p<0.001. Five patients with undetectable variant copy numbers in 
ctDNA are removed from plot B.
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FIGURE 3. Β-ACTIN FRAGMENTATION ASSAY FOR DIFFERENT PRE-ANALYTICAL CONDITIONS. (A) 
Principles of β-actin fragmentation assay. dPCR wells containing only 136bp signal are indicative of fragmented 
DNA (fragments <200 bp), whereas the 420 bp set will only binwd to intact DNA (>420bp). When a large intact 
DNA fragment (>2000 bp) is present in one of the wells both primer sets can bind, resulting in a mixed signal. 
In theory, this can also occur when a small (<200 bp) and large (>420 bp) DNA fragment is present together in 
one well. (B) Results of β-actin fragmentation assay. Boxes (interquartile ranges (IQR)) and whiskers (1.5x IQR) 
are shown together with the median (black horizontal line) of the number of β-actin copies for the different 
pre-analytical conditions. Outliers are displayed as black points. The Wilcoxon signed rank test was used 
to compare the difference between matched 1 hour and 24 hour samples relative to the difference between 
matched 1 hour and 96 hour samples for the different fragment sizes. *p=0.002; **p<0.001.
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similar in all blood collection tubes (Figure 1). We also did not observe any differences in 
the DNA fragment size distribution with the β-actin fragmentation assay for the different 
tubes at 1 hour (Figure 3B). 
In order to investigate whether the used preservatives in BCT and CellSave tubes could 
prevent the time-dependent increase in cfDNA concentration observed in EDTA tubes. 
We observed stable cfDNA concentrations in all 24 and 96 hours samples compared 
to their matched 1 hour samples (Figure 1). Also, we did not observe any differences 
in the DNA size distribution with the β-actin fragmentation assay for the matched time 
intervals for both tube types (Figure 3B).
THE INTERACTION BETWEEN DIFFERENT PRESERVATIVES AND PLASMA 
ISOLATION TIME INTERVALS ON SOMATIC VARIANT DETECTION IN CTDNA
To study the effect of time-dependent increase in cfDNA concentrations and wild type 
copy numbers on somatic variant detection, we analyzed VAF in the different pre-
analytical conditions compared to their matched 1 hour sample. If a somatic variant 
was detected in the EDTA 1 hour sample, the somatic variant could also be detected 
in BCT and CellSave 1 hour samples. There was no correlation between the VAF in 
tumor tissue and the VAF in plasma (Supplementary figure 2). There was a significant 
decrease in VAFs in samples from EDTA 96 hours (p=0.003; Figure 4), which was not 
observed for the other pre-analytical conditions. Since all tubes were drawn within a 
single blood draw we expected, in contrast to VAF, that all tubes within each patient 
contains similar amounts of variant copy numbers. Indeed, variant copy numbers 
appeared largely similar between tubes and in all tubes compared to their matched 1 
hour sample. (Figure 5 and Supplementary figure 3).
FIGURE 4. VAF FOR DIFFERENT PRE-ANALYTICAL CONDITIONS. The log variant allele frequency (VAF) of 
11 patients for the different pre-analytical conditions. Data points correspond to VAF for each individual patient 
and assay. The Wilcoxon signed rank test was used to compare the difference between matched 1 hour and 24 
hour samples relative to the difference between matched 1 hour and 96 hour samples. *p=0.003.
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D I S C U S S I O N
The purpose of this study was to investigate the effects of various pre-analytical 
conditions on the quality of cfDNA in general and of ctDNA in particular. The main aim 
was to investigate whether BCT and CellSave tubes processed within 96 hours after 
blood draw into plasma were suitable for downstream analyses of ctDNA.
Patients were recruited with a high prior probability to harbor ctDNA in their plasma, i.e. 
patients with metastatic disease without current anti-cancer treatment. In 69% of our 
patients we were able to detect the known somatic variant from tissue in ctDNA and 
this corresponds to the detection of 68% of all tested somatic variants. In 2/6 missed 
somatic variants, the somatic variant status in tissue was assessed > 3 years ago. It 
may be possible that other cancer subclones have emerged, resulting in undetectable 
somatic variants in ctDNA. Unfortunately, in these cases more recent information on 
somatic variant status was not available. Detection of somatic variants in plasma may 
also be influenced by the site and extent of metastases, which is exemplified by patient 
#05. This patient had a widespread pattern of metastases with corresponding high 
levels of cfDNA and high levels of variant copy numbers in plasma. However, due to 
our heterogeneous cohort this relationship could not be tested statistically for the other 
patients. 
FIGURE 5. Variant copy numbers for different pre-analytical conditions. The log variant copy numbers 
of 11 patients for the different pre-analytical conditions. Data points correspond to variant copy numbers for 
each individual patient and assay. The Wilcoxon signed rank test was used to compare the difference between 
matched 1 hour and 24 hour samples relative to the difference between matched 1 hour and 96 hour samples.
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The clinical utility and potential importance of our methods is evidenced by our findings 
in patient #02, who was thought to have metastases from his pancreatic carcinoma (first 
primary cancer) harboring a KRAS mutation. However, we could only detect BRAF and 
PIK3CA mutations in his ctDNA, highly suggestive that the metastases were originating 
from the patients’ colorectal cancer (second primary cancer), which can have important 
implications for his disease management. 
The formation of small DNA fragments (180-200 bp lengths) is a biochemical hallmark 
of apoptosis, whereas during cell lysis or necrosis intact genomic DNA and thus much 
larger DNA fragments (50-300 kbp) remain (19). Through an increase in wild type copy 
numbers and mainly intact DNA fragments we were able to demonstrate that the time-
dependent increase in cfDNA concentration in EDTA tubes originates from leukocyte 
lysis. In addition, we observed low levels of intact DNA fragments in all pre-analytical 
conditions, indicating a background level of leukocyte lysis here. Both Norton et al. (12) 
and Rothwell et al. (15) observed a similar increase in cfDNA concentrations in samples 
collected in EDTA tubes. In both BCT and CellSave tubes cfDNA concentrations, 
wild type copy numbers and β-actin fragment sizes remained stable up to 96 hours, 
indicating that the preservative in these tubes does not adversely affect cfDNA quality. 
Interestingly, there was also a significant increase in fragmented DNA in samples from 
EDTA 96 hours, which might be attributed to nucleases remaining active. 
As we only used dPCR for downstream analysis of ctDNA we cannot rule out the 
possibility that the used preservatives in BCT and CellSave tubes could potentially 
damage the cfDNA and thus affect other downstream analyses. Rothwell et al. assessed 
the number of single nucleotide variants through whole genome sequencing of cfDNA 
isolated from plasma collected in CellSave tubes (15). They did not observe introduction 
of DNA errors. Thus, the preservative used in CellSave tubes does not seem to influence 
cfDNA downstream analysis using NGS. 
Despite the contamination with intact cfDNA we were still able to detect all somatic 
variants in ctDNA from EDTA 96 hours samples, in those samples where we were able 
to detect a somatic variant in the EDTA 1 hour samples. These data suggests that 
stored samples which have not been processed optimally for ctDNA analysis can still 
be used to determine the presence of somatic variants in ctDNA. As a consequence 
of increased cfDNA concentrations and correlated wild type copy numbers, we did 
observe a significant decrease in VAF in the EDTA 96 hours samples. With respect 
to ctDNA applications for treatment response evaluation, this could result in serious 
misinterpretations of VAFs. However, variant copy numbers remained stable in all tubes 
and might thus be a more accurate outcome measure to evaluate treatment response in 
cancer patients. However, further investigation is needed to determine the inter-assay 
variability regarding the range of variant copy numbers and VAFs we observed among 
the different tubes. 
The results in this study indicate that EDTA tubes processed at 96 hours after blood 
draw are not suitable for blood collection for subsequent cfDNA/ctDNA analysis as the 
time-dependent increase in cfDNA concentration significantly affects VAF. In patient 
samples with low variant copy numbers this increase cfDNA concentration, resulting 
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from leukocyte lysis, may cause variant copies to fall below the limit of detection of the 
dPCR assay and thus may lead to false-negative results. Both BCT and CellSave tubes 
preserve cfDNA/ctDNA quality equally well up to 96 hours and the used preservatives 
did not affect downstream cfDNA/ctDNA analyses by dPCR. Variant copy numbers and 
VAFs also remained stable in these tubes. 
Therefore, we recommend for all future clinical studies, in which flexibility regarding the 
processing of blood samples is needed, to isolate plasma from blood collected in either 
BCT or CellSave tubes within 96 hours. This will make large multi-center trials using a 
central processing facility feasible, and will lead to optimal quality of ctDNA research 
and diagnostics.
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S U P P L E M E N TA R Y  D ATA
SUPPLEMENTARY FIGURE 1. Overview of study 
design. At time point 0h 9x10 mL blood tubes (3x EDTA; 
3x BCT; 3x CellSave) were collected within a single blood 
draw from each recruited patient (N=16). From each type 
of tube plasma was isolated within 1 hour, after 24 hours 
and after 96 hours. Plasma was directly stored at -80°C 
after processing.
SUPPLEMENTAL FIGURE 2. Correlation between 
variant allele frequency in tumor tissue and in ctDNA 
in plasma. The log percentage of tumor tissue variant 
allele frequency (tVAF) on the x-axis is plotted against 
the log precentage of ctDNA in plasma variant allele 
frequency (pVAF) on the y-axis. Data points correspond 
to single somatic variants. Correlation was tested by 
Spearman’s rank correlation coefficient.
131
SUPPLEMENTARY FIGURE 3. Variant copy numbers for 1 hour samples. The log variant copy numbers 
from 11 patients for the 1 hour samples. Data points correspond to variant copy numbers for each individual 
patient and assay. 
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SUPPLEMENTARY TABLE 1. Used SNP genotyping assays.
Assay ID Assay Name Gene Cosmic ID Amino acid change Nucleotide change
AH6R5PH BRAF_476 BRAF 476 p.V600E c.1799T>A
AHRSROS EGFR_6240 EGFR 6240 p.T790M c.2369C>T
AHRSRSV EGFR_6224 EGFR 6224 p.L858R c.2573T>G
AH6R5PI KRAS_521 KRAS 521 p.G12D c.35G>A
AHX1IHY KRAS_520 KRAS 520 p.G12V c.35G>T
AHD2BW0 KRAS_532 KRAS 532 p.G13D c.38G>A
AHQJTKH KRAS_552 KRAS 552 p.Q61R c.182A>G
AHS1P6Q NRAS_584 NRAS 584 p.Q61R c.182A>G
AHLJ0TP PIK3CA_776 PIK3CA 776 p.H1047L c.3140 A>T
AHPAVCD PIK3CA_775 PIK3CA 775 p.H1047R c.3140 A>G
SUPPLEMENTARY TABLE 2. Primer and probe designs for digital PCR.
Gene Forward primer Reverse primer Probe
β-actin 136 bp 5’-GCG CCG TTC CGA AAG TT-3’ 5’- CGG CGG ATC GGC AAA -3’ 6FAM-ACC GCC GAG ACC GCG TC-MGBNFQ
β-actin 420 bp 5’-CCG CTA  CCT CTT CTG GTG-3’ 5’-GAT GCA CCA TGT CAC ACT G-3’ VIC-CCT CCC TCC TTC CTG GCC TC-BHQ
133
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A B S T R A C T
Assessing circulating tumor DNA (ctDNA) is a promising method to evaluate somatic 
mutations from solid tumors in a minimally-invasive way. In a group of twelve metastatic 
colorectal cancer (mCRC) patients undergoing liver metastasectomy, from each patient 
DNA from cell-free DNA (cfDNA), the primary tumor, metastatic liver tissue, normal 
tumor-adjacent colon or liver tissue, and whole blood were obtained. Investigated was 
the feasibility of a targeted NGS approach to identify somatic mutations in ctDNA. 
This targeted NGS approach was also compared with NGS preceded by mutant allele 
enrichment using synchronous coefficient of drag alteration technology embodied in the 
OnTarget assay, and for selected mutations with digital PCR (dPCR). All tissue and cfDNA 
samples underwent IonPGM sequencing for a CRC-specific 21-gene panel, which was 
analyzed using a standard and a modified calling pipeline. In addition, cfDNA, whole 
blood and normal tissue DNA were analyzed with the OnTarget assay and with dPCR for 
specific mutations in cfDNA as detected in the corresponding primary and/or metastatic 
tumor tissue. NGS with modified calling was superior to standard calling and detected 
ctDNA in the cfDNA of 10 patients harboring mutations in APC, ATM, CREBBP, FBXW7, 
KRAS, KMT2D, PIK3CA and TP53. Using this approach, variant allele frequencies in 
plasma ranged predominantly from 1 to 10%, resulting in limited concordance between 
ctDNA and the primary tumor (39%) and the metastases (55%). Concordance between 
ctDNA and tissue markedly improved when ctDNA was evaluated for KRAS, PIK3CA 
and TP53 mutations by the OnTarget assay (80%) and digital PCR (93%). Additionally, 
using these techniques mutations were observed in tumor-adjacent tissue with normal 
morphology in the majority of patients, which were not observed in whole blood. In 
conclusion, in these mCRC patients with oligometastatic disease NGS on cfDNA was 
feasible, but had limited sensitivity to detect all somatic mutations present in tissue. 
Digital PCR and mutant allele enrichment before NGS appeared to be more sensitive to 
detect somatic mutations. 
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I N T R O D U C T I O N
The use of targeted therapies has markedly transformed cancer treatment in the last 
decade (1). Unfortunately most of the responses to targeted therapies in the advanced 
setting are transitory at best, because intrinsic or acquired resistance to these agents 
is present or rapidly develops (2). Tumor heterogeneity is thought to play a pivotal role 
in the development of acquired resistance (3). Heterogeneity is present in the tumor 
lesion itself (intra-tumor heterogeneity), while in the advanced setting also heterogeneity 
between different metastatic lesions (inter-metastatic heterogeneity) can be present (4, 
5). Furthermore, during effective treatment the genomic landscape of tumor cells evolves. 
For example, there are strong indications that the emergence of KRAS mutations in 
metastatic CRC (mCRC) patients who initially harbored a tumor wildtype for KRAS, 
contributes to resistance against anti-EGFR monoclonal antibodies (6, 7). Altogether, 
this clearly stresses that in the advanced setting, particularly after treatment with agents 
dependent on a genetic aberration, the analysis of a single biopsy to evaluate the cancer 
genome and to guide treatment decision making is likely insufficient. The only way to 
acquire a comprehensive overview of the cancer genome would be to take multiple 
biopsies from metastases, which is cumbersome and even impossible in some patients 
due to inaccessibility of lesions. 
As an alternative approach to taking biopsies from solid lesions, assessing circulating 
tumor DNA (ctDNA) in the peripheral blood has been proposed as a minimally-invasive 
way to evaluate the tumor mutation status. Tumor cells release fragmented DNA into 
the peripheral blood, and these DNA fragments can be detected as ctDNA in the cell-
free compartment (i.e., serum and plasma) of the blood. It is thought that ctDNA can 
represent the most prevalent tumor clones from primary tumors as well as metastatic 
lesions. In the last years, various techniques have been introduced to detect and quantify 
mutations in ctDNA. Generally, for choosing a technique to detect mutant ctDNA one 
has to take into account the rarity of ctDNA alleles relative to wildtype DNA alleles in 
the cell-free compartment of the blood. Frequencies of ctDNA vary largely, from roughly 
<0.1% to >10% (8, 9). Techniques such as digital PCR (dPCR) (10) and BEAMING (11) 
have the advantage of superior sensitivity, being able to detect ctDNA in frequencies 
as low as 0.01%. However, using these techniques only one or a limited number of 
specific somatic mutations can be analyzed simultaneously. Recently, a technique 
called synchronous coefficient of drag alteration (SCODA) (12, 13) has been used to 
develop an assay (OnTarget assay) which is able to analyze up to 96 mutant alleles in 9 
genes with reported sensitivity similar to dPCR and BEAMING of 0.01 - 0.001% (14). This 
OnTarget assay firstly enriches for mutant alleles and subsequently genes are targeted 
next-generation sequenced (NGS). Still, when all somatic variants in numerous genes 
are of interest, NGS for multiple genes is indicated. A potential drawback of these NGS 
techniques is however their lack of sensitivity for detecting ctDNA frequencies below 
1-2% (15).
The current study set out to explore the feasibility of Ion Torrent PGM (IonPGM) 
targeted NGS on plasma cfDNA of patients with mCRC undergoing colorectal liver 
metastasectomy. To this purpose, 12 patients undergoing resection of CRC metastases 
were investigated. In these patients the primary tumor, the resected liver metastasis, 
cfDNA and normal tumor-adjacent tissue were sequenced using a 21-gene CRC-specific 
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panel on the IonPGM platform. In addition, to gain more insight into the advantages 
and disadvantages of ctDNA detection with different techniques, results generated with 
the IonPGM platform were compared with the OnTarget assay and with digital PCR for 
specific variants.   
  
M E T H O D S
PATIENTS AND SAMPLE COLLECTION
Patients with colorectal liver metastases undergoing resection of liver metastases were 
included as part of a prospective study in the Erasmus MC Cancer Institute evaluating 
the prognostic value of circulating tumor cells (CTCs) as described before (16, 17). Prior to 
surgery 30 mL of blood was drawn in EDTA tubes from all patients for DNA isolation from 
plasma or whole blood as described in the next paragraph. In addition, 30 mL of blood 
was drawn in CellSave tubes and subsequently processed for CTC enumeration on the 
CellSearch system (Janssen Diagnostics, Raritan, NJ, USA) as described previously 
(16). During surgery, the liver metastases and normal tissue of the liver were collected 
and freshly frozen (FF) for later analyses. In all cases the tissue was also stored as 
formalin-fixed paraffin-embedded (FFPE). In patients presenting with synchronous CRC 
metastases, the resection of the colon was combined with the resection of the liver 
metastases and normal tumor-adjacent colon was also collected. 
For this mutation analysis study, only patients with a complete set of available plasma 
cfDNA, primary tumor tissue, metastatic tumor tissue and normal tumor-adjacent tissue 
of the liver or the colon were included. Other criteria for inclusion were 1) acquisition of 
metastatic tissue, normal tissue and plasma on the same day; 2) a minimum percentage 
of 30% tumor cells in the primary tumor sample and the liver metastasis sample as 
assessed using hematoxylin and eosin (H&E) slides from macro-dissected tissue by 
an experienced pathologist; 3) no tumor cells detected in macro-dissected tissue 
from tumor-adjacent colon and liver as assessed on H&E slides by an experienced 
pathologist; 4) no adjuvant treatment given in case of metachronous metastases. All 
patients provided written informed consent and the institutional board approved the 
protocols (Erasmus MC ID MEC-2006-089).  
DNA ISOLATION 
DNA was isolated from all tissues using the NucleoSpin DNA tissue kit (Macherey-Nagel, 
Düren, Germany). For FFPE materials deparaffinization was done prior to isolation of DNA 
(18). For the isolation of cell-free DNA (cfDNA), 30 mL of peripheral blood was pooled 
and centrifuged for 10 min at 800g within 24 hours after the blood draw. Subsequently 
plasma was removed and snap frozen at -80°C. Cell-free DNA was isolated from 3x1 mL 
plasma and eluted in 20 µL buffer using the QIAamp circulating nucleic acid kit (Qiagen, 
Venlo, The Netherlands) according to the manufacturers instructions. Subsequently the 
eluate from 3x1 mL of plasma was used for each assay (IonPGM, dPCR and OnTarget) 
(Supplementary Table 1). DNA from whole blood samples was isolated using the 
QIAamp Blood Mini kit (Qiagen), according to the manufacturer’s instructions. Extracted 
DNA was quantified using the Qubit dsDNA HS Assay kit (Thermo Fisher, Waltham, MA, 
USA).    
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TARGETED NGS USING IONPGM
A CRC-specific 21-gene panel was established based on the top 19 most frequently 
mutated genes for CRC in the Catalogue of somatic mutations in cancer (COSMIC, 
June 2014). Based on the clinical relevance of NRAS in CRC (19) and recent literature 
suggesting that KDR is a marker for hypermutation in CRC (20), these genes were also 
included in the panel. This resulted in a 21-gene panel consisting of TP53, APC, KRAS, 
ATM, PTEN, PIK3CA, BRAF, FBXW7, SMAD4, NF1, RB1, ARID1A, PTCH1, CREBBP, KIT, 
KMT2D, CDH1, MLH1, EGFR, NRAS & KDR. These 21 genes were included in a custom 
amplicon-based sequencing panel (1115 amplicons, ~89kb), where the amplicons 
covered the whole exome of the gene, except for genes KRAS, PIK3CA, BRAF, EGFR 
and NRAS in which only the hotspot regions were sequenced (Supplementary Table 
2). Libraries for these genes were constructed using the Ion AmpliSeq library kit 2.0 
(Thermo Fisher) and subsequently the libraries were sequenced on the Ion Torrent NGS 
platform (Thermo Fisher), all as described before (21).
IonPGM data was analyzed using our previously described standard calling pipeline (21, 
22). In short, raw IonPGM data was first loaded into the TorrentSuite variant caller 4.3, 
and variants were called with somatic low stringency setting. Then additional filtering 
was applied: variants were excluded if they were not present in the targeted exonic 
regions, if they were present in ≥90% of the samples, if they had a Q-score of ≤20, 
strand bias of ≥90%, read depth ≤100 (≤20 for normal tissue) or mutant allele read depth 
of ≤10. Then variants detected in normal tissue with a variant allele frequency of ≥35% 
and/or variants present in the virtual normal database (23) were excluded as somatic 
variants. Lastly, all detected variants were inspected in all patient-matched samples 
using raw data without any of the filtering steps (IonPGM hotspot file). The remaining 
variants were considered to be true somatic variants.
A modified approach to sensitively call known variants in cfDNA was also evaluated. In 
this modified calling pipeline, all variants observed in the primary tumor or the metastasis 
as identified with the standard calling pipeline were analyzed in the cfDNA. All of the 
above criteria to call a variant were used, except for the criterion that variants had to be 
called by the TorrentSuite variant caller. The somatic low stringency calling was omitted 
in this approach, as this calling was originally developed for variant calling in tissue, in 
which variant allele frequencies are usually higher than in cfDNA. 
NGS PRECEDED BY ONTARGET ENRICHMENT
DNA isolated from all plasma samples and a selected set of tissue samples and whole 
blood samples were sent to Boreal Genomics (Vancouver, BC, Canada), and processed 
with the OnTarget assay (13) followed by targeted sequencing on the MiSeq platform 
(Illumina, San Diego, CA, USA) as described before (14). Boreal Genomics was blinded 
from all results obtained with IonPGM and digital PCR.The OnTarget assay targets 96 
mutations in 9 genes (BRAF, CTNNB1, EGFR, KRAS, FOXL2, GNAS, NRAS, PIK3CA and 
TP53; Supplementary Table 3). The assay detects mutant DNA by electrophoretically 
removing wild-type DNA from the sample before significant PCR amplification or 
sequencing. Mutations were called positive if they were detected above a limit of 
detection (LOD), which was calculated as the mean plus 3 standard deviations of the 
mutant background (as observed on >100 known wild-type samples), plus two copies 
of the mutant. In cases where a mutant was called positive on a given PCR amplicon, 
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the LOD for all other mutants on the same amplicon was raised by 1% of the detected 
mutant abundance to prevent false positives from PCR errors on the detected mutant. 
The limit of detection was calculated separately for each mutation in each sample to 
maximize assay sensitivity and specificity. To evaluate the linearity, accuracy, and 
precision of the OnTarget assay, a set of samples designed for validation of cfDNA 
assays (Multiplex I cfDNA Reference Standard, from Horizon DX, Cambridge UK) were 
tested. These validation experiments demonstrated high sensitivity and specificity of 
the assay (Supplementary Table 4). 
DIGITAL PCR
Digital PCR for somatic variants was performed using validated Taqman SNP genotyping 
assays for KRAS p.G12D, KRAS p.G12V, KRAS p.G13D, PIK3CA p.E545K, TP53 p.R273H 
and TP53 p.R248Q (Thermo Fisher) on the Quantstudio 3D digital PCR system (Thermo 
Fisher), according to the manufacturer’s instructions. In case of cfDNA, the maximum 
input of 7.8 µL DNA was used. The presence of at least 2 mutant signals (FAM-positive, 
VIC-negative) was considered positive for a certain mutation.
To assess the proportion of cfDNA fragments, a Taqman β-actin dPCR assay was used 
based on the assay described by Norton et al. (24) which is able to detect small (≥136 
bp) and long (≥420 bp) β-actin fragments. This assay was used to quantify the extent of 
leukocyte lysis, which is characterized by an increased number of large DNA fragments 
relative to small DNA fragments (25) . A standardized input of 2 ng was used for the 
assay, to minimize the chances of double-positive events related to high input. Double-
positive events (positive for ≥136 bp & ≥420 bp) were classified as long fragments ≥2000 
bp, as the primers for the 136 bp and 420 bp span about 2000 bp. All dPCR experiments 
were analyzed in the Quantstudio 3D AnalysisSuite (Thermo Fisher) by one experienced 
technician (JH). 
STATISTICAL CONSIDERATIONS
Our primary endpoint was the feasibility of ionPGM sequencing on ctDNA using 
our standard algorithm. Secondary endpoints included to explore if ctDNA is more 
resembling of the primary tumor or the metastases, to explore associations between the 
number of circulating tumor cells and ctDNA detection, to explore associations between 
cfDNA fragmentation and ctDNA detection, and to explore how ionPGM sequencing 
relates to other methods detecting mutations in ctDNA. As this study was meant to be 
exploratory, no formal statistics were performed to compare groups or methods. 
07
142
R E S U LT S
PATIENTS AND TISSUES
Twelve patients were identified whom matched the inclusion criteria (Supplementary 
Table 5). Six patients presented with synchronous metastases, and 6 patients had 
metachronous metastases. Median number of days between the resection of the primary 
tumor and the resection of the liver metastases for the patients with metachronous 
metastases was 830 days (range 270-2522 days). None of the patients received adjuvant 
therapy after surgery of the primary tumor or induction-therapy prior to the surgery for 
the liver metastases. In the set of 36 tissue samples (primary tumor, metastases and 
normal liver or colon), 25 tissue samples were FF and 11 tissue samples were FFPE. The 
median tumor cell percentage was 80% (interquartile range 20%).
PLASMA ISOLATION AND RAW ANALYSIS OF SAMPLES
Median cfDNA concentration after isolation was 564 pg/µL (range 442-1224). A total of 
5.75 - 15.91 ng cfDNA was sequenced on the IonPGM platform (Supplementary Table 
6). Median coverage was 751x (range 582x- 1141x) for tissue samples and 728x (range 
527x-812x) for cfDNA samples. Raw data was analyzed and variants not meeting our 
criteria for somatic mutations were excluded with the exception of one variant (TP53 
p.R273H). This variant was observed in one of the 478 virtual normal genomes (0.2%), 
but since this variant is enriched in TCGA CRC data (3,3%) (26) and linked to enhanced 
proliferation and invasion (27) it was evaluated as a somatic variant. Following further 
filtering of variants using the standard variant calling pipeline, a median of 3 variants were 
called per primary tumor or metastasis. However, in the primary tumors of patients 1, 4 & 
5 more than 200 variants remained after filtering. Further investigation of these variants 
revealed that >97% of the called variants were C > T or G > A variant substitutions, which 
had previously been linked to sequencings artefacts caused by formalin fixation (28, 29). 
In an attempt to reduce these artefacts one FFPE-derived DNA was treated with uracil-
DNA glycosylase (UDG), which has been described to reduce FFPE-related sequencing 
artefacts (28, 29). While a great reduction of variants was observed after UDG treatment, 
still more than 100 variants remained after filtering (data not shown). Since these FFPE-
related artefacts severely limited somatic mutation detection, the primary tumor FFPE 
samples of patients 1, 4 & 5 were omitted from further analysis. 
CONCORDANCE BETWEEN PRIMARY TUMOR, METASTASIS
AND CFDNA USING IONPGM NGS
Following standard filtering 28 variants were observed in the primary tumor and 33 
variants in the metastases, comprising a total of 29 distinct variants (Table 1). Of these 
29 variants, 10 variants were not previously described in COSMIC. Concordance of all 
variants between the primary tumor and the metastases was 72%. In the cfDNAs, a 
total of 11 variants were observed in the blood of 6 patients. Two variants were found 
exclusively in ctDNA (KMT2D p.G794R & ATM p.A2301T) which were not previously 
described in COSMIC. From 28 variants observed in the primary tumor, 5 were retrieved 
in cfDNA (18%). Of note is that 4 of these 5 retrieved variants were observed in the 
same patient (patient 9). Out of 33 variants observed in the metastases, 9 variants were 
retrieved in the cfDNA (27%). 
143
TABLE 1. Variants called in the primary tumor, metastases and plasma.  
Patient Gene Position COSMIC Primary ionPGM Meta ionPGM Plasma ionPGM
m
etachronous
1 APC p.Q1388X yes X 54 2.7
 APC p.R858X yes X 27.4 . 
       
2 CREBBP p.P2383L no 5.4 . . 
 FBXW7 p.D399Y no 19.8 39.4 . 
 KRAS p.G12D yes 28.6 38.6 . 
 PIK3CA p.E545K yes 41.1 74.8 . 
 TP53 p.G108S yes 40.9 78.4 . 
 TP53 p.L130I no 44.1 74.7 . 
       
3 APC p.C1369X no 52.0 78.2 3.7
 CREBBP p.P2383S no 6.0  . . 
 TP53 p.R273H yes 50.6 82.0 7.3
       
4 APC p.R223X yes X 66.8 25.8
       
5 APC p.E1288X yes X 5.4 . 
 APC p.R284X yes X 10 1.6
 TP53 p.R248Q yes X 17.9 2.2
       
6 APC p.R481X yes  . 76.2 15.8
 FBXW7 p.R689W yes 22.0  . . 
 FBXW7 p.S582L yes 23.8  . . 
 PIK3CA p.E545K yes 5.3  . . 
 KRAS p.G12V yes  . 49.7 5.3
 TP53 p.R273H yes  . 72.3 12.2
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synchronous
7 KRAS p.G12D yes 12.7 8.5 . 
 ATM p.A2301T no  . . 3.4
       
8 APC p.E1390X yes 22.3 50.7 1.3
 KRAS p.G12D yes 30.9 51.2 2.3
 TP53 p.R175H yes 37.2 69.2 . 
 KMT2D p.G794R no  . . 4.2
       
9 APC p.R858X yes 24.4 41.2 17.2
 CREBBP p.P937Q no 4.2 4.3 7.2
 KRAS p.G12D yes 39.7 35.0 20.5
 TP53 p.R248Q yes 37.5 55.7 14.1
       
10 TP53 p.R282W yes 66.8 61.7 . 
       
11 APC p.R481X yes 23.9 16.3 2.9
 TP53 p.M237I yes 55.4 37.3 1.3
       
12 APC p.E1390X yes 26.0 20.9 . 
 APC p.E564X no 19.1 12.5 . 
 CREBBP p.P975S no  . 4.2 . 
 CREBBP p.R601Q no 13.0 9.8 . 
 KRAS p.G13D yes 37.9 26.6 1.5
 PIK3CA p.E545K yes 18.0 12.9 . 
       
TABLE 1. Variants called in the primary tumor, metastases and plasma.  
Patient Gene Position COSMIC Primary ionPGM Meta ionPGM Plasma ionPGM
Variants in plasma only called after modified variant calling are italicized and bold. Excluded samples because 
of FFPE-related artefacts are indicated with an “X”. Not detected variants are indicated with a dot.
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INVESTIGATION OF MODIFIED CALLING PIPELINE FOR CFDNA
To explore whether the sensitivity for calling variants in cfDNA from plasma with the 
standard filtering strategy could be improved, variants previously observed in the 
primary tumor or the metastasis were investigated for their presence in cfDNA using a 
modified calling pipeline. For this pipeline, the variant in cfDNA did not have to be called 
by the TorrentSuite variant calling program. The modified calling approach led to the 
identification of 9 additional variants in cfDNA and showed variants in the blood of 10 
patients (Table 1). In the primary tumor now 11 of 28 variants could be retrieved in the 
cfDNA samples (39% compared to 18% with standard filtering). In the metastases 18 of 
33 variants were retrieved in the cfDNA samples (55% compared to 27% with standard 
filtering). 
After using the modified pipeline, 20 different variants in cfDNA (5 in cfDNA versus 
primary tumor, 3 in cfDNA versus metastases, 12 in cfDNA versus both primary tumor 
and metastases) still remained undetected. When the raw data for these variants was 
explored (Supplementary Table 7), for 10 variants no mutant reads were observed at 
all in cfDNA, while for 5 other variants the number of mutant reads did not exceed the 
number of mutant reads found in cfDNA of patients without that variant found in their 
tissue. For 5 additional variants the number of mutant reads did exceed the number 
of mutant reads observed in cfDNA of patients without that variant in tissue, however, 
these were generally low-confidence variants with Q-scores below 20.    
ONTARGET ENRICHMENT FOLLOWED BY NGS
To explore whether enrichment of mutant alleles with the OnTarget technique followed 
by NGS would improve sensitivity compared to IonPGM NGS, all cfDNA samples and 
normal tissues were analyzed with the OnTarget assay (Supplementary Table 8). A 
total of 3.0 - 10.0 ng cfDNA was used for the procedure, which was a similar input as 
used with IonPGM. The OnTarget assay covers 96 hotspot mutations in 9 genes, and 
based on our IonPGM sequencing in the primary tumor and metastases, a maximum 
of 15 mutations could potentially be detected by the OnTarget assay in the samples of 
9 patients included in our study (for 3 patients the OnTarget assay did not comprise the 
observed mutations in the tissues of these patients). These 15 mutations were detected 
with IonPGM in 5 cfDNA samples with the standard pipeline (33%) and in 8 cfDNA 
samples with the modified pipeline (58%). Using the OnTarget assay 12 out of 15 variants 
(80%) could be retrieved in the cfDNA (Table 2). No additional variants were detected in 
cfDNA with the OnTarget assay. Interestingly, the OnTarget assay also detected a total 
of 13 variants in 7 of 9 normal tumor-adjacent tissues (Supplementary Table 8). For 5 
patients in which mutations in tumor-adjacent normal tissue were observed there was 
whole blood available, and all of these variants were absent in whole blood.  
DIGITAL PCR
For 14 mutations observed in the primary tumor and/or the metastases, we had validated 
dPCR assays available (Supplementary Table 9). Using dPCR, 13 of 14 mutations (93%) 
observed in the primary tumor and/or the metastases were detected (Table 2). Of note 
is that the one mutation that was not detected was only observed in the primary tumor 
of patient 6 at a low frequency (5%), and not the metastases. Digital PCR was however 
able to detect all mutations that occurred in the liver metastasis of this particular patient. 
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TABLE 2. Detection of plasma ctDNA mutations using various techniques and strategies. 
Patient Gene Position Plasma IonPGM 
standard filtering 
VAF%
Plasma ionPGM 
modified filtering 
VAF%
Plasma OnTarget
VAF%
Plasma dPCR
VAF%
2 KRAS p.G12D . . . 1.94%
 PIK3CA p.E545K . . . 2.23%
       
3 TP53 p.R273H 7.3% 7.3% 3.5% 7.03%
       
5 TP53 p.R248Q . 2.2% 1.5% 2.7%
       
6 KRAS p.G12V 5.3% 5.3% 3.6% 8.5%
 TP53 p.R273H 12.2% 12.2% 4.9% 7.03%
 PIK3CA p.E545K . . . .
       
7 KRAS p.G12D . . 0.92% 1.57%
       
8 KRAS p.G12D . 2.3% 1.6% 1.66%
 TP53 p.R175H . . 2.8% no assay 
       
9 KRAS p.G12D 20.5% 20.5% 14.0% 12.87%
 TP53 p.R248Q 14.1% 14.1% 20.0% 15.02%
       
10 TP53 p.R282W . . 0.67% 2.94%
       
12 KRAS p.G13D . 1.5% 3.1% 3.96%
 PIK3CA p.E545K . . 2.7% 2.9%
Not detected variants are indicated with a dot. VAF%= variant allele frequency.
Compared to the OnTarget assay, dPCR detected two additional mutations, both in 
patient 2. Again, a significant number of mutations (9 out of 14) were detected in tumor-
adjacent tissue with normal appearing histology (Supplementary Table 10), confirming 
the findings with the OnTarget assay. None of these mutations were observed in whole 
blood. 
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TABLE 3. Associations between the number of CTCs, the percentage of small fragments and detection of 
somatic mutations with ionPGM using two filtering variants, and with OnTarget and dPCR. 
Patient Number of 
CTCs/30 mL
% of 
small DNA 
fragments
Mutations present 
in plasma with 
standard filtering
Mutations present 
with modified 
filtering
Mutations 
present with 
OnTarget assay 
Mutations 
present with 
digital PCR
9 0 46% yes (4 of 4) yes (4 of 4) yes (2 of 2) yes (2 of 2)
10 0 55% no no yes (1 of 1) yes (1 of 1)
11 0 64% no yes (2 of 2) not applicable not applicable
1 0 70% no yes (1 of 2) not applicable not applicable
7 1 61% yes (2 of 3) yes (2 of 3) yes (1 of 1) yes (1 of 1)
12 1 63% no yes (1 of 6) yes (2 of 2) yes (2 of 2)
3 1 66% yes (2 of 3) yes (2 of 3) yes (1 of 1) yes (1 of 1)
4 1 72% yes (1 of 1) yes (1 of 1) not applicable not applicable
8 2 62% yes (2 of 5) yes (4 of 5) yes (2 of 2) yes (2 of 2)
2 5 69% no no no yes (2 of 2)
5 8 73% no yes (2 of 3) yes (1 of 1) yes (1 of 1)
6 35 71% yes (3 of 6) yes (3 of 6) yes (2 of 3) yes (2 of 3)
For OnTarget and dPCR, only mutations previously found in the primary tumor or metastases are reported in 
thi
CTC ENUMERATION & DNA FRAGMENTATION ASSAY
To gain more insight into why ctDNA was or was not detected in some samples, the 
number of CTCs and fragmentation of cfDNA were assessed. CTC enumeration results 
of the main study were retrieved (16) for each patient at the time of cfDNA isolation 
(Table 3). In 4 patients, no CTCs were detected in 30 mL of blood, and in 1 of these 
patients, mutations in ctDNA were detected using IonPGM with our standard calling 
pipeline. The use of the modified pipeline, the OnTarget assay or dPCR however led 
to the identification of mutations in most patients, including the patients without 
CTCs. Because EDTA blood was used that was processed within 24 hours, it was 
also evaluated whether large DNA fragments from lysed leukocytes diluted out small 
DNA fragments and decreased sensitivity for ctDNA analyses. A dPCR-based assay 
was used to detect small fragments (136 bp) and large fragments (>400 bp), the latter 
indicative of the presence of large DNA fragments from lysed leukocytes. The median 
percentage of small DNA fragments out of the total number of fragments (small + large) 
was 65% (range 46% - 73%; Table 3). When patients were separated in two groups 
using the median of small fragments, we found that mutations in ctDNA using IonPGM 
and modified filtering were detected in 5 of 6 patients (in which 53% of all potentially 
detectable mutations were detectable) with a number of small fragments above the 
median, and in 5 of 6 patients (in which 62% of all potentially detectable mutations were 
detectable) with a number of small fragments below the median.      
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D I S C U S S I O N
In the era of precision medicine in oncology, there is a high need for accurate biomarkers 
that can be used before, during and after treatment in a minimally invasive way. Assessing 
ctDNA has sparked much interest to become such a biomarker. To date, most reports 
using ctDNA in CRC have reported on strategies using a limited set of genes (most often 
KRAS, BRAF & PIK3CA) (7, 14, 30-34) or an approach in which personalized assays 
based on mutations found in the primary tumor or metastases were developed to detect 
ctDNA (35, 36). Of note is that this latter approach also focuses on a limited set of 
somatic mutations only. The current study reported on the feasibility of a NGS panel 
on ctDNA in mCRC patients covering the 21 most prevalent and relevant genes in CRC 
known to date. It was observed that NGS with IonPGM is feasible on cfDNA, however 
only a limited number of variants observed in the primary tumor and the metastases 
could be retrieved in the cfDNA. A number of specific variants not observed in cfDNA 
with IonPGM could however be detected using alternative methods such as OnTarget 
enrichment followed by NGS and dPCR.
The sensitivity of IonPGM sequencing with standard filtering to retrieve mutations found 
in tissue in ctDNA was less than expected. As the plasma was not optimally collected 
(out of EDTA blood within 24 hours of the blood draw), the percentage of small fragments 
in cfDNA as a measure of leukocyte lysis was assessed. In addition, the number of 
CTCs was assessed as the number of CTCs was previously described to be associated 
with the probability to detect ctDNA in breast cancer (37). However, both the extent of 
leukocyte lysis as well as the number of CTCs did not provide obvious explanations as to 
why mutant ctDNA was or was not detected in some patients, although the power of this 
analysis was limited due to the small sample size of the presented cohort. Interestingly, 
for example, is patient 9, in whom ctDNA variant allele frequencies of 7 to 20% were 
observed, but in whom no CTCs were detected and who had the lowest percentage 
of small DNA fragments. This illustrates that we have limited insight into why some 
patients have high or low ctDNA frequencies. The ratio of ctDNA versus wildtype cfDNA 
probably plays an important role, however to date our understanding of this ratio, or a 
measure how to quantify it, is lacking.
The observation that a modified calling pipeline for ctDNA, instead of a standard calling 
pipeline based on calls by the TorrentSuite variant caller, resulted in an increased 
detection of mutations as found in tissue is in accordance with Couraud et al. (38). This 
group performed IonPGM sequencing on ctDNA in patients with non-small cell lung 
cancer and observed an increase in concordance rate between matched tissue and 
ctDNA from 16% to 58% using an in-house calling algorithm instead of using standard 
IonPGM variant calling. Also similar to our results with the modified calling pipeline is the 
report by Frenel et al. (39) whom reported that 59% of variants observed in metastases 
of patients with various tumors could be retrieved with IonPGM sequencing. However, 
others have also reported higher concordance between tissue and ctDNA using IonPGM 
of >80-90% (40, 41). A reason for the lower concordance as observed in our study may 
be that in our study CRC patients with oligometastatic disease were included, while in 
the studies with higher concordances heavily pretreated patients were included with 
probably a higher tumor load. This is also reflected by the fact that in these studies, very 
high ctDNA variant frequencies of >50% were observed in multiple patients.
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The presented results of high concordance between tissue and ctDNA when applying 
dPCR is in accordance with previous reports using similar techniques (30-33, 35, 36). 
High concordance between tissue and ctDNA with OnTarget followed by NGS was also 
observed in the current study, which is consistent with a previous report on this assay 
(14). Interestingly, using dPCR and the OnTarget assay somatic mutations were observed 
at very low frequencies in the tumor-adjacent control tissue with normal-appearing 
histology in the majority of patients, which were also observed in the matched tissue 
samples. As the majority of these mutations were observed by both methods, and the 
fact that none of these mutations were detected in whole blood of the same patient, we 
believe these are true somatic mutations present in normal-appearing tumor-adjacent 
tissue. An explanation for this finding may be that tumor DNA or tumor cells diffused or 
migrated into the surrounding normal tissue . Further examination of these findings is 
warranted, for example by investigating whether mutations in normal-appearing tissue 
are related to an increased chance of local disease relapse. 
The study as presented here has some limitations. The small sample size, combined 
with having to omit 3 primary tumor samples from the analysis due to FFPE-related 
variant noise, together with the low sensitivity of IonPGM sequencing to detect 
mutations, makes exploration whether or not ctDNA resembles the metastases rather 
than the primary tumor impossible. Also for this reason differences between patients 
with metachronous metastases versus synchronous metastases could not be explored. 
This data does however provide perspectives on the advantages and disadvantages 
of current ctDNA methods for detecting somatic mutations, and which one to use for 
which particular research purpose.
At least in this group of patients with oligometastatic disease, IonPGM sequencing on 
ctDNA lacks sensitivity to detect mutations, especially if the tissue mutational status 
is unknown. If the tissue mutational status is known, IonPGM with the modified calling 
pipeline is a feasible option but still sensitivity remains an issue to evaluate mutations 
in multiple genes in ctDNA. However, NGS of multiple genes like we performed here is 
probably the only option if resistance mutations not present in tissue and not previously 
reported need to be identified. This is also reflected by the fact that two novel mutations 
in ctDNA were identified that have not been previously reported. However, given the 
limited sensitivity of IonPGM sequencing to detect mutations this approach is likely to 
be of restricted value since many variants remain undetected. IonPGM sequencing of 
ctDNA in patients with higher tumor loads may however yield better results.  
If one would like to monitor certain mutations during treatment, an NGS approach using 
the primary tumor or metastases for discovery and subsequent tracing of mutations 
with dPCR is likely a successful approach, given the high sensitivity to detect mutations 
with dPCR as described here. Reinert et al. (35) reported on this approach and 
developed 2 to 6 individualized dPCR assays per patient for a total of 11 patients. They 
observed 100% sensitivity and 100% specificity to detect recurrence of CRC using 
these individualized dPCRs. However, disadvantages of such an approach are labor-
intensity because many individualized dPCR assays have to be produced. In addition, 
novel or known mutations causing resistance not present in the tissue, or developing 
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during treatment, are missed. Alternatively, the OnTarget assay had high sensitivity to 
detect many hotspot mutations, tackling the issue of labor-intensity and potentially of 
mutations not present in the tumor tissue. While dPCR seemed to be slightly more 
sensitive than the OnTarget assay to detect mutations in ctDNA and tumor-adjacent 
tissue, the OnTarget assay identified some mutations in tumor-adjacent normal tissue 
that were not detected in the matched tumor tissue. These mutations would certainly 
have been missed by an approach using dPCR assays based on previous findings in 
tumor tissue. Nonetheless, the OnTarget assay is still bound to a limited repertoire of 
mutations, and currently unknown resistance mutations are potentially missed by the 
technique. Finally, our sample size is limited to make firm conclusions about the OnTarget 
assay versus dPCR. At the very least, the OnTarget assay seems like an attractive option 
for ctDNA detection to screen for multiple mutations if no tumor tissue is available. 
In summary, three targeted methods to detect somatic mutations in ctDNA were 
described and pros and cons were provided for each method. Future efforts using 
ctDNA as a tool to detect somatic mutations in cancer patients should carefully consider 
all available methods for ctDNA detection and choose the method most fit to answer the 
specific research question.
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S U P P L E M E N TA R Y  D ATA
SUPPLEMENTARY TABLE 2. Included genes in custom IonPGM CRC 21-gene panel
Gene Aliases Number Amplicons Custom  IonPGM CRC 21-gene panel total size design (in bp)
TP53  19 1569
APC  97 8873
KRAS  3 363
ATM  138 9853
NF1  143 9310
PTCH1  57 4962
RB1  43 3084
CREBBP  89 7670
ARID1A  74 7330
SMAD4  27 1780
PIK3CA  3 354
KIT  42 3355
KMT2D MLL2 184 17208
BRAF  2 126
CDH1  35 2825
PTEN  18 1311
FBXW7  35 2675
MLH1  37 2581
EGFR  4 551
KDR VEGFR2 62 4371
NRAS  3 350
Total  1115 90501
SUPPLEMENTARY TABLE 1. Study flowchart of cfDNA analyses
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BRAF G469A 1406G>C
BRAF K601E 1801A>G
BRAF L597R 1790T>G
BRAF V600E 1799T>A
BRAF V600E_cpx 1799_1800TG>AA
BRAF V600K 1798_1799GT>AA
CTNNB1 S33Y 98C>A
CTNNB1 S45F 134C>T
CTNNB1 S45P 133T>C
CTNNB1 T41A 121A>G
EGFR G719A 2156G>C
EGFR G719C 2155G>T
EGFR G719S 2155G>A
EGFR E746_A750del 2235_2249del15
EGFR E746_A750del 2236_2250del15
EGFR E746_A750>IP 2235_2248>AATTC
EGFR E746_P753>VS 2237_2257>TCT
EGFR E746_S752>A 2237_2254del18
EGFR E746_S752>D 2238_2255del18
EGFR E746_S752>I 2235_2255>AAT
EGFR E746_S752>V 2237_2255>T
EGFR E746_T751>A 2237_2251del15
EGFR E746_T751>I 2235_2252>AAT 
EGFR E746_T751>IP 2235_2251>AATTC
EGFR E746_T751>V 2237_2252>T 
EGFR E746_T751>VA 2237_2253>TTGCT
EGFR E746_T751del 2236_2253del18
EGFR K745_E749del 2233_2247del15
EGFR L747_A750>P 2238_2248>GC
EGFR L747_A750>P 2239_2248>C
EGFR L747_E749del 2239_2247del9
EGFR L747_P753>Q 2239_2258>CA  
SUPPLEMENTARY TABLE 3. Included genes in OnTarget assay
Gene Amino Acid Mutation Coding DNA sequence Mutation
07
158
EGFR L747_P753>S 2240_2257del18
EGFR L747_S752>Q 2239_2256>CAA 
EGFR L747_S752del 2239_2256del18
EGFR L747_T751>P 2239_2251>C
EGFR L747_T751>Q 2238_2252>GCA 
EGFR L747_T751>S 2240_2251del12
EGFR L747_T751del 2238_2252del15
EGFR T790M 2369C>T
EGFR L858R 2573T>G
EGFR L861Q 2582T>A
FOXL2 C134W 402C>G
GNAS R201C 601C>T
GNAS R201H 602G>A
KRAS G12A 35G>C
KRAS G12C 34G>T
KRAS G12D 35G>A
KRAS G12R 34G>C
KRAS G12S 34G>A
KRAS G12V 35G>T
KRAS G13A 38G>C
KRAS G13C 37G>T
KRAS G13D 38G>A
KRAS G13S 37G>A
KRAS G13V 38G>T
KRAS Q61H 183A>C
KRAS Q61H 183A>T
KRAS Q61K 181C>A
KRAS Q61L 182A>T
KRAS Q61R 182A>G
KRAS A146T 436G>A
KRAS A146V 437C>T
SUPPLEMENTARY TABLE 3. Included genes in OnTarget assay
Gene Amino Acid Mutation Coding DNA sequence Mutation
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NRAS G12C 34G>T
NRAS G12D 35G>A
NRAS G12S 34G>A
NRAS G12V 35G>T
NRAS G13D 38G>A
NRAS G13R 37G>C
NRAS Q61H 183A>T
NRAS Q61K 181C>A
NRAS Q61L 182A>T
NRAS Q61R 182A>G
PIK3CA E542K 1624G>A
PIK3CA E545K 1633G>A
PIK3CA E545Q 1633G>C
PIK3CA Q546E 1636C>G
PIK3CA H1047L 3140A>T
PIK3CA H1047R 3140A>G
PIK3CA H1047Y 3139C>T
PIK3CA M1043I 3129G>A
PIK3CA E81K 241G>A
PIK3CA R88Q 263G>A
PIK3CA K111E 331A>G
PIK3CA R108H 323G>A
PIK3CA N345K 1035T>A
PIK3CA C420R 1258T>C
TP53 R175H 524G>A
TP53 G245D 734G>A
TP53 G245S 733G>A
TP53 R248Q 743G>A
TP53 R248W 742C>T
TP53 R249S 747G>T
TP53 R273C 817C>T
TP53 R273H 818G>A
TP53 R282W 844C>T
SUPPLEMENTARY TABLE 3. Included genes in OnTarget assay
Gene Amino Acid Mutation Coding DNA sequence Mutation
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SUPPLEMENTARY TABLE 4. Validation experiment using the OnTarget assay
5% Cell Line    Rep: 1  Rep: 2  Rep: 3
 Input Mass 29.6 Input Mass 32.9 Input Mass 43.2
Gene Mutation ddPCR VAF% Copies VAF% Copies VAF% Copies VAF%
BRAF V600E   3498 38.97%  4789 48.00%  5254 40.10%
CTNNB1 S33Y   2492 27.76%  2077 20.82%  2048 15.63%
EGFR G719S   2382 26.54%  2140 21.45%  2272 17.34%
EGFR delE746-A750 6.0% 509 5.7% 634 6.4% 590 4.5%
EGFR T790M 4.5% 826 9.2% 876 8.8% 696 5.3%
EGFR L858R 4.4% 592 6.6% 535 5.4% 555 4.2%
KRAS G12D 6.1% 659 7.3% 619 6.2% 601 4.6%
NRAS Q61K 6.4% 869 9.7% 801 8.0% 808 6.2%
PIK3CA E545K 6.1% 445 5.0% 666 6.7% 704 5.4%
PIK3CA H1047R   1915 21.34%  2069 20.74%  2438 18.60%
1% Cell Line    Rep: 1  Rep: 2  Rep: 3
 Input Mass 31.3 Input Mass 31.3 Input Mass 30.9
Gene Mutation ddPCR VAF% Copies VAF% Copies VAF% Copies VAF%
BRAF V600E   3304 34.80%  4286 45.12%  4565 48.75%
CTNNB1 S33Y   2024 21.32%  1809 19.05%  1764 18.84%
EGFR G719S   1866 19.66%  1368 14.41%  1609 17.19%
EGFR delE746-A750 1.4% 95 1.0% 100 1.0% 107 1.1%
EGFR T790M 0.9% 131 1.4% 126 1.3% 117 1.2%
EGFR L858R 0.9% 104 1.1% 63 0.7% 89 1.0%
KRAS G12D 1.3% 95 1.0% 91 1.0% 87 0.9%
NRAS Q61K 1.3% 149 1.6% 137 1.4% 126 1.3%
PIK3CA E545K 1.2% 85 0.9% 120 1.3% 122 1.3%
PIK3CA H1047R   1702 17.93%  1731 18.22%  2081 22.22%
0.1% Cell Line    Rep: 1  Rep: 2  Rep: 3
 Input Mass 26.1 Input Mass 34.3 Input Mass 28.8
Gene Mutation ddPCR VAF% Copies VAF% Copies VAF% Copies VAF%
BRAF V600E   3430 43.44%  4293 41.31%  3857 44.24%
CTNNB1 S33Y   1879 23.79%  1772 17.05%  1511 17.32%
EGFR G719S   1717 21.74%  1363 13.11%  1500 17.20%
EGFR delE746-A750 0.16% 16 0.2% 8 0.1% 8 0.1%
161
EGFR T790M 0.09% 14 0.2% 13 0.1% 14 0.2%
EGFR L858R 0.15% 3 0.0% 6 0.1% 8 0.1%
KRAS G12D 0.14% 9 0.1% 14 0.1% 11 0.1%
NRAS Q61K 0.12% 9 0.1% 17 0.2% 14 0.2%
PIK3CA E545K 0.12% 11 0.1% 8 0.1% 9 0.1%
PIK3CA H1047R   1497 18.95%  1815 17.46%  1919 22.01%
0.01% Cell 
Line    Rep: 1  Rep: 2  Rep: 3
 Input Mass 114 Input Mass 131 Input Mass 111
Gene Mutation ddPCR VAF% Copies VAF% Copies VAF% Copies VAF%
BRAF V600E   40 0  55 0  36 0
CTNNB1 S33Y   14 0.04%  16 0.04%  19 0.06%
EGFR G719S   16 0.05%  18 0.05%  11 0.03%
EGFR delE746-A750 0.011% 6 0.018% 13 0.032% 6 0.019%
EGFR T790M 0.015% 9 0.023% 9 0.027%
EGFR L858R 0.010% 5 0.014% 5 0.011%  
KRAS G12D 0.025% 8 0.023% 8 0.020% 5 0.014%
NRAS Q61K 0.008% 6 0.018% 6 0.015%  
PIK3CA E545K 0.011% 4 0.011% 8 0.021% 3 0.010%
PIK3CA H1047R   18 0.05%  14 0.03%  20 0.06%
BG WT 
Control    Rep: 1  Rep: 2  Rep: 3
 Input Mass 93 Input Mass 103 Input Mass 110
Gene Mutation ddPCR VAF% Copies VAF% Copies VAF% Copies VAF%
BRAF V600E           
CTNNB1 S33Y           
EGFR G719S           
EGFR delE746-A750  
EGFR T790M  
EGFR L858R  
KRAS G12D  
NRAS Q61K  
PIK3CA E545K  
PIK3CA H1047R           
SUPPLEMENTARY TABLE 4. Validation experiment using the OnTarget assay
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SUPPLEMENTARY TABLE 5. Patient characteristics
Pt Metachronous 
or synchronous 
metastases
Days between 
resection of 
primary and 
resection of 
metastasis
TNM stage at 
diagnosis
Number 
of liver 
metastases
Primary tumor 
preservation 
and % of tumor 
cells
Metastasis 
preservation 
and % of tumor 
cells
1 Metachronous 281 T2 N0 M0 1 FFPE; 40% FF; 100%
2 Metachronous 531 T3 N2 M0 1 FFPE; 50% FF; 100%
3 Metachronous 1841 T3 N2 M0 1 FFPE; 70% FF; 100%
4 Metachronous 2522 T3 N0 M0 1 FFPE; 90% FF; 90%
5 Metachronous 1129 T2 N0 M0 1 FFPE; 70% FFPE; 70%
6 Metachronous 270 T3 N1 M0 1 FFPE; 80% FF; 100%
7 Synchronous 0 T3 N0 M1 1 FF; 90% FF; 60%
8 Synchronous 0 T3 N1 M1 2 FF; 80% FF; 100%
9 Synchronous 0 T4 N1 M1 1 FFPE; 90% FFPE; 80%
10 Synchronous 0 T3 N0 M1 2 FF; 90% FF; 60%
11 Synchronous 0 T3 N2 M1 1 FF; 80% FF; 80%
12 Synchronous 0 T3 N0 M1 1 FFPE; 30% FFPE; 90%
Supplementary Table 6 is too large to be included in this thesis, can be found online 
http://www.moloncol.org/article/S1574-7891(16)30110-7/addons
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A B S T R A C T
BACKGROUND: There is a lack of robust and clinically utilizable markers for the 
diagnosis and prognostication of malignant pleural mesothelioma (MPM). Here, several 
novel approaches were optimized and explored for their potential to improve diagnosis 
and prognostication of MPM in pleural effusion (PE) and peripheral blood (PB). 
METHODS: CellSearch-based and flow cytometry (FC)-based assays using melanoma 
cell adhesion molecule (MCAM) to identify tumor cells in the PE and PB of MPM 
patients were optimized, validated, explored clinically, and in case of PE compared with 
cytological analysis. Additionally, tumor-associated circulating endothelial cells (tCECs) 
were measured in PB. These assay were investigated in a MPM cohort consisting of 
patients with histology-confirmed MPM (n=27), and in a control cohort of patients with 
alternative diagnoses (n=22). Exploratory analyses for the prognostic value of all assays 
were performed.
 
RESULTS: Malignancy of MCAM-positive cells in PEs from MPM patients was confirmed. 
Detecting MPM tumor cells in PE with CellSearch had poor specificity. FC had superior 
sensitivity (48%) to standard cytological analysis (15%) to detect MPM tumor cells 
(p=0.03). In PB CTCs were observed in 26%, and 42% of the MPM patients had tCECs 
above the upper limited of normal (ULN). In exploratory analyses the absence of tumor 
cells in PEs, and tCECs above the ULN appeared to be associated with worse overall 
survival.
 
CONCLUSION: MCAM-based FC analysis of PEs was more sensitive than routine 
cytological analysis. FC analysis of PEs and tCECs in PB are promising markers for the 
prognostication of MPM patients deserving further study.
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I N T R O D U C T I O N
Malignant pleural mesothelioma (MPM) is an aggressive and treatment-resistant 
asbestosis-induced neoplasm, whose incidence is expected to increase in the next 
years (1). Diagnosing MPM can be a challenging process. Especially the distinction 
between benign and malignant mesothelial proliferation can be extremely difficult (2). 
While markers such as mesothelin and osteopontin in plasma and pleural effusions 
(PEs) have been described, intending to improve diagnosis (3, 4), they are currently not 
used in clinically. Furthermore, the first encouraging reports of fibulin-3 (5) were shown 
to be disappointing in clinical practice as a diagnostic marker (6). Therefore, performing 
a pleural biopsy with histological sampling is still the golden standard for diagnosing 
MPM (7). A pleural biopsy, either done by video-assisted thoracic surgery (VATS) or with 
an open procedure, however, is an invasive procedure with associated morbidity, and 
even with adequate tissue it can be difficult to conclusively diagnose MPM (8). While 
MPM patients often present with pleural effusion (PE), fluid cytology alone has poor 
sensitivity of 26% (7). 
In addition to the difficulties in diagnosing MPM, another clinical challenge is the current 
lack of robust prognostic or predictive markers in MPM (9), limiting options to further 
personalize treatment in MPM patients. Putative interesting tools to improve diagnosis 
and prognostication of patients with MPM are the assessment of (circulating) tumor 
cells (CTCs) or circulating endothelial cells (CECs) in PEs and/or in peripheral blood (PB). 
CTCs are tumor cells detected in the peripheral circulation of patients with solid 
malignancies, and robust prognostic value of CTCs has been demonstrated for 
various tumor types (10-12). Of the currently available assays for CTC detection, the 
CellSearch CTC test is the only one that has been approved by the Food and Drug 
Administration (FDA). This method isolates tumor cells by immunomagnetic enrichment 
from bodily fluids, using ferrofluid nanoparticles coated with epithelial cell adhesion 
molecule (EpCAM) specific antibodies. We previously demonstrated that in breast 
cancer, melanoma cell adhesion molecule (MCAM or CD146) is an alternative marker 
that is expressed in EpCAM-negative cell lines (13), and that a modification in the 
CellSearch CTC enumeration kit can be used to detect MCAM-positive CTCs in breast 
cancer patients (14). The expression of MCAM in cytological smears of PEs of MPM 
patients has been suggested as a novel marker to discriminate between malignant and 
reactive mesothelium (15). However, the malignant nature of MCAM-positive cells was 
not confirmed, and sensitivity issues are likely to occur in MPM patients with a low 
occurrence of tumor cells in PE when preparing a cytological smear. Therefore, the use 
of a CellSearch MCAM-based enrichment approach might specifically detect MPM cells 
at low occurrences in PE and PB of MPM patients. 
CECs are endothelial cells that have been sloughed of the vessel wall, and are increased 
in the blood of patients with solid malignancies (16, 17). We recently introduced a novel 
marker, CD276, to distinguish CECs derived from normal endothelium from CECs 
that are tumor-derived (18). Especially since MPM is a well-vascularized tumor and 
angiogenesis is thought to be important in MPM (19), CECs may serve as a prognostic 
marker in MPM (20).    
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This research aimed to optimize techniques to detect tumor cells in the PE and PB of 
MPM patients, and to obtain more insight into the potential use of tumor cells detected 
by these techniques and CECs as biomarkers in MPM. To this end, data are presented 
here on a cohort of patients with PE due to MPM, and a cohort of patients with PE due 
to other causes. In all patients, PE was evaluated using MCAM-based methods with 
CellSearch and flow cytometry (FC). Additionally, the PB of MPM patients was evaluated 
for the presence of MCAM-CTCs and CECs.  
M E T H O D S
MCAM EXPRESSION AND RECOVERY OF MPM TUMOR CELLS 
Three primary MPM cell lines were stained with MCAM-APC (clone 541–10B2; Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany), and acquired on the FACS Fortessa flow 
cytometer (BD Biosciences, San Jose, CA, USA). Subsequently expression of MCAM was 
quantified compared to an unstained tube (signal/noise) using FCS Express (De Novo 
Software, Los Angeles, CA, USA). To determine the recovery of mesothelioma cells by 
using CellSearch technology (Janssen Diagnostics, Raritan, NJ, USA) with MCAM-based 
enrichment, 100 cells of MPM cell lines were spiked into 7.5 mL healthy donor blood in 
duplo. Then MCAM-based CTC enumeration was performed as described before (13, 
14). Briefly, to enumerate MCAM-CTCs the anti-EpCAM ferrofluids from the Circulating 
Epithelial Cell Kit (Janssen Diagnostics) were substituted with anti-MCAM ferrofluids 
from the Circulating Endothelial Cell Kit (Janssen Diagnostics). Other components of 
the Circulating Epithelial Cell Kit were left untouched. As an extra marker we used FITC-
conjugated CD34 (BD Biosciences, San Jose, CA, USA) to exclude cytokeratin (CK)18-
expressing CECs. MCAM-positive tumor cells were defined as CK8/18/19+, DAPI+, 
CD45- and CD34- after enrichment for MCAM. 
SNP ARRAY
PEs were flow cytometrically sorted using a FACS Aria sorter (BD Biosciences). The 
following populations were sorted: 1) MCAM+, DRAQ5+, CD45- cells; 2) MCAM-, 
DRAQ5+, CD45- cells and 3) CD45+ cells (leukocyte control), Supplementary Figure 
1. DNA was isolated from these populations using the Nucleospin DNA kit (Macherey-
Nagel, Düren, Germany), and DNA concentrations were quantified using the Qubit 
dsDNA HS Assay kit (Thermo Fisher, Waltham, MA, USA). DNA from these populations 
was then subjected to an SNP array using the CytoScan HD Array Kit (Affymetrix, 
Santa Clara, CA, USA). SNP array data were subsequently analyzed for the presence of 
copy number variations (CNVs) with the Chromosome Analysis Suite (ChAS) software 
(Affymetrix). 
PATIENTS AND INCLUSION
Two cohorts of patients were included for this prospective study. The first cohort (MPM 
cohort) consisted of patients with pathology-confirmed MPM or a high suspicion of 
MPM, presenting with PE who needed to undergo a pleural drainage or video-assisted 
thoracoscopy as part of standard care. The second cohort (control cohort) consisted 
of patients who presented with PE with a need to drain the PE as part of standard 
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care and in whom there was an established diagnosis other than MPM. In all patients 
the PE was sent to the pathological laboratory and processed as a part of standard 
care. Additionally, in all patients 20 mL of PE residual material was sent for the MCAM-
based CTC enumeration and FC. In the MPM cohort also 2x 10 mL of blood was drawn 
for MCAM-based CTC enumeration and CEC enumeration. This study ran from March 
2014 to January 2016 in two centers in The Netherlands (Erasmus MC Cancer Institute, 
Rotterdam, The Netherlands and Amphia Hospital, Breda, The Netherlands). All patients 
provided written informed consent, and the institutional boards of both participating 
centers approved the protocols (Erasmus MC ID MEC-2014-116; Netherlands Trial 
Register NTR4575).
 
PROCESSING OF PE AND PB SAMPLES
PEs were processed for standard cytology analyses as a part of standard care. All 
PE cytology slides were revised by one pathologist (MdB), who is a member of the 
Dutch national mesothelioma expert pathology panel. PEs for research purposes were 
always first filtered on a Falcon Cell Strainer (70 uM; Corning Incorporated, Corning, 
NY, USA) and processed within 24 hours after the pleural drainage. PB was drawn in 
CellSave tubes, and processed within 96 hours for MCAM-CTC enumeration and CEC 
enumeration.
The MCAM-based CTC enumeration in PEs (3 mL) and PB (7.5 mL) was performed as 
described above and before (13, 14). After centrifugation of the PE a ‘dummy’ tube with 
the bottom of the tube marked black (marking the area in which packed red blood cells 
are expected) was used to process the erythrocyte-poor PE samples on the CellSearch 
system. All CK+, DAPI+, CD45-, CD34- were considered positive events. In case 5 or 
more cells were closely connected to each other, the event was counted as a cluster.   
For flow cytometry of PE samples, 10 mL filtered PE was washed twice in phosphate 
buffered saline (PBS), and resuspended in 1 mL of PBS with 1% added bovine serum 
albumin. Then 100 uL of suspension was stained according to our PE antibody panel 
containing MCAM, DAPI, pan-cytokeratin (pan-CK), CD45, CD34, two MPM markers 
thrombomodulin (CD141) & podoplanin (D2-40) and two carcinoma-specific markers 
CEA (CD66e) and Claudin-4 (Supplementary Table 1 & 2). All antibodies were carefully 
titrated using positive and negative controls. DAPI and pan-CK were stained after fixation 
and permeabilization of the cells using the FIX&PERM Cell fixation and permeabilization 
kit (Nordic-MUbio, Susteren, the Netherlands) according to the manufacturers’ 
instructions. Samples were acquired on an FACS Fortessa flow cytometer (BD 
Biosciences) and were analyzed in FCS Express (De Novo Software). Cells that were 
MCAM+, DAPI +, pan-CK +, CD45- and CD34- were considered as putative MPM tumor 
cells. If these cells were also negative for carcinoma markers the cells were considered 
to be true MPM tumor cells. Positivity for a marker was evaluated against unstained 
controls for each fluorochrome, and positivity for the MPM and carcinoma markers was 
defined as ≥20% of the putative MPM tumor cells being positive for that marker.   
The enumeration of CECs was performed in 4 mL of PB as described before (17, 18). 
Cells that were CD34+, DRAQ5+, MCAM+, CD45- were defined as CECs, and CECs 
expressing CD276 were defined as tumor-associated CECs (tCECs).
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STATISTICAL CONSIDERATIONS AND ANALYSIS
Our primary objective was to increase sensitivity of PE evaluation in MPM with the 
MCAM-based CellSearch CTC enrichment compared to fluid cytology by the pathologist. 
Based on reports on the expression of MCAM in tissue (21) and PE specimens (15) of 
MPM patients, which was reported to be >80%, we assumed a sensitivity of at least 
80% could be reached by using the CellSearch enrichment technology. According to 
the literature, fluid cytology by a pathologist has a sensitivity of approximately 30%. 
We powered the study according to a statistical worst-case scenario of discordant 
proportions of 0.2 and 0.7 with the McNemar test, and 34 patients with a confirmed 
diagnosis of MPM would be needed to reach significance at level of α=0.05 and β=0.10. 
Twenty patients with PE due to another cause than MPM were planned to be included 
to explore specificity of the test. Secondary objectives of the study were to confirm 
the malignant nature of MCAM-positive tumor cells in PE, to develop a flow cytometric 
strategy on PE to diagnose MPM, to investigate the presence of CTCs and tumor-
associated CECs in PB, and to perform exploratory analyses on the prognostic value 
of all measured biomarkers in the context on this study. Numbers of cells between two 
cohorts were compared using the Mann-Whitney U test, and presence or absence of a 
biomarker between two groups were compared using the chi-square test. All reported 
p-values are two-sided, and a significance level α = 0.05 was used. All constructed 
Kaplan-Meier curves were exploratory as the number of patients and events was low, 
and no formal statistics were performed on these curves. All data analyses were done 
using Stata/SE version 12 (StataCorp LP, College Station, TX, USA).  
R E S U LT S
MCAM EXPRESSION AND RECOVERY OF MPM TUMOR CELLS 
MCAM expression was evaluated on three primary MPM cell lines. Two cell lines 
demonstrated high expression of MCAM, while one cell line had moderate to low 
expression of MCAM. The recovery of mesothelioma cells spiked into PB by using the 
MCAM-based CellSearch technology (performed in duplicate for each cell line) was 48-
63% for two MPM cell lines with high MCAM expression (MESO2 & MESO 4), and 4-8% 
for MPM cell line MESO 3 with low MCAM expression.
CONFIRMATION OF MALIGNANT NATURE
To confirm the malignant nature of MCAM-positive cells in PE, PEs from two patients 
with a pathology-confirmed diagnosis of MPM were flow cytometrically sorted 
for subsequent SNP array analysis. The MCAM-positive populations (MCAM+, 
DRAQ5+, CD45-) of both patients exhibited a number of CNVs, while the leukocyte 
population did not have CNVs as expected (Supplementary Figure 1). These 
results demonstrated the malignant nature of MCAM-positive tumor cells in PE 
of MPM patients and led to the initiation of the clinical study as described below. 
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TABLE 1. Baseline characteristics
MPM cohort (n=27) Control cohort (n=22)
Diagnosis
          Malignant pleural mesothelioma 27
          Epithelial malignancy 9
          Non-epithelial malignancy other than mesothelioma 3
          Benign 10
Gender
          Female (%) 1 (4%) 8 (36%)
Age
          Years (range) 70 (27 - 90) 67 (30 - 91)
WHO stage
          WHO 0 - 1 14 11
          WHO 2 11 8
          WHO 3 2 3
Smoking
          Never 9 6
          Past 10 11
          Current 8 5
Asbestosis exposure
          No 7 3
          Yes 20 6
          Unknown 0 13
Pathology
          Epithelial MPM 22
          Biphasic MPM 5
Stage
          MPM stage I-II 14
          MPM stage III-IV 13
Prior treatments for MPM
          No 19
          Yes 8
Currently on treatment for MPM
          No 23
          Yes 4
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CLINICAL STUDY - PATIENT CHARACTERISTICS
A total of 49 patients were included. The MPM cohort consisted of 27 patients, and 
the control cohort of 22 patients (Table 1). Patients in the control cohort were a mixed 
population with regard to malignant PEs (52%) and benign PEs (48%). In the MPM 
cohort, the majority of the patients had an epithelial type MPM (81%). The MPM patients 
were evenly divided between stage I-II (52%) and stage III-IV (48%), and most of them 
(70%) did not receive any prior treatments for MPM.   
PE ANALYSIS USING MCAM-BASED ENRICHMENT
PEs of 41 patients could be evaluated with the CellSearch MCAM-based enrichment. 
Cells meeting our criteria for tumor cells were observed in 21 of 23 patients (91%) in the 
MPM cohort, and in 17 of 18 patients (94%) in the control cohort. Median number of 
cells was 416/3 mL in the MPM cohort, and 440/3 mL in the control cohort (p=0.86). Cell 
clusters were present in 15 patients (65%) in the MPM cohort and 11 patients (61%) in 
the control cohort (p=0.79). 
PE ANALYSIS USING FC ASSAY
Using the FC assay, tumor cells meeting our criteria for MPM tumor cells (MCAM+, CK+, 
DAPI+, CD45-, CD34-, CEA-, Claudin-4-) were observed in the PE of 12 of 25 patients in 
the MPM cohort (48%). One patient (6%) in the control cohort had these cells, leading 
to a specificity of 94%. The median number of MPM tumor cell events in the MPM 
patients was 337 (range 23 – 10017 events). No MPM tumor cells were observed in 4 
patients with biphasic MPM histology. In the majority of MPM patients the tumor cells 
expressed thrombomodulin (92%); podoplanin expression on these cells was observed 
in only one patients’ PE (8%). MPM tumor cells expressed EpCAM in 33% of the cases, 
and GLUT1 in 58% of the cases. Of note was that in the control group two patients had 
MCAM-positive cells, not meeting the criteria for MPM tumor cells given the strong 
expression of epithelial markers CEA and Claudin-4, suggesting carcinoma cells. These 
patient indeed had metastatic epithelial cancers (breast cancer and thyroid cancer, 
respectively). 
Observations with the FC assay were compared to analysis by the pathologist, which is 
the current clinical standard. Paired observation data were present for 20 patients in the 
MPM cohort, and 18 patients in the control cohort. Pathology review correctly identified 
3 MPM patients as having MPM, and none of the patients in the control cohort were 
scored as having MPM, yielding a sensitivity of 15% and specificity of 100%. The FC 
assay identified 6 more MPM patients than pathology review of PE (Table 2, McNemar 
p= 0.03). The MPM patients in whom MPM tumor cells were observed using FC may have 
a better overall survival than patients in whom these cells were not observed (Figure 1). 
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CIRCULATING TUMOR CELLS AND CIRCULATING ENDOTHELIAL CELLS
CTCs were observed in 6 of 23 MPM patients (26%). In five patients one CTC per 7.5 mL 
of blood was observed, while one patient had 3 CTCs/7.5 mL. Two patients with CTCs 
had stage I-II disease, the other 4 patients with CTCs had stage III-IV disease. Four of 
the patients with CTCs had received prior chemotherapy. CEC enumeration results were 
available for 24 MPM patients. The median number of CECs was 37/4 mL (range 3 – 179). 
The tumor-associated marker CD276 was expressed in a median of 24% (range 7% - 
78%) of the CECs, resulting in 10 patients (42%) having tCECs higher than the upper 
limit of normal (≥8 tCECs/4 mL (18)). Four of these patients had stage I-II disease, and 6 
patients had stage III-IV disease. 
In exploratory survival analyses, the presence of CTCs or a CEC number above the 
median did not appear to be associated with OS. However, the presence of tCECs 
higher than the upper limit of normal may be associated with OS (Figure 2).
TABLE 2. Pathology review versus FC assay for patients with MPM in whom matched cytology and FC 
results from PE obtained on the same day were available
FC positive for MPM FC negative for MPM Total
PA positive for MPM 3 0 3
PA negative for MPM 6 11 17
Total 9 11 20
0.0
0
0.2
5
0.5
0
0.7
5
1.
00
12 11 10 6 5 4MPM tumor cells in PE
13 11 8 4 2 0No MPM tumor cells in PE
Number at risk
0 100 200 300 400 500
No MPM tumor cells in PE MPM tumor cells in PE
FIGURE 1. Overall survival according to the detection of tumor cells in pleural effusion using flow 
cytometry in the MPM cohort
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FIGURE 2. Overall survival in the MPM cohort according to biomarkers in peripheral blood. Panel A 
demonstrates the patients separated by the median number of CECs. Panel B demonstrates patients above 
and below the upper limit of normal for tCECs. Panel C demonstrates overall survival according to the presence 
of CTCs. 
D I S C U S S I O N
The diagnosis and treatment of MPM are hampered by limited availability of biomarkers 
that are clinically utilizable. The current manuscript presented and validated techniques 
to identify tumor cells in PE and PB of MPM patients and subsequently explored 
whether detecting these tumor cells in PEs might improve the diagnosis of MPM, and 
whether enumerating CTCs and CECs improves prognostication of MPM patients. It was 
observed that the enumeration of tumor cells in PE using the FDA-cleared CellSearch 
machine had limited specificity. Using FC higher sensitivity than with standard 
pathological assessment was observed and accompanied by acceptable specificity. 
Additionally, flow cytrometically enumerating tumor cells in PE and enumerating tCECs 
in PB seemed to have prognostic value.   
It was hypothesized that sensitivity and specificity for diagnosing MPM could be 
improved by enriching for the presumed MPM-specific marker MCAM. The malignant 
nature of MCAM-positive cells was confirmed using flow cytometric sorting combined 
with genomic analyses, and the CellSearch system was chosen to enrich and 
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enumerate these cells, as an MCAM-specific enrichment was already up-and-running 
on this machine (13, 14). Using this latter technique, however, it was observed that a 
large number of non-mesothelioma PEs had high numbers of cells meeting the criteria 
for tumor cells. This observation of limited specificity with the CellSearch machine is 
in accordance with the report by Schwed Lustgarten and colleagues (22). This group 
intended to improve diagnosis of malignant PEs by using the CellSearch system using 
EpCAM to enrich for CTCs. They observed up to 2556 EpCAM-positive cells/3 mL in 
patients with benign effusions and non-epithelial effusions. Since in the present study 
high number of cells with CellSearch were observed in patients who had no detectable 
MCAM-positive cells using FC, we hypothesize that reactive mesothelium is aspecifically 
enriched if it is excessively present in PE. When one of the PE samples was treated with 
immunoglobulins prior to CellSearch enrichment to block aspecific binding of MCAM 
antibodies to Fc receptors, 60% less cells were observed than without treatment with 
immunoglobulins. These findings suggest that aspecific binding of reactive mesothelium 
through Fc receptor binding partly underlies the limited specificity using CellSearch. The 
poor specificity as observed with CellSearch led to early discontinuation of the study, 
because the primary study endpoint could not be reached anymore. Using FC, better 
specificity than with the CellSearch system was observed. In addition, the FC assay had 
improved sensitivity over standard cytological analysis by an experienced pathologist. 
However, where the cytological review had 100% specificity, the FC assay had one false-
positive finding leading to 94% specificity. This finding should however be interpreted 
with caution, because beyond the diagnosis of a benign mesothelial proliferation in this 
patient, the patient is currently still clinically suspect for MPM. However, during a follow-
up period of 1.5 years, MPM has not been pathologically confirmed.
In the past years a lot of research has been done on novel markers to diagnose MPM in 
PEs, but none of these markers have been widely incorporated in clinical practice. Most 
recently, others have reported that p16 FISH and BRCA1-associated protein 1 (BAP1) 
immunohistochemistry may improve sensitivity of PE cytology, and have reported 
sensitivity of 45% to 84% for p16 and of 33% to 74% for BAP1 (23). The sensitivity 
of the flow cytometric assay in the current study falls into the range of these assays. 
Unfortunately, there was no availability of cytological slides to compare the FC assay 
with p16, BAP1 or MCAM staining on cytological slides. Importantly, however, the 
numbers of observed MPM tumor cells in PE using FC were often low, suggesting that 
there is a fairly low chance of them being detected with standard cytological analysis. 
Surprisingly, we observed that patients who had MPM tumor cells in their PE using FC, 
had improved OS compared to patients who did not have MPM tumor cells in the PE. If 
true, there are two possible explanations for this observation: 1) MCAM is a marker for 
good prognosis; 2) the presence of tumor cells in PE is related to an increased chance 
of response to therapy. Obviously, validation of this finding and if confirmed, exploration 
of the underlying reason in a larger cohort is necessary. 
In a quarter of the patients CTCs in the PB were observed using our MCAM-based 
enrichment. This CTC-positivity rate using MCAM-based CTC enrichment as reported 
here was lower than previously reported by other groups using the standard EpCAM-
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based CTC enrichment. The group of Yoneda and colleagues (24) reported 33% of their 
MPM patients to have EpCAM-positive CTCs, while Raphael et al. (25) detected EpCAM-
positive CTCs in 44% of their MPM patients. As MCAM is more widely expressed than 
EpCAM in MPM tissues, the lower CTC-positivity rate as observed in the current study 
was surprising. This finding may be explained by the inclusion of more patients with 
stage IV disease in both studies evaluating EpCAM-positive CTCs than in the current 
study. Our observations along with the observations regarding EpCAM-positive CTCs 
suggest that the presence of CTCs is limited in patients with MPM, as is also reflected 
by the fact that clinically detectable metastasis outside the thorax is a relatively rare 
and late event in MPM (26). The presence of MCAM-positive CTCs did not appear to 
be associated in exploratory overall survival analysis in our cohort. Also the presence 
of CECs above the median did not appear to be related to OS, however when only 
tCECs were analyzed they seemed to be of prognostic value for OS. Yoneda et al. (20) 
previously reported a modest relation between poor OS and high numbers of CECs in 
a cohort of 79 MPM patients. Our findings in a much smaller cohort of patients suggest 
that if a marker specific for tumor-associated CECs is added, thereby omitting CECs 
derived from normal vasculature (27), the prognostic power of CECs possibly improves.
In conclusion, this exploratory study demonstrated the malignant nature of MCAM-
positive cells in PEs of patients with MPM, and evaluated several markers to improve 
diagnosis and prognostication of patients with MPM. Enumerating tumor cells using FC 
and enumerating tCECs may lead to improvement of both and warrant further research 
in a larger cohort of MPM patients.
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S U P P L E M E N TA R Y  D ATA
SUPPLEMENTARY FIGURE 1. Gating strategy for flow cytometric sorting
185
SUPPLEMENTARY FIGURE 2. SNP arrays of gated populations presented in Supplementary Figure 
1. Blue lines represent the normal control lymphocytes (CD146-neg, CD45-pos, DNA+; gate 2), Purple lines 
represent putative tumor cells (CD146-pos, CD45-neg, DNA+; gate 3), and green lines represent a CD146-neg, 
CD45-neg, DNA+ population (gate 4). 
SUPPLEMENTARY TABLE 1. Flow cytometric panel for pleural effusion 
Tube Pacific blue Brilliant Violet 711 FITC PE PerCP PE-Cy7 APC
1 DAPI* CD146 unstained unstained CD45 CD34 unstained
2 DAPI* unstained unstained unstained CD45 CD34 pan CK* 
3 DAPI* CD146 unstained unstained CD45 CD34 pan CK* 
4 DAPI* CD146 CD66e CD141 CD45 CD34 pan CK* 
5 DAPI* CD146 EpCam D2-40 CD45 CD34 pan CK* 
6 DAPI* CD146 Claudin-4 GLUT1 CD45 CD34 pan CK* 
*: intracellular staining after fixation and permeabilization
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CHAP TER  9
Prognostic value and kinetics of circulating 
endothelial cells in patients with recurrent 
glioblastoma randomised to bevacizumab plus 
lomustine, bevacizumab single-agent or lomustine 
single-agent. A report from the Dutch Neuro-
Oncology Group BELOB trial
Nick Beije, Jaco Kraan, Walter Taal, Bronno van der Holt, 
Hendrika M. Oosterkamp, Annemiek M. Walenkamp, 
Laurens Beerepoot, Monique Hanse, Myra E. van Linde, 
Aja Otten, Rene M. Vernhout, Filip Y.F de Vos, 
Jan W. Gratama, Stefan Sleijfer, Martin J. van den Bent 
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A B S T R A C T
 
BACKGROUND: Angiogenesis is crucial for glioblastoma growth, and anti-vascular 
endothelial growth-factor (VEGF) agents are widely used in recurrent glioblastoma 
patients. The number of circulating endothelial cells (CECs) is a surrogate marker for 
endothelial damage. We assessed their kinetics and explored their prognostic value in 
patients with recurrent glioblastoma. 
METHODS: In this side-study of the BELOB trial, 141 patients with recurrent glioblastoma 
were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab 
plus lomustine. Before treatment, after 4 weeks and after 6 weeks of treatment, CECs 
were enumerated.
RESULTS: The number of CECs increased during treatment with bevacizumab plus 
lomustine, but not during treatment in the single-agent arms. In patients treated with 
lomustine single-agent, higher absolute CEC numbers after 4 weeks (log10 CEC  HR 0.41, 
95% CI 0.18-0.91) and 6 weeks (log10CEC  HR 0.16, 95% CI 0.05-0.56) of treatment were 
associated with improved OS. Absolute CEC numbers in patients receiving bevacizumab 
plus lomustine or bevacizumab single-agent were not associated with OS.
CONCLUSIONS: CEC numbers increased during treatment with bevacizumab plus 
lomustine but not during treatment with either agent alone, suggesting that this 
combination induced the greatest vascular damage. Although the absolute number of 
CECs was not associated with OS in patients treated with bevacizumab either alone or in 
combination, they could serve as a marker in glioblastoma patients receiving lomustine 
single-agent. 
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I N T R O D U C T I O N
Glioblastoma is the most common and most aggressive malignant primary brain 
tumor in adults. Angiogenesis is crucial for glioblastoma growth, and the presence of 
endothelial proliferation is a key WHO-criterion for diagnosing glioblastoma (1). Tumor 
vessels in glioblastoma are morphologically and functionally different from normal 
blood vessels and are characterised by their high complexity, disorganisation and 
leakiness (2). Hypoxic glioblastoma tumor cells are able to interact with endothelial cells 
and promote angiogenesis by producing high numbers of vascular endothelial growth 
factor (VEGF) (3, 4). Therefore, a strong rationale exists for using anti-VEGF agents such 
as bevacizumab, a humanized monoclonal antibody against circulating VEGF, in the 
treatment of glioblastoma. Accordingly, numerous clinical trials have explored the value 
of bevacizumab in glioblastoma patients (5-7), but none of them showed clear survival 
benefit of single-agent bevacizumab in newly diagnosed or recurrent glioblastoma. 
Treatment response is critical in these studies and in daily clinical practice and is generally 
assessed by radiographic response on MRI. However, besides inter-observer (8) and intra-
observer (9) variability in radiographic assessments, clear limitations are encountered 
with current treatment response evaluation in glioblastoma, especially in patients 
treated with anti-VEGF monoclonal antibodies. Most importantly, the administration of 
anti-VEGF monoclonal antibodies may result in radiographic pseudoresponse caused 
by the rapid normalisation of abnormally permeable blood vessels (10). While these 
issues were taken into account in the revised response assessment criteria proposed 
by the Response Assessment in Neuro-Oncology (RANO) working group (11), alternative 
methods of response assessment focusing on the extent of angiogenesis could be 
helpful to guide prognosis and treatment success in glioblastoma.    
Circulating endothelial cells (CECs) are mature endothelial cells that are present in 
the peripheral circulation and are presumed to be a marker of vascular injury (12) and 
angiogenesis. CECs were shown to have a clinically relevant prognostic value in various 
solid tumors (13). Given the high rate of angiogenesis in glioblastomas and the lack of 
prognostic markers for anti-VEGF treatments in general, we prospectively assessed the 
kinetics and prognostic relevance of CECs in the BELOB trial (14). In this randomised 
phase II trial, patients were treated for recurrent glioblastoma with bevacizumab plus 
lomustine, or with bevacizumab or lomustine single-agent.
M E T H O D S
 
PATIENTS AND TREATMENT
This prospective study was a side-study of the randomised multi-centre phase II trial 
from the Dutch Neuro-Oncology Group (LWNO) “BELOB” (Netherlands Trial Register 
ID NTR1929). In-depth information regarding eligibility criteria, treatment and outcome 
assessments were described in the paper regarding the primary clinical endpoints of 
the study (14). Briefly, patients with recurrent glioblastoma were stratified according to 
centre, ECOG performance status and age, to be subsequently randomised between 
bevacizumab in combination with lomustine, bevacizumab single-agent or lomustine 
single-agent. 
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Lomustine was given orally every 6 weeks, for a maximum of 6 cycles. Bevacizumab 
was given intravenously every two weeks until disease progression. One treatment cycle 
was defined as 6 weeks. Overall survival was measured from the day of randomisation 
until death from any cause.
The central and local institutional review boards approved the protocol and all patients 
provided written informed consent. Peripheral blood (PB) samples for CEC analyses 
were acquired in CellSaveTM tubes (Janssen Diagnostics, Raritan, NJ, USA) before 
the start of treatment (baseline) and after 4 and 6 weeks of treatment. Samples were 
maintained at room temperature and processed within 96 hours of blood collection.
ENUMERATION OF CIRCULATING ENDOTHELIAL CELLS
CECs were enumerated according to our previously reported flow cytometric approach 
(15), in which we demonstrated excellent reproducibility of the assay between duplicate 
CEC samples. The following directly conjugated monoclonal antibodies were used to 
identify CEC: CD34-FITC (clone 8G12; BD Biosciences, San Jose, CA, USA), CD146-
APC (clone 541-10B2; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and CD45-
PerCP (clone 2D1; BD Biosciences). DRAQ5 (Biostatus Ltd, Shepshed, UK) was used as 
a cell permeable nuclear dye to exclude platelets and microparticles. The definition of a 
CEC was CD34+, CD146+, CD45- and DRAQ5+. 
Samples were acquired on a FACS Canto II or Fortessa flow cytometer (BD Biosciences) 
and were later analysed using FCS Express (De Novo Software, Los Angeles, CA, USA). 
One experienced technician (JK) evaluated and checked all analyses before the result of 
the CEC enumeration were considered final to minimise inter-rater variability. 
STATISTICAL ANALYSIS
Several time intervals were constructed to minimise inter-patient variability regarding 
the time of CEC measurement. For a sample to be eligible as a baseline sample, the 
blood should have been drawn at least within two weeks before the start of treatment. 
A sample was eligible as a 4 weeks sample if the sample was drawn between day +25 
and +31 after treatment start, while a sample was eligible as a 6 weeks sample if the 
sample was drawn before the administration of the second cycle and between day +39 
and +45 after treatment start. 
For comparisons between CEC numbers at baseline versus during treatment in the 
same treatment arm, the Wilcoxon signed-rank test was used. Correlation between 
corticosteroid use and CEC numbers was assessed using point biserial correlation. 
Correlation between maximum tumor diameter and CEC numbers was assessed using 
Spearman correlation. CEC values were log 10-normalised before inclusion in Cox 
regression analyses. For the increase or decrease of CECs relative to baseline, the 
logarithm was calculated of the quotient between baseline (t0) and the appropriate time 
point (tx), formula: log10 (tx/t0). 
In case a statistically significant result was observed in the univariate Cox regression 
crude hazard ratio (HR) calculation, an adjusted HR was calculated adjusting for maximum 
tumor diameter and corticosteroid use at baseline or after 6 weeks of treatment. These 
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TABLE 1. Baseline patient characteristics (n=141) 
Parameter Value
Age, median (range) 57 (24-77)
Sex female (%) 55 (39%)
WHO status (%)
          WHO 0 40 (28%)
          WHO 1 86 (61%)
          WHO 2 15 (11%)
Patients using corticosteroids (%) 68 (48%)
Maximum enhancing tumor diameter in mm, median (range) 35 (11-93)
Treatment arm (%)
          Bevacizumab + Lomustine 51 (36%)
          Bevacizumab single-agent 48 (34%)
          Lomustine single-agent 42 (30%)
parameters were not available for the 4 weeks after start of treatment sample, thus no 
adjusted HRs were calculated for this sample. Maximum enhancing tumor diameter was 
assessed by RANO criteria (11). For a maximum diameter to be eligible for adjustment 
in the multivariate model after 6 weeks of treatment, the corresponding MRI should 
have been performed before the administration of the second cycle of lomustine (only 
if applicable). All reported p values are two-sided, and a significance level α = 0.05 was 
used. All data analyses were done using Stata/SE version 12 (StataCorp LP, College 
Station, TX, USA).  
R E S U LT S
PATIENT AND TREATMENT CHARACTERISTICS
A total of 153 patients were enrolled in the BELOB study between December 2009 
and November 2011. From the 148 eligible patients as reported in the paper regarding 
the primary endpoint (14), 141 patients were included in this side-study. Patient and 
treatment characteristics are presented in Table 1. 51 patients were randomised in 
the bevacizumab plus lomustine arm, 48 patients received bevacizumab single-agent 
therapy, while 42 patients received lomustine single-agent therapy. Only four patients 
were still alive at the end of follow-up, and these patients had a median follow-up of 35.3 
months (range 28.9 - 41.5 months).  
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CEC MEASUREMENTS AND KINETICS
A total of 382 samples were evaluated for the presence of CECs. 30 samples were 
excluded from the analysis because they were not drawn in the appropriate time interval 
(n=28) or because they were drawn after the administration of the second cycle (n=2). 
Consequently, out of 423 expected samples, 352 samples (83% of expected samples) 
were included in the final analysis, of which 129 were eligible as baseline samples, 119 
were eligible as 4 weeks samples and 104 were eligible as 6 weeks samples (Table 2). 
Baseline CEC numbers were not significantly correlated with corticosteroid use 
(r=0.06, P=0.54) or the maximum diameter of the tumor lesion (r=-0.11, P=0.22). Since 
we expected that CEC kinetics would differ between the three treatment arms, we 
analysed CEC kinetics separately in each treatment arm (Figure 1). In patients receiving 
bevacizumab plus lomustine combination therapy, patients had higher CECs after 4 
weeks (P<0.001) and 6 weeks (P<0.001) of treatment compared to the baseline value. 
In contrast, in patients receiving bevacizumab single-agent and in patients receiving 
lomustine single-agent, CECs at baseline were similar to CECs after 4 weeks and 6 
weeks of treatment.      
FIGURE 1. Box-whisker plots of 
CEC kinetics during treatment per 
treatment arm. (boxes show 25th 
percentile, median and 75th percentile, 
whiskers show the lower and upper 
adjacent values, according to Tukey. 
Dots represent outliers).
TABLE 2. Characteristics of CEC 
measurements per treatment arm   
Bevacizumab + Lomustine Bevacizumab single-agent Lomustine single-agent
Month 
of CEC 
count
n median  (CEC/4 mL)
range  
(CEC/4 mL) n
median  
(CEC/4 mL)
range  
(CEC/4 mL) n
median  
(CEC/4 mL)
range  
(CEC/4 mL)
Baseline 47 54 9 - 282 40 78 7 - 793 37 52 7 - 292
4 weeks 43 128 19 - 2122 41 76 17 - 1056 35 65 7 - 2232
6 weeks 39 170 24 - 1796 38 103 4 - 1330 32 71 16 - 442
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ASSOCIATION OF CEC NUMBERS WITH OVERALL SURVIVAL
The prognostic relevance of CECs with respect to overall survival in this study was 
explored using a Cox regression model. No association was found between the absolute 
number of CECs at baseline and overall survival. Since we observed that CEC kinetics 
differed between the three treatment arms, Cox regression for absolute CEC counts 
after 4 weeks and 6 weeks of treatment with respect to OS was performed separately 
for each treatment arm (Table 3). In patients receiving bevacizumab plus lomustine and 
bevacizumab single-agent, no significant associations between absolute CEC counts 
and OS were observed. However, in patients receiving lomustine single-agent, an 
association between OS and higher absolute CEC counts at 4 weeks (log10 CEC 4 weeks 
 HR 0.41, 95% CI 0.18-0.91) and 6 weeks (log10CEC 6 weeks 
 HR 0.16, 95% CI 0.05-0.56) 
was observed. After addition of data regarding corticosteroid use and the maximum 
tumor diameter after 6 weeks of treatment to the model, the CEC count after 6 weeks 
was still significantly associated with OS (log10CEC 6 weeks 
 HR 0.18, 95% CI 0.05-0.74). 
Besides the absolute threshold model as described above, we also analysed whether 
changes in CECs from baseline to 4 weeks and baseline to 6 weeks were associated 
with OS in the Cox regression model. In contrast to our findings using the absolute CEC 
numbers after 4 weeks and 6 weeks of treatment, we did not observe any association 
between CEC changes and OS.
TABLE 3. Cox regression absolute CEC numbers 
CEC time point & treatment arm log10CEC crude HR (95% CI) P-value log10CEC
Baseline all treatment arms 1.10 (0.68 - 1.80) 0.69
4 weeks bevacizumab + lomustine 1.21 (0.59 – 2.50) 0.59
4 weeks bevacizumab single-agent 1.32 (0.66 – 2.65) 0.44
4 weeks lomustine single-agent 0.41 (0.18 - 0.91) 0.03
6 weeks bevacizumab + lomustine 0.71 (0.27 - 1.86) 0.49
6 weeks bevacizumab single-agent 1.09 (0.49 - 2.46) 0.83
6 weeks lomustine single-agent 0.16 (0.05 - 0.56) 0.004 *
* log10CEC adjusted HR 0.18 (95% CI 0.05-0.74), P=0.02. Adjusted HR was only calculated if crude HR was 
significant and adjusted for corticosteroid use and maximum tumor diameter after 6 weeks of treatment. 
No data regarding corticosteroid use and tumor diameter after 4 weeks of treatment were available.
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D I S C U S S I O N
There is a clear clinical unmet need for alternative response evaluation during treatment 
of glioblastoma. As glioblastomas are highly angiogenic tumors, we proposed CEC 
enumeration as a surrogate marker for endothelial damage and assessed CEC kinetics 
and explored their possible prognostic relevance during the randomised BELOB 
trial. We observed that CECs increased only during treatment in patients receiving 
combination treatment with bevacizumab plus lomustine. We also found an association 
between higher absolute CEC numbers and improved overall survival during treatment 
with lomustine single-agent, but not in bevacizumab treated patients.
Our observation of increased CECs during treatment with bevacizumab plus lomustine 
in contrast to the single-agent treatment arms suggests that there is a synergistic 
effect of bevacizumab and lomustine in triggering endothelial damage. The results from 
the BELOB study suggested survival benefit from the combination of bevacizumab 
and lomustine, as the primary endpoint (OS at 9 months) was reached to justify the 
exploration of this combination treatment in a phase III trial (14). Our results indicate 
that this treatment combination may have had a positive effect in triggering endothelial 
damage in the glioblastoma tumor itself. Our observation of increased CECs during 
treatment with bevacizumab and lomustine cytotoxic chemotherapy is in accordance 
with previous reports in metastatic breast cancer and advanced colorectal cancer (16, 
17), in which CEC numbers were increased after combination treatment with cytotoxic 
chemotherapy and bevacizumab.   
During treatment with the single-agent lomustine cytotoxic chemotherapy, CEC numbers 
remained stable. Reynes and colleagues observed a similar pattern in glioblastoma 
patients before and after treatment with cytotoxic chemotherapy and radiotherapy (18). 
To our knowledge, no other studies have reported on CEC changes during bevacizumab 
single-agent therapy, therefore our finding of stable CECs during bevacizumab single-
agent therapy remains to be confirmed by other studies.
We did not observe an association between baseline CEC counts and OS. In addition, 
we explored whether or not absolute CEC numbers during treatment or the relative 
changes during treatment were associated with outcome. During single-agent therapy 
with lomustine, an association was revealed between improved OS and higher 
absolute CEC numbers after 4 weeks and 6 weeks of treatment. Since we observed 
the association between CECs and OS in the patients receiving single-agent lomustine 
after both 4 weeks and 6 weeks of treatment, and this association remained statistically 
significant in multivariable Cox regression analysis, it is unlikely that these findings are 
false positives. Our findings that CEC changes relative to baseline did not correlate with 
OS, suggests that the absolute CEC number, which reflects the extent of endothelial 
damage during treatment at a specific point in time, is more important than the actual 
pattern of endothelial damage over time.  
The lack of association between baseline CECs and OS is in contrast to two other 
glioblastoma studies (18, 19). It should however be noted that in these studies other CEC 
enumeration techniques were used. It is known that the CEC compartment in patients 
with solid tumors consists of both tumor-derived endothelial cells (tumor CECs; tCECs) 
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and normal tissue-derived endothelial cells (normal CECs; nCECs). There are a few 
potential pitfalls associated with measuring the nCEC compartment. Since the nCEC 
compartment is relatively large, smaller changes taking place in the tCEC compartment 
may be masked. In addition, changes in the nCEC compartment because of non-tumor 
related causes might lead to incorrect interpretations regarding the tCEC compartment. 
The use of tumor-endothelial markers therefore allows more precise tCEC measurement. 
Cuppini and colleagues used a putative tumor-endothelial specific marker (CD109) to 
detect CECs in their study (19). 
The study by Cuppini et al. reported decreased CD109-positive CECs in patients who 
responded to bevacizumab plus irinotecan and bevacizumab single-agent after 2 
months of treatment, while we could not find such associations for the bevacizumab-
containing regimens in our study. Interestingly, while the study by Cuppini et al. did not 
observe such an association between CD109-CECs and response in patients receiving 
cytotoxic chemotherapy, we observed that higher CEC numbers were associated with 
improved OS only in the single-agent lomustine cytotoxic chemotherapy group. It 
should be realised however that there are important differences between the used CEC 
enumeration method by Cuppini and colleagues and our CEC enumeration method, 
which may explain differences in prognostic value between our studies. Cuppini et al. 
investigated an entirely different CEC population than we did, with no CD146 expression 
(20). While they used CD31 to identify a CD109-positive, CD146-negative CEC population 
and a separate CD146-positive, CD109-negative CEC population with no overlap 
of both markers, we used CD34 to identify CD146-positive CECs. Apart from these 
differences in CEC enumeration techniques, differences in the chosen fixed time points 
and differences in treatment regimens may also explain the differences between our 
studies. Another explanation for the differences between our studies may be that single-
agent irinotecan has no proven efficacy in glioblastoma (5), in contrast to lomustine.  
The most likely explanation that can be thought of as to why we observed prognostic 
value of circulating endothelial cells in the patients receiving lomustine single-agent 
but not in patients receiving bevacizumab-based therapy is our sample size. Although 
the number of patients per treatment arm was relatively large for any study evaluating 
recurrent glioblastoma patients, only a limited number of patients were evaluated 
per treatment arm. This may have provided insufficient statistical power to associate 
CEC numbers with OS in the bevacizumab-based treatment arms. However, we can 
speculate on biological mechanisms that may have accounted for the lack of prognostic 
value in the bevacizumab-based treatment arms as well. Since CEC numbers remained 
stable in the whole group of lomustine single-agent treated patients, high CEC numbers 
during treatment in the lomustine single-agent arm may represent only those patients 
in whom a larger extent of endothelial damage was present as a consequence of more 
lomustine-induced damage of the tumor. In contrast to the lomustine single-agent arm, 
CECs increased in the whole group of patients receiving bevacizumab plus lomustine, 
suggesting that endothelial damage occurred in the majority of these patients. The 
origin of CECs responsible for the increased CEC counts (from the tumor vasculature 
or the normal vasculature) is however unknown. Endothelial damage of tumor vessels 
might have occurred in the majority of patients because of an improved penetration 
of lomustine into the tumor, which has been demonstrated in preclinical experiments 
using neuroblastoma xenografts treated with bevacizumab and systemic chemotherapy 
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(21). Alternatively, combination treatment with lomustine and bevacizumab might have 
triggered significant endothelial damage in normal tissues in addition to tumor tissue, 
consequently masking changes in the tCEC compartment. Both these mechanisms may 
have made it more challenging to associate CECs with outcome in the bevacizumab 
plus lomustine combination arm, which further stresses the high need for robust assays 
to discriminate tCECs from nCECs. The lack of association between CEC numbers 
and outcome in the bevacizumab single-agent arm is probably due to the fact that 
bevacizumab as a single-agent has low activity in glioblastoma (14).   
There are several strong points of our study including the randomised set-up of our 
study, the high number of collected samples and the use of OS as the endpoint for 
associations with CECs. However, our study also had some limitations. The number of 
patients per treatment was relatively limited. In addition to limiting the statistical power 
of associating CEC numbers with OS in the bevacizumab-based treatment arms as 
mentioned before,, the limited number of patients prevented a definition of CEC cut-off 
points associated with prognosis and did not allow intergroup comparisons.
Another limitation is that the CEC assay used in our study does not specifically detect 
tumor-derived CECs. Our observation that CECs increased during treatment with 
bevacizumab plus lomustine but were not associated with prognosis, may have been 
caused by changes occurring in the nCEC compartment, therefore masking changes 
in the tCEC compartment. We recently reported that CD276 is a putative tCEC marker 
that was expressed more highly in CECs from patients with glioblastoma than in CECs 
from healthy donors (22). We are currently participating in an EORTC phase III study 
that compares outcomes following bevacizumab plus lomustine versus lomustine 
single-agent in recurrent glioblastoma (trial registry number NCT01290939); it includes 
a side-study to evaluate the clinical value of CD276+ tCECs. This will enable us to 
validate our findings regarding the prognostic value of CECs and possibly CD276+ 
tCECs in glioblastoma patients receiving lomustine single-agent. In addition, as we 
believe CD276+ tCECs are more sensitive for measuring the tCEC compartment, we 
hope to identify the true clinical value in patients receiving bevacizumab plus lomustine 
combination therapy.
Altogether, the results from our study indicate that it may be worthwhile to further 
explore CEC enumeration as a marker in recurrent glioblastoma, as was also suggested 
by Cuppini and colleagues. Given the heterogeneity of tumor types and patient 
populations, different anti-tumor agents administered and different CEC enumeration 
techniques used, one should nonetheless be careful in interpreting CEC data between 
studies (13, 23). Consensus is needed on the optimal CEC enumeration technique, as 
this would enable researchers to compare findings between studies and ultimately 
take the application of CECs to the next level. In addition, the initiation of studies using 
promising tCEC markers will be essential for CECs to eventually make it as a reliable and 
robust biomarker in clinical oncology.
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A B S T R A C T
Although outcomes following allogeneic stem cell transplantation (allo-SCT) have 
improved, graft-versus-host disease (GVHD), infections and conditioning related toxicity 
still cause significant morbidity and mortality. Circulating endothelial cells (CECs) 
are mature endothelial cells found in the peripheral blood and are presumed to be a 
marker of vascular damage. We here used CEC enumeration to assess the extent of 
conditioning-related endothelial damage, enabling to compare the extent and duration 
of vascular damage between myeloablative (MAB) and reduced intensity conditioning 
(RIC) regimens. In addition, we explored the use of CECs as a marker for GVHD or post-
transplant infections. CECs were enumerated by a flow-cytometric approach in 112 
adult patients undergoing allo-SCT at fixed time points up to 24 months post-transplant. 
Recipients of MAB conditioning had significantly more CECs than patients receiving RIC 
in the first year post-transplant. Strikingly, we observed lower CEC numbers in patients 
with either acute or chronic GVHD, evoking the hypothesis whether alloreactivity 
towards endothelial cells might play a role. CECs appeared to express both class I and 
class II HLA antigens. Collectively, the lower CEC counts during RIC regimens suggest 
less vascular damage compared to MAB, which may translate into less cardiovascular 
morbidity in the long term. Further studies are warranted to investigate the clinical 
relevance of the increased CEC numbers in MAB conditioned allo-SCT patients, as well 
as to investigate alloreactivy towards endothelial cells during GVHD.
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I N T R O D U C T I O N
Allogeneic stem cell transplantation (allo-SCT) has the potential to cure patients with 
various hematological malignancies. Significant morbidity and mortality however 
occurs following allo-SCT due to complications such as graft-versus-host disease 
(GVHD), infections and conditioning related toxicity. Additionally to early morbidity, it is 
increasingly appreciated that long-term allo-SCT survivors have an increased incidence 
of cardiovascular risk factors and have a greater burden of cardiovascular morbidity 
(1, 2) with odds ratios ranging from 2.3 to 3.0 in recipients of allo-SCT compared to a 
matched general population (2).
There is mounting evidence that many of the complications of allo-SCT are at least 
partially related to endothelial damage. Consequently, there is a high need for parameters 
to accurately assess allo-SCT conditioning regimen-related effects on the endothelium 
as well as the potential role of the endothelium in the untoward events accompanying 
allo-SCT. Circulating endothelial cells (CECs) are mature endothelial cells present in the 
peripheral circulation and are a surrogate marker for endothelial damage. In a previous 
study to investigate the impact of conditioning regimen-related endothelial damage 
following allo-SCT, it was demonstrated that patients who received reduced-intensity 
conditioning (RIC) had significantly lower CEC numbers than patients who underwent 
myeloablative (MAB) conditioning (3). However, patients were only followed for 21 days 
post-transplant and consequently the extent of long-term endothelial damage was not 
established. 
Given the current trend in allo-SCT towards the use of more RIC regimens (4), we 
investigated the impact of RIC versus MAB conditioning on endothelial damage in 
greater detail. CECs were enumerated at fixed time points in a large group of adults 
undergoing allo-SCT for up to 2 years post-transplant. We also explored the use of 
CECs as a putative marker for GVHD and infections. 
M E T H O D S
PATIENTS AND BLOOD COLLECTION
This retrospective, single-center study included adult patients receiving allo-SCT in the 
Erasmus MC Cancer Institute in Rotterdam between August 2009 and November 2011 
in two prospective trials. 
One of these trials involved sibling donor patients and matched unrelated donor 
patients (Netherlands Trial Registry -NTR- number NTR2252, HOVON 96), while the 
other trial involved double umbilical cord blood patients (NTR1573, HOVON 106) (5, 
6). The institutional review board approved the protocols, and all patients and donors 
provided written informed consent. Peripheral blood (PB) samples were acquired in 
EDTA tubes at baseline (one month before transplantation) and 3, 6, 12 and 24 months 
post-transplant to determine post-transplant kinetics of CECs. In patients undergoing 
a double umbilical cord blood transplantation (dUCBT), additional PB samples for 
the same purpose were acquired at 1 and 2 months post-transplant. Samples were 
maintained at room temperature and processed within 24 hours of blood collection.
207
CONDITIONING REGIMEN AND SUPPORTIVE CARE
All patients received either a RIC, RIC-umbilical cord blood (RIC-UCB)  or a MAB 
regimen. TBI in the RIC regimen consisted of 2 Gy or 4 Gy, while TBI in the RIC-UCB 
regimen consisted of 4 Gy. MAB TBI dose was 10 Gy or 12 Gy in all patients.
All MUD and sib donors received granulocyte colony-stimulating factor (G-CSF; 2x 5 µg/
kg s.c.) to mobilize peripheral blood stem cells, starting at day -5 and ending at the last 
day of apheresis. Stem cells were infused at day 0 in all cohorts. In the dUCBT cohort, 
grafts were routinely infused at two consecutive days (day 0 and day +1). Hematopoietic 
growth factors (G-CSF) were not routinely given to allo-SCT recipients in any of the 
cohorts. 
All patients received cyclosporine A (CsA; trough level 250-350 μg/l) and mycophenolate 
mofetil (MMF; 2 x 16 mg/kg) as additional post-transplant GVHD prophylaxis for at least 
three months and one month, respectively, with gradual tapering of the drug thereafter. 
Acute GVHD (aGVHD) was graded according to the Glucksberg criteria updated 
according to Przepiorka et al. (7, 8). All patients who suffered from aGVHD grade II-IV 
received prednisone (2 mg/kg/day). Chronic GVHD (cGVHD) was scored according to 
the Seattle classification for limited and extensive chronic GVHD (9). Chronic GVHD for 
which local therapy was not applicable, was treated with a combination of prednisone 
and cyclosporine according to clinical response. 
All patients received prophylactic cotrimoxazol (1 x 480 mg) to prevent infections 
with pneumocystis carinii and valaciclovir (3 x 500 mg) to prevent CMV-reactivations 
for at least one year following allo-SCT. In the case of chronic GVHD or delayed 
immunosuppressive tapering, infectious prophylaxis was prolonged. 
INFECTIONS
All infections were scored according to the NCI common toxicity criteria (CTC) version 
3.0 (10) between day 1 and day 365 post-transplant, as described before (11, 12). All 
CTC grade 3-4 infections were scored and, if applicable, the location and causative 
microorganism of the infection were documented. In addition, CTC grade 2 CMV 
reactivations were scored, because CMV is known to infect endothelial cells and 
promote angiogenesis.  
 
ENUMERATION OF CIRCULATING ENDOTHELIAL CELLS
Enumeration of circulating endothelial cells (CECs) was performed according to our 
previously reported flow cytometric approach (13). We used the following directly 
conjugated monoclonal antibodies for the identification of CEC: CD34-FITC (clone 8G12; 
BD Biosciences, San Jose, CA, USA), CD146-APC (clone 541-10B2; Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany) and CD45-PerCP (clone 2D1; BD Biosciences). 
DRAQ5 (Biostatus Ltd, Shepshed, UK) was used as a cell permeable nuclear dye to 
exclude platelets and microparticles. CECs were defined as CD34+, CD146+, CD45- 
and DRAQ5+. 
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Samples were acquired on a FACS Fortessa flow cytometer (BD Biosciences) and were 
subsequently analyzed using FCS Express (De Novo Software, Los Angeles, CA, USA). 
Analyses were always checked by one experienced technician to minimize inter-rater 
variability.
EXPRESSION OF HLA CLASS I AND II ANTIGENS ON CECS
To study expression of HLA-DR on CECs, HLA-DR-PE (clone L243, BD Biosciences) was 
used. For the HLA-class I and HLA-mismatch analyses, HLA-A2, HLA-A9, HLA-B12, 
HLA-B27 & HLA-Bw6 biotinylated monoclonal antibodies (IgG2b; One Lambda, 
Canoga Park, CA, USA) were used and subsequently coupled to Streptavidin-PE (BD 
Biosciences).  
STATISTICAL CONSIDERATIONS
Several time intervals were constructed to define which CEC measurements were eligible 
for a given time point. These time intervals were also used to define the presence of 
absence of GVHD at that given time point. CEC samples that were drawn after disease 
relapse were excluded from the analysis, as the presence of very high numbers of 
disease-related CD34+ stem cells in these patients may interfere with the CEC analysis. 
CEC numbers between conditioning types or the presence of GVHD were compared 
using the Mann-Whitney U test. For the comparison of CEC numbers within the same 
patients on different time points, the Wilcoxon signed-rank test was used. Multivariable 
linear regression was performed using log-normalized CEC numbers to assure normality 
of the CEC data. Parameters used as variables included age, gender, HCT-CI score, 
donor source, conditioning intensity, occurrence of GVHD and occurrence of infections. 
A backward stepwise approach was used with a significance level of ≥0.2 to omit a 
given variable from the model. Age and gender were then subsequently added to the 
model, even if they did not have a significant contribution to the model, to assure that 
the most clinically relevant model was used. All reported p values are two-sided, and 
a significance level α = 0.05 was used. All data analyses were done using Stata/SE 12 
(StataCorp LP, College Station, TX, USA).  
R E S U LT S
Our retrospective study included 112 adult patients receiving allo-SCT in the Erasmus 
MC Cancer Institute. One patient was excluded because of the application of a unique, 
alternatively intensified conditioning regimen prior to double umbilical cord blood 
transplantation (dUCBT), which differed from other dUCBT recipients and also differed 
from RIC and MAB conditioned patients. Patient characteristics from the 111 remaining 
patients are presented in Supplementary Table 1. All patients were transplanted 
between August 2009 and November 2011 in the context of two prospective trials. Sibling 
donor patients (n=37) and matched unrelated donor patients (n=56) were included in the 
context of the HOVON 96 study (Netherlands Trial Registry - NTR2252), while dUCBT 
(n=18) were included in the context of the HOVON 106 study (NTR1573) (5, 6). MAB 
conditioning was received by 24 patients, consisting mainly of myeloablative TBI (12 Gy) 
and cyclophosphamide. RIC was received by 69 patients, consisting mainly of 2 Gy TBI 
combined with fludarabin (14). Lastly, 18 patients received a RIC-UCB consisting of 2x2 
Gy TBI combined with fludarabin and cyclophosphamide prior to UCBT. None of the 
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patients received in vivo T cell depletion. The minimal follow-up time was one year, and 
the median follow-up time for living patients was 34 months.  
A total of 357 peripheral blood samples were evaluated for the presence of CECs at 
baseline, 1 (dUCBT recipients only), 2 (dUCBT recipients only), 3, 6, 12 and 24 months 
post-transplant. Based on the number of follow-up days, we expected 473 samples, 
while 357 were analyzed, indicating that 75% of the expected samples were analyzed. 
CECs were defined as CD34+, CD146+, DRAQ5+, CD45- events and enumerated 
according to our previously described flow cytometric approach (13). Absolute CD34 
counts did not correlate with CEC counts (r=0.09, Supplementary Methods Figure 1). 
The influence of RIC and MAB conditioning on CEC kinetics is presented in Figure 1 
(left panel). While CEC numbers did not differ between RIC and the MAB conditioned 
patients pre-transplant (P=0.71) , patients who received MAB conditioning had higher 
CEC numbers than RIC recipients for up to 12 months following allo-SCT (P=0.000, 
P=0.000 and P=0.002 at 3, 6 and 12 months post-allo-SCT, respectively). At 24 months 
following allo-SCT, CEC numbers were similar in RIC and MAB conditioned patients 
(P=0.64). In the MAB group, CEC numbers were higher 12 months post-transplant than 
pre-transplant (one-sided Wilcoxon signed-rank test P=0.04).
In patients receiving an RIC-UCB conditioning additional CEC numbers at 1 and 2 
months post-allo-SCT were available. A significant rise in CEC numbers was observed 
at one month following dUCBT (P=0.006), to decrease significantly towards baseline 
values from 2 months post-allo-SCT onwards (P=0.009) (Figure 1, right panel). 
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FIGURE 1. Box-and-whisker plots showing the influence of conditioning intensity on CECs. Left panel 
shows CEC kinetics in MAB and RIC conditioned patients. Right panel shows CEC kinetics in dUCBT patients 
receiving RIC-UCB conditioning. (Boxes show 25th percentile, median and 75th percentile, whiskers show the 
lower and upper adjacent values, according to Tukey).
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We observed a CTC grade III-IV infection in 54%, 17% and 18% of the patients in the first 
3 months, month 3 to 6 and month 6 to 12 post-transplant, respectively. No significant 
differences in CEC numbers were observed at 3 months (P=0.12), 6 months (P= 0.51) 
and 12 months (P=0.99) post-transplant between those patients with versus those 
without a grade III-IV infection. Apart from CTC grade III-IV infections, CMV reactivations 
including those meeting CTC grade II criteria were separately scored in all patients. In 
37 patients (33%), a CMV reactivation was observed. No significant differences in CEC 
numbers and the occurrence of CMV reactivation at 3, 6 and 12 months post-allo-SCT 
were observed.       
     
In multivariable analysis at 3, 6 and 12 months post-transplant taking age, gender, 
HCT-CI score, donor source, conditioning intensity (MAB, RIC and UCB conditioning), 
occurrence of GVHD and occurrence of infections into account, MAB conditioning was 
associated with higher CEC numbers (P=0.000, P=0.000 and P=0.008, respectively) 
(Table 1). At 3 months following allo-SCT, the occurrence of aGVHD grade II-IV 
appeared associated with lower CEC numbers (P=0.003). The occurrence of cGVHD, 
limited and/or extensive was also associated with lower CEC numbers at 6 (P=0.019) 
and 12 (P=0.012) months post-transplant.
TABLE 1. Multivariable linear regression analysis on variables associated with the number of CECs. 
Month of CEC count Variable Beta P-value
Pre No variables associated with CEC numbers
3 aGVHD grade 2-4  -0.26 0.003
 MAB conditioning   0.70 0.000
6 cGVHD present  -0.22 0.019
 MAB conditioning   0.57 0.000
12 cGVHD present  -0.33 0.012
 MAB conditioning   0.47 0.008
We further explored the reasons underlying the differences in CEC numbers between 
patients experiencing GVHD versus those who had not. To exclude that our findings 
were due to the occurrence of donor-derived CECs in our assay, we evaluated CEC-
chimerism 1 month after transplantation by using HLA class II mismatch-specific 
monoclonal antibodies in two dUCBT recipients with a class II mismatch with their 
donor graft (Figure 2A-B). We did not observe CEC-chimerism: all CECs appeared of 
recipient origin. We then hypothesized that the unexpected lower number of CEC in 
patients with overt GVHD could be due to a direct immune response of alloreactive donor 
lymphocytes towards recipient CEC. Unfortunately it appeared technically impossible to 
visualize an immune response towards the small number of CECs that were detected by 
flow cytometry. Since an immune response of alloreactive donor T-cells to CECs would 
require HLA-expression on CECs, we evaluated in peripheral blood mononuclear cell 
(PMBC) samples the percentage of CECs expressing a HLA class I antigen (8 samples) 
and HLA-class II antigens (13 samples). A large subset of CECs was found to express 
a HLA class I antigen (median CEC HLA class I positive 94%, range 81-100%)  as well 
as HLA class II antigens (median CEC HLA-DR positive 86%, range 80-99%) (Figure 
2C-D). 
Negative standardized betas represent a correlation with lower CECs, while positive standardized betas 
represent a correlation with higher CECs.
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D I S C U S S I O N
This study confirmed the previous observation that MAB induces more endothelial 
damage than RIC in the first month following allo-SCT (3, 15). We now showed for the 
first time that in MAB conditioned patients, endothelial damage is present for at least 12 
months following transplantation. In contrast, in dUCBT patients receiving a 4 Gy TBI 
conditioning, a significant rise in CEC numbers as opposed to baseline was observed 
only at one month following allo-SCT. This suggests that endothelial damage following 
a relatively modest dose of TBI is only present for a short period of time. At 24 months 
post-transplant, CEC numbers of RIC and MAB conditioned patients were similar. The 
prolonged endothelial damage in patients receiving MAB conditioning may possibly be 
associated with more long-term cardiovascular conditions, as compared to RIC. This 
may be an important observation, especially since MAB conditioning is predominantly 
applied in younger patients, who will have more time to actually develop cardiovascular 
conditions. Thereby, our data may support the suggestion to further examine the use 
of RIC regimens in subsets of younger patients (16), especially in younger patients who 
already have relevant cardiovascular risk factors or comorbidity. 
FIGURE 2. Panel A & B show the presence of donor-specific HLA-A9 on lymphocytes (green) and CECs (red). 
Panel A shows that 100% of all CECs did not express HLA-A9 prior to SCT. Panel B shows that all CECs 
at 1 month following allo-SCT are of recipient origin, while virtually all lymphocytes are of donor origin and 
express HLA-A9. Panel C & D show representative images of HLA class I and HLA class II expression on 
lymphocytes (green) and CECs (red). Panel C shows that HLA-B27 is expressed in 98,89% of all CECs at 3 
months post-transplant (both donor and recipient harbored the HLA phenotype HLA-B27). Panel D shows HLA-
DR expression in 84,62% of all CECs at 3 months post-transplant.
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In contrast with some reports that suggested that GVHD is associated with increased 
endothelial damage (17-19), we observed significant lower CEC numbers in patients 
who experienced GVHD. It should however be noted that these previous studies were 
not all performed in humans, and different methods to assess endothelial damage were 
used. Following our observations that CECs strongly express HLA class I and class II 
antigens, we formulated the hypothesis that an alloreactive immune response may be 
exerted against CECs.
Because we did not observe CEC-chimerism in 2 patients at 1 month following SCT, 
it is unlikely that the lower CEC numbers in patients with overt GVHD were due to 
the occurrence of donor-derived CECs. Unfortunately no suitable PBMC samples 
were available to test the occurrence of CEC-chimerism at later time points following 
transplantation. Prospective studies investigating whether or not CEC-chimerism occurs 
in the post-transplant period, and if so from what time point onwards, are needed.
We also hypothesized that GVHD-associated treatments, such as steroids and 
calcineurin inhibitors (CNI), which were routinely given to all patients might account for 
the occurrence of less CECs in GVHD patients. However, since increased endothelial 
dysfunction has been linked to prednisone use (20) and cortisol excess (21) and therefore 
likely leads to higher CEC numbers, it is unlikely that the lower CEC numbers in GVHD 
patients are due to steroid treatment. Additionally, patients with and without GVHD in 
our study were fairly balanced regarding CNI treatment and had proper ciclosporin or 
tacrolimus trough levels at the time of CEC measurement, further rendering it unlikely 
that our findings were due to differences in CNI treatment or CNI toxicity.
Another explanation for the lower CEC numbers in GVHD patients could be that vascular 
damage occurs to such an large extent that only endothelial fragments remain, which do 
not meet our criteria for intact endothelial cells and are therefore missed by the current 
flow cytometric approach. 
There are several potential limitations of this study. Fixed time points were chosen to 
evaluate long-term changes related to the conditioning intensity, but are less suitable 
for the analysis of allo-SCT related complications such as GVHD. Clearly, these 
complications do not necessarily coincide with these fixed time points and therefore 
rapid CEC kinetic changes might be missed by this approach. Other limitations include 
the relatively small number of patients for subgroup analyses, especially at 24 months 
post-allo-SCT, and the relatively short follow-up, which made it impossible to explore 
whether those patients with highest CEC numbers are indeed at increased risk to 
develop cardiovascular diseases.
In summary, we present the largest study to date evaluating the impact of conditioning 
regimens on CECs as parameter for vascular damage in allo-SCT. We found that patients 
receiving MAB conditioning have long-term endothelial damage as opposed to patients 
receiving RIC. Further studies are warranted to investigate the clinical relevance of the 
increased CEC numbers in MAB patients, especially regarding the possible association 
with long-term cardiovascular outcomes. In addition, we observed lower CEC numbers 
in GVHD patients, which may possibly be explained by a direct immune response 
against CECs. Future research should investigate whether such an immune response is 
indeed present.
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S U P P L E M E N TA R Y  D ATA
SUPPLEMENTARY TABLE 1. Patient and graft characteristics (n=111).
Parameter RIC (n=69) RIC-UCB (n=18) MAB (n=24)
Age, median(range) 55 (26-66) 53 (34-64) 32 (19-52)
Sex female (%) 31 (45) 6 (33) 10 (42)
Diagnosis
          ALL 4 0 8
          AML 28 9 13
          CLL 6 1 0
          CML 2 2 2
          MDS 6 2 1
          MM 3 0 0
          NHL 9 1 0
          Other 11 3 0
Graft source
          Sib 27 0 10
          MUD 42 0 14
          dUCBT 0 18 0
Conditioning regimen
          Cyclo+TBI 12 Gy 0 0 21
          Cyclo+Busu 0 0 2
          Flu+TBI 12 Gy 0 0 1
          Flu+Cyclo+TBI 2x2 Gy 9 18 0
          Flu+TBI 2 Gy 57 0 0
          TBI 2 Gy 3 0 0
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Supplementary Figure 1. Correlation plot between CEC numbers and CD34 numbers. All values were 
log transformed in order to compress the figure. Spearman correlation coefficient was calculated with non-
normalized values.
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CHAP TER  11
Summary and general discussion
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I N T R O D U C T I O N
The capacity to optimally treat cancer patients is nowadays challenged by several 
factors. The introduction of this thesis already addressed several of these challenges, in 
particular tumor heterogeneity and plasticity, causing tumor characteristics to change 
over time and under treatment pressure. Besides these challenges, which are related 
to the biology of cancer, we also have to deal with important exterior factors that may 
challenge our ability to deliver the best possible cancer care. Demographics such as 
an increasing age of the population, in combination with an increasing availability of 
new diagnostics, surgical techniques and especially the continuous stream of new 
and expensive cancer medicine have driven cancer-related costs to be sky-high (1, 2). 
Hospitals in the Netherlands have reported an annual increase of about 10% in costs 
spent on expensive cancer medicine, and this trend is expected to continue in the next 
years (3). 
While the problem of increasing costs related to cancer care is a complex issue, in 
which efforts on multiple levels are necessary (which are outside the scope of this 
thesis), the ability to personalize treatment for cancer patients is likely to decrease 
costs. This was for example demonstrated for metastatic colorectal cancer (mCRC) 
patients, in which screening for KRAS and BRAF mutations in the primary tumor prior to 
anti-EGFR therapy has been proven to be cost-effective (4, 5). The availability of robust 
biomarkers which can tailor the right therapeutic strategy, for the right person, at the 
right time, is where we can use knowledge on the biology of cancer to treat cancer in the 
most optimal fashion, combined with a decrease in cancer-related costs in the long run. 
Liquid biopsies are of great interest to further personalize cancer treatment. However, 
their clinical utility is still rather limited. The next paragraphs will further discuss the 
current status of liquid biopsies on their way to personalize cancer treatment, and will 
set the observations as done in this thesis into a broader perspective. 
C I R C U L AT I N G  T U M O R  C E L L S
CLINICAL APPLICATIONS OF ENUMERATING
CTCS USING THE CELLSEARCH MACHINE
The CellSearch assay to count CTCs is FDA-approved for diagnostic purposes in 
patients with metastatic colorectal, prostate and breast cancer, but not recommended 
in the ASCO or ESMO guidelines for clinical use in any of those tumor types. In Chapter 
2 of this thesis, an effort was made to come to recommendations for the use of CTC 
enumeration by the CellSearch machine in breast cancer patients. We observed a lack 
of sufficient data to recommend the use of CTC enumeration in patients with primary 
breast cancer. New data from a meta-analysis in primary breast cancer patients 
(n=3,173), not published yet at the time that the review article was written, demonstrated 
that the presence of CTCs was associated with shorter overall survival in multivariate 
analysis (HR 1.97, 95%CI 1.5-2.6) (6). However, the clinical relevance of these results 
and how it should impact treatment decision-making is still unclear. In patients without 
CTCs, disease-free survival (DFS) after 5 years was ±85%, while assays as currently 
used in the clinic such as Oncotype DX or Mammaprint are able to identify patients 
with a DFS of >94% after 5 years (7, 8), meaning that CTC enumeration is unlikely to be 
superior to such assays in primary breast cancer. 
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As further narrated in Chapter 2, in metastatic breast cancer (MBC) patients the use 
of CTC enumeration can be recommended in two clinical situations. First, given that 
CTCs are superior over serum biomarkers such as CEA and CA15.3 (9), CTC counting 
should be done in MBC patients with poorly evaluable disease such as those with bone 
metastases only. Second, CTC enumeration can be advocated to be used in clinical 
trials as a marker for response, as enumerating CTCs is an excellent early response 
marker. This could lead to a quicker examination of the efficacy of new drugs, already 
3-4 weeks after treatment start.  
While we recommend CTC enumeration in certain clinical situations in MBC patients, 
its true clinical utility is still only applicable to a small proportion of patients. Especially 
disappointing were the results from the SWOG S0500 interventional study. In this study, 
early switches in chemotherapeutic regimens, based on changes in CTC counts during 
treatment, did not results in an overall survival (OS) benefit (10). These results were 
somewhat discouraging for the future of CTC enumeration as a clinical tool, as these 
are the kind of strategies that everyone had hoped would bring benefits for large groups 
of patients. 
New studies are now on the way to further examine whether counting CTCs may still have 
clinical utility. Concerning MBC patients, some French studies are now investigating other 
strategies to use CTC enumeration to guide treatment decision-making (11). An example 
is the CirCe01 trial, in which early switches are performed based on CTC response after 
one cycle of chemotherapy in MBC patients receiving third-line chemotherapy, as this 
allows to more easily search for the regimen that is most worthy to be pursued for more 
than one cycle. 
In tumor types other than breast cancer opportunities are also present for the use of 
CTC enumeration. For instance, in patients with muscle-invasive bladder cancer (MIBC) 
we are currently performing the CirGuidance study (12). Because the OS benefit of 
neoadjuvant chemotherapy (NAC) in MIBC patients is small (5% 10-year OS benefit), we 
hypothesize that MIBC patients without CTCs have such a good prognosis that these 
patients do not need NAC. This is a good example of a study in which CTCs are being 
investigated as a tool to guide treatment-decision making. 
ALTERNATIVE CTC ENUMERATION ASSAYS
Given that the EpCAM-dependancy of the CellSearch assay has disadvantages, a lot 
of other assays to enumerate CTCs have been described, for example other EpCAM-
dependent assays (e.g., IsoFlux), RNA-based assays (e.g., AdnaTest), size-based 
assays (e.g., Screencell, ISET, VyCAP Microsieve), immunofluorescence-based assays 
(e.g., Epic Sciences, CytoTrack), vimentin-based assays (13), and assays based on the 
depletion of leukocytes (e.g., CTC-iChip (14, 15)). Especially of interest are techniques 
that are able to capture more mesenchymal CTCs. Previously, Yu et al. (16) reported 
interesting results that CTCs (microfluidically enriched using an antibody cocktail of 
EpCAM, EGFR and HER2) may exhibit either epithelial characteristics, mesenchymal 
characteristics or a combination of both. In addition, they reported that the presence 
of mesenchymal-type CTCs appeared to be associated with disease progression in a 
series of 11 MBC patients. However, these results, published in 2013, have to date not 
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been validated in a larger cohort of patients. Also of particular interest are results by 
Satelli and colleagues, who have used an assay that is able to detect mesenchymal 
CTCs using cell-surface vimentin (CSV) in patients with epithelial cancers (17, 18). Lastly, 
our group has suggested the use of MCAM as a marker for EpCAM-negative CTCs (19), 
and have shown that a combined EpCAM/MCAM capturing approach increases the 
capture rate of CTCs in primary breast cancer patients (20). 
These assays, which are EpCAM-independent, and for the CSV assay also cytokeratin-
independent, are nice additions to the arsenal of CTC assays currently available. While 
the true clinical relevance of mesenchymal-like CTCs in patients with epithelial tumors 
still seems unclear, the use of the assays for EpCAM-negative or more mesenchymal-
type cancers is promising, for instance as shown with the CSV assay in sarcoma patients 
(13). Another example is the detection of MCAM-positive tumor cells in malignant pleural 
mesothelioma (MPM) patients. In contrast to EpCAM, MCAM is widely expressed in 
mesothelioma tissues (21). In Chapter 8, we investigated whether MCAM-positive CTCs 
are present in the peripheral blood (PB) and pleural effusion (PE) of patients with MPM, 
and explored their relevance in diagnosing MPM and in improving prognostication in 
MPM. MCAM-CTCs were detected in the peripheral blood of 26% of the patients, but 
did not appear to be of prognostic significance in MPM patients. MPM-CTCs measured 
in PEs using flow cytometry were detected in half of the patients, and this technique 
was superior to the current clinical standard, cytology review by the pathologist, for 
diagnosing MPM. In addition, the presence of MPM tumor cells in PE appeared to be 
associated with good prognosis. These results provide new options to improve the 
diagnosis and prognostication of MPM patients, and show the potential of the available 
assays able to detect EpCAM-negative CTCs. 
CHARACTERIZATION OF CTCS
Counting CTCs is merely a one-dimensional use of CTCs. Because CTCs are intact 
tumor cells, they contain DNA and express RNA and proteins, and their characterization 
thus provides interesting opportunities to get multidimensional insight into tumor 
characteristics. Recently, a lot of research has been done on both the technical side 
of CTC characterization, as well as on the biological relevance and potential clinical 
relevance of CTC characterization.  
PROTEIN LEVEL CHARACTERIZATION 
Characterization of CTCs on the protein level has generally been limited to 
immunofluorescence directly on CTCs enumerated with CellSearch. Several protein 
markers have been described, some of them related to targets for therapy (i.e., ER, 
HER2, AR), apoptosis (M30), proliferation (Ki-67) or other markers associated with 
particular subtypes of CTCs (e.g., EGFR, CD44, Bcl-2). The characterization of HER2 
and ER in MBC patients have received the most attention till date. Discrepancies 
between the ER-status and the HER2-status of the primary tumor and the CTCs in MBC 
have been demonstrated by numerous groups (22-36). However, reports on the clinical 
relevance of these discrepancies have been scant (35, 36). In Chapter 3, the clinical 
relevance of HER2-positive CTCs in MBC patients with a HER2-negative primary tumor 
was investigated in the context of endocrine resistance, as HER2-positivity in primary 
tumors had previously been linked to endocrine resistance. In addition, the prognostic 
impact of HER2-positive CTCs was assessed in a control cohort of patients receiving 
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chemotherapy. Notably, HER2-positive CTCs occurred in 29% of all patients (n=154) in 
this study, demonstrating that HER2-positive CTCs are frequently present in patients 
with a HER2-negative primary tumor. However, in the cohort of MBC patients receiving 
endocrine therapy, the occurrence of HER2-positive CTCs was not associated with 
impaired response to endocrine therapy. Also in the control cohort of patients receiving 
chemotherapy, the HER2 status of the CTCs did not have any prognostic impact. 
The relatively high frequency of HER2-positive CTCs as demonstrated in our study 
provides opportunities to target patients with HER2-positve-CTCs with anti-HER2 
targeting therapies Therefore, we recently initiated a study in which chemotherapy-
naive MBC patients with HER2-negative primary tumors but HER2-positive CTCs are 
treated with the combination of trastuzumab and docetaxel (CareMore-Trastuzumab 
study; Netherlands Trial Register number NTR5115 (37)). Another interesting approach 
may be to treat HER2-positive CTC patients with trastuzumab emtansine (T-DM1), which 
targets HER2 overexpressing cells with a cytotoxic agent (DM1) (38, 39). The delivery of 
the cytotoxic agent might yield additional benefit, given that HER2 overexpression alone 
on CTCs does not necessarily mean that the HER2-signaling pathway is truly activated. 
Studies evaluating the success of treating patients with HER2-positive CTCs with 
these sorts of anti-HER2 treatments are of utmost importance to answer the clinically 
important question whether HER2-positive CTCs are predictive for outcome to anti-
HER2 targeted therapies. 
Besides the immunofluorescent staining of HER2 on CellSearch-enumerated CTCs, 
other markers have only been assessed anecdotally. Some other interesting results 
were obtained with a marker panel containing HER2, ER, Bcl-2 and Ki-67 on CellSearch-
enumerated CTCs, in which a score derived from the combination of these markers was 
dubbed the CTC-endocrine therapy index (CTC-ETI) (40). In patients with MBC, CTC-
ETI risk classifications were constructed (low, intermediate, high) and the outcome of 
patients for each risk classification is now investigated in a prospective trial. 
 
RNA LEVEL CHARACTERIZATION
Our group previously demonstrated that molecular characterization of RNA from CTCs 
in a background of leukocytes is feasible in CTCs from MBC patients. We developed a 
96-gene mRNA profile, of which 65 genes were considered to be CTC-specific. Using 
a similar approach as in MBC, a gene expression profile consisting of 34 CTC-specific 
genes was generated for use in CTCs from mCRC patients (41). Since then, using these 
mRNA profiles, we have carried out multiple studies to further evaluate whether CTCs 
are resembling of the primary tumor or the metastases, and to assess the prognostic 
relevance of these mRNA profiles. We demonstrated that discrepancies between the 
primary tumor and CTCs from MBC patients regarding gene expression are frequently 
present (48% discrepant) (35), however, without that having prognostic consequences. 
In line with the results in MBC patients, we found that CTCs from mCRC patients 
undergoing resection of liver metastases were often discrepant with the primary tumor 
(43% discrepant), while the CTCs better resembled the liver metastases (42). Regarding 
the prognostic value of the mRNA profile in MBC patients, we identified a 16-gene profile 
in CTCs that was associated with poor prognosis, but this profile could not be validated 
in an independent cohort (43). An 8-gene profile for resistance to endocrine therapy was 
also identified, but similarly to the 16-gene profile this profile could not be validated.
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In addition to these mRNA gene expression profiles, also single genes of interest can 
be analyzed. In Chapter 3, besides characterization of HER2 on the protein level as 
discussed above, the expression levels of the gene coding for the ER, ESR1, were 
assessed in CTCs. We observed a discordance in ER status between the primary tumor 
and the CTCs in 25% of the patients, which did not seem to have prognostic relevance in 
exploratory analysis. Interestingly, frequently switches in ER status were observed from 
ER-negative in the primary tumor to ER-positive in the CTCs. As these patients might 
benefit from endocrine therapy, these results warrant further investigation. 
Recently it has also become of huge interest to determine aberrant splice variants in 
mRNA from CTCs. In a landmark study by Antonarakis and colleagues, the presence of 
the AR-V7 splice variants in CTCs (enriched with AdnaTest) from patients with mCRPC 
predicted resistance to endocrine agents, demonstrating a 0% response rate in patients 
harboring an AR-V7 splice variant (44). Following these results, our group showed that 
the response to chemotherapy with cabazitaxel is not impaired in patients with the AR-
V7 splice variants (45). Both the resistance to endocrine therapy (46) and the intact 
response to taxanes (46, 47) have now been independently validated using various 
assays (AdnaTest, CellSearch, Epic AR-V7 Test) to detect AR-V7 in CTCs. These data 
suggest that mCRPC patients with an AR-V7 splice variant in CTCs should receive 
chemotherapy, and patients without an AR-V7 splice variant should receive either 
endocrine therapy or chemotherapy. 
Given the strong predictive value of AR splice variants in mCRPC, in Chapter 5 we 
evaluated whether splice variants of the ER were present in CTCs from MBC patients 
and whether they were enriched during endocrine therapy. We found the ∆5 ESR1 
splice variant to be more highly expressed in CellSearch-enriched CTC fractions of 
MBC patients than in healthy blood donors. Since this splice variant has been linked 
to constitutive activity of the ER, this finding may be relevant, however, the ∆5 splice 
variant was not enriched during endocrine therapy. 
DNA LEVEL CHARACTERIZATION
Characterization of DNA from CTCs has generally been hampered by the lack of purity 
of CTCs after isolation. In 2013, our group used several PCR methods to analyze 
CellSearch-enriched DNA from CTCs, but these PCR techniques lacked sensitivity to 
detect low-frequency mutations (48). More recently highly sensitive digital PCR (dPCR)-
based assays have become available and may be used to detect mutations in DNA from 
CTCs. For example, ESR1 mutations may be assessed using dPCR-based techniques. 
As reviewed in Chapter 4, these mutations are rare in primary breast cancer tumors, but 
enriched in patients with metastatic disease who have had prior treatment with aromatase 
inhibitors (AIs). As these mutations can only be assessed in metastatic tumor cells, the 
use of liquid biopsies to assess these mutations is of interest. We described in Chapter 
5 that dPCR is able to detect ESR1 mutations in DNA from CellSearch-enriched CTCs, 
however, cell-free DNA was observed to be a superior substrate for ESR1 mutation 
detection. We hypothesize that the background of nonspecifically CellSearch-enriched, 
leukocyte-derived, wildtype DNA hampers the detection of mutations in CTCs. 
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ANALYSIS OF CTCS AT THE SINGLE CELL LEVEL
The described results on the DNA and RNA level, limited by leukocyte contamination, 
have called for analysis of single or pure CTCs. A potential avenue could be to perform 
fluorescence in situ hybridization (FISH) or use padlock probes (PLP), both in-situ 
assays, to characterize single cells for single markers (49). However, when we want to 
quantify multiple genes or mutations, for example by sequencing, what is really needed 
are pure CTCs, without contaminating leukocytes. This has recently become feasible by 
using devices that are able to isolate single CTCs using for example micro-manipulation 
(e.g., CellCelector), electric fields (DEP-Array) or a punching needle (VyCAP puncher). 
The promise of these techniques has been demonstrated in DNA from single CTCs 
from patients with mCRC (50), mCRPC (51) and MBC (52). DNA from these single 
CTCs is subjected to whole-genome amplification and followed by targeted NGS or 
even whole-exome sequencing. The analysis of single CTCs in these studies generally 
demonstrated mutational heterogeneity between CTCs, and characteristics of CTCs 
seem to be representative of metastatic tumor lesions (51).
     
INCREASING THE NUMBER OF CTCS SUITABLE FOR CHARACTERIZATION
CTC characterization is not only complex because CTC enrichment methods yield CTC-
containing fraction that is not pure. CTCs are also rare cells, and if an increased number 
of CTCs could be obtained, more cells would be available for characterization. Some 
have reported on the culture of CTCs to obtain more cells for molecular analysis and to 
perform direct drug sensitivity analyses on CTC (53-55). While long-term cultures have 
been achieved by multiple groups, the chance of success is very low, and seems to be 
limited to patients with very high CTC counts >300 CTCs/7.5 mL (55).
Another method to obtain more cells for analysis is to obtain higher volumes of blood 
for CTC enrichment. A mathematical extrapolation of increasing blood volume for CTC 
enrichment to 5 liters predicted that in about 99% of metastatic cancer patients at least 
one CTC would be detectable (56). Therefore, efforts have been undertaken to perform 
diagnostic leukapheresis to increase the blood volume (57), which in non-metastatic 
cancer patients was demonstrated to markedly increase the number of available CTCs 
for analysis (58). We recently initiated the CIRCLE study, in which the two concepts 
mentioned in this paragraph will be combined. In this study, diagnostic leukapheresis 
will be performed to obtain CTCs for long-term culture and drug sensitivity analyses in 
mCRPC patients.     
C I R C U L AT I N G  T U M O R  D N A
As summarized above, CTCs have certain disadvantages, mainly their rarity and 
complexity for characterization. When CTCs or tumor cells in the tumor themselves 
go into apoptosis, DNA is released which can be found as cfDNA in the circulation. In 
patients with primary cancer and metastatic cancer, ctDNA (the tumorous part of cfDNA 
as a whole) is more frequently detected than CTCs (59, 60). The introduction of several 
high-throughput technologies has ignited research on cfDNA in the past years, with 
high potential for clinical utility. This had recently led to FDA-approval of a companion 
diagnostic EGFR mutation test to identify metastatic lung cancer patients eligible 
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for treatment with erlotinib (61). While the exact prognostic and predictive relevance 
of cfDNA is not clear yet, and procedures to process blood for cfDNA analysis and 
downstream techniques are still being optimized, non-FDA-approved assays like the 
Guardant360 (62), able to detect mutations in the cfDNA, are currently already offered 
as commercial assays to patients. The availability of these kind of commercial tests 
illustrates the enthusiasm in the community to incorporate these techniques into clinical 
practice.
STANDARDIZATION OF PRE-ANALYTICAL CONDITIONS
The enthusiasm for cfDNA analysis is understandable. Plasma from whole blood can 
be easily obtained, and downstream techniques to detect ctDNA are relatively user-
friendly. The processing of plasma and the use of downstream techniques, however, 
vary widely at this point. In Chapter 6, we demonstrated that plasma DNA isolated 
from CellSave tubes and BCT tubes 96 hours after the blood draw, have similar cfDNA 
concentrations and mutation frequencies as plasma isolated from blood one hour after 
the blood draw. Since blood for CTC enumerations is also collected in CellSave tubes, 
this means that plasma isolated from CellSave tubes collected for CTC enumeration 
have optimal cfDNA quality and can be used in the context of multicenter trials.
CHALLENGES OF SEVERAL TECHNIQUES FOR DOWNSTREAM CFDNA ANALYSES
While most groups have used dPCR to detect mutations in cfDNA, the downside of 
using dPCR-based techniques is that you have to know beforehand what mutations to 
look for, and that only a limited number of mutations can be assessed. Therefore, assays 
in which more mutations or whole genes can be assessed are of interest. In Chapter 
7, we compared several techniques for the detection of ctDNA in mCRC patients 
undergoing liver metastasectomy. We used a CRC-specific 21-gene NGS panel, which 
performed well on DNA from tissues of these patients, but had limited sensitivity to 
detect mutations in the cfDNA of patients. In contrast, dPCR was very sensitive for 
the detection of mutations in cfDNA. The OnTarget assay, able to assess 96 hotspot 
mutations, also appeared to be very sensitive for the detection of mutations in cfDNA. 
This work further highlighted the pros and cons of current assays for cfDNA analysis. 
The assay of choice should be based on the research question. When one wants to 
identify novel mutations, for example related to resistance, NGS remains the only 
available option. While we observed poor sensitivity using NGS, its sensitivity may 
be improved by using optimally collected plasma, by the use of other NGS-based 
techniques using pre-enrichment (e.g., SafeSeqS (63), CAPP-Seq (64)), or by assessing 
patients with a higher tumor load. Panels with hotspot mutations like the OnTarget assay 
are especially of interest if the mutation status of the primary tumor or the metastases 
are unknown. Digital PCR can also be of interest if the mutation status of the tissue is 
unknown, however, it can only be used if a few specific mutations need to be assessed. 
For example, in Chapter 5 we demonstrated that dPCR is able to readily detect 4 ESR1 
hotspot mutations in the cfDNA of MBC patients.
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CLINICAL RELEVANCE OF CFDNA ANALYSIS
The efforts as performed by our group provided insight into the optimal pre-analytical 
conditions, and into the different available choices of assays and their relative strengths 
and weaknesses. The next step is to unravel the true clinical relevance of cfDNA 
analysis. As mentioned before, in Chapter 4 we reviewed current evidence on the 
clinical relevance of ESR1 mutations in MBC patients, where we made a case for the use 
of cfDNA to assess these mutations. In Chapter 5, we demonstrated that CellSearch-
enriched CTCs were inferior to cfDNA regarding the detection of ESR1 mutations 
using dPCR. In addition, we demonstrated that ESR1 mutations are rarely present in 
patients starting first-line endocrine therapy, but are enriched in patients progressing 
on endocrine therapies, further emphasizing the role of ESR1 mutations in endocrine 
resistance.  
These results have been amongst the first to further substantiate the potential clinical 
relevance of cfDNA. Clinical utility of cfDNA analyses could be present through various 
avenues.
First, like ESR1 mutations, there may be clinical utility by detecting resistance mutations 
in cfDNA. For instance, a mutation in the EGFR, T790M, confers resistance against 
tyrosine kinase inhibitors (TKIs) in lung cancer patients (65), and patients with an 
EGFR T790M mutation benefit from new third-generation TKIs such as osimertinib 
(66). Another example is the occurrence of KRAS mutations that cause resistance to 
monoclonal antibodies targeting the EGFR (67). Recent evidence has also suggested 
that upon discontinuation of EGFR-specific antibodies KRAS mutations decay and drug 
sensitivity is regained, meaning that re-challenges with EGFR-specific antibodies may 
be effective (67).
Second, there may be clinical relevance by using cell-free DNA to identify patients 
suitable for a certain treatment. The above mentioned EGFR mutations for treatment 
with erlotinib (in case of EGFR exon 19 deletions or L858R mutation) and osimertinib 
(in case of EGFR T790M mutation) are examples of this. An analysis of 171 patients 
who were analyzed by the Guardant360 cfDNA assay revealed that in about 40% of the 
screened patients with various types of cancer, a potential target for therapy was found 
and suggested that patients could be treated accordingly (62). While it is currently still 
debated whether these kind of strategies indeed provide true PFS-benefit for patients 
(68), it is likely that this could offer new treatment possibilities for at least a small subset 
of these patients.  
Third, relapse after surgery may be detected earlier using cfDNA. Several groups have 
reported on an approach in which the primary tumor is sequenced to identify mutations, 
and then subsequently “personalized” dPCR assays are made for one or more mutations 
found in the primary tumor. These personalized dPCR assays are then used to monitor 
the plasma for ctDNA. This approach was found to be associated with relapse-free 
survival in relatively small studies of patients after surgery for primary breast cancer 
(69), colorectal cancer (70, 71) and bladder cancer (72). While this certainly is very 
exciting data, disadvantages are that these sorts of approaches are labour-intensive 
and that novel clones or resistant mutations that were not present in the primary tumor 
are still missed.
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Fourth, cfDNA may be used as a surrogate of drug response. When a specific mutation, 
or multiple mutations, are identified in a patient, these mutations can be sampled 
longitudinally. To date, most of the studies have been performing longitudinal sampling 
merely anecdotal, for example as reviewed in Chapter 4 for ESR1 mutations, or as done 
for other personalized mutations in MBC patients (59), in mCRC patients receiving EGFR 
monoclonal antibodies (67, 73) or in lung cancer patients receiving erlotinib (74). 
GOING BEYOND SOMATIC MUTATIONS
Most reports thus far have focused on determining somatic mutations in cfDNA. While 
it may also be interesting to assess structural variants (75) in cfDNA, most of these 
options are limited by the fact that you need to know beforehand what abberations 
to look for. As we demonstrated in Chapter 7, NGS targeting multiple genes currently 
still lacks sensitivity, and hotspot panels (e.g., OnTarget assay) are often tumor-type 
dependent and limited to hotspot mutations. Another promising alternative to detect 
ctDNA is to identify tumor-specific copy number alterations (CNAs) using whole-genome 
sequencing (WGS) techniques rather than to focus on specific point mutations. Two 
groups have suggested that WGS techniques may be used to detect CNAs in ctDNA (76, 
77). However, these techniques were optimized to detect CNAs in the metastatic setting 
(76) or only when CNAs were as large as whole chromosome arms (77), meaning that 
more research on the use of CNAs to detect cfDNA will be necessary.
C I R C U L AT I N G  E N D O T H E L I A L  C E L L S
CTCs and cfDNA are both able to provide important insights into the biology of tumor 
cells. However, besides the broad spectrum of morphologies, gene expression profiles, 
and functional roles of tumor cells, also infiltrating lymphocytes, endothelial cells and 
other stromal cell types from the microenvironment form an integral part of the tumor 
(78). While the characterization of immune cells and stromal cells are outside of the scope 
of this thesis, we did focus on endothelial cells that circulate in the blood called CECs. 
Reports on these CECs have been scarce in the past years, which can be explained 
by several reasons. First, there is a lack of consensus in the field on how to optimally 
enumerate CECs. Second, as CEC assays also detect CECs from normal, non-tumor-
derived, endothelium, assessing tumor-specific effects is more challenging. Third, the 
community is treating circulating endothelial progenitor cells (EPC) as a separate entity, 
while the reported phenotypes of CECs and EPCs often overlap (79). All these factors, 
combined with the almost sole availability of small and heterogeneous studies, have 
led to contrasting findings with CECs, limiting the evaluation of CECs as a bona fide 
biomarker in oncology and thereby its clinical validity. 
TOWARDS CLINICAL VALIDITY: VALIDATION OF THE CEC ASSAY
Our group has presented a CEC enumeration assay in which CECs are defined as 
DRAQ5/DNA+, CD34+, MCAM+ & CD45-, and confirmed the endothelial nature of these 
cells using morphology, immunohistochemistry and gene expression (80). Using this 
definition for CECs, in Chapter 9 we evaluated the prognostic relevance of CECs in 
patients with recurrent glioblastoma multiforme (GBM) from the BELOB study, who 
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were randomized to the combination of lomustine/bevacizumab, lomustine alone or 
bevacizumab alone. We observed that the number of CECs significantly increased in 
patients receiving lomustine/bevacizumab, but not in patients receiving either of these 
agents alone, suggesting that lomustine and bevacizumab are synergistic in their ability 
to induce endothelial damage. In the patients treated with lomustine alone, which is still 
the agent with the most activity in recurrent glioblastoma (81), an increase in CEC counts 
was associated with improved OS. These findings have underlined the prognostic 
potential of CECs. However, in the subgroups of patients randomized to bevacizumab-
containing regimens, CEC changes did not have any prognostic relevance, while an 
endothelial marker would be expected to provide information on the efficacy of anti-
angiogenic treatments. 
DETECTING TUMOR-SPECIFIC CECS
The fact that CECs represent both the compartment of CECs from normal endothelium 
as the compartment of CECs from tumor endothelium, may have played a role in the 
limited prognostic power of CECs in patients receiving bevacizumab and lomustine. 
Therefore, our group identified a marker, CD276, which can be reliably determined on 
CECs and which we showed to be tumor-associated (82). The use of CD276 to identify 
tumor-associated CECs (tCECs) is likely to improve the specificity of the CEC assay to 
measure CECs from tumor vasculature. We are currently investigating the prognostic 
relevance of tCECs in the follow-up study of the BELOB study, the EORTC 26101 study, in 
which patients are randomized to lomustine alone or bevacizumab/lomustine. While the 
main study did find a longer PFS in patients receiving bevacizumab/lomustine, this PFS 
benefit did not translate in an OS benefit (81). We hope that the measurement of tCECs 
will give more insight into which patients are experiencing benefit from bevacizumab/
lomustine. 
In our mesothelioma study described in Chapter 8, we already demonstrated the 
potential for tCECs as a prognostic marker. In this study 42% of the patients had tCEC 
levels above the upper limit of normal as observed in healthy donors. In exploratory 
analysis, a higher number of tCECs appeared to be associated with poorer OS, 
in contrast to the number of CECs, which was not associated with OS. While these 
results should be validated in a larger cohort, they might emphasize the added value of 
measuring tCECs over CECs. 
APPLICATION OF CECS OUTSIDE THE FIELD OF ONCOLOGY
While the obtained results with tCECs look promising, it should be noted that CECs 
can also be used outside of the field of oncology, without the need to specifically 
identify tumor-associated CECs. CECs have for example been described to play a role 
in myocardial infarction (83) and in short-term endothelial damage in allogeneic stem 
cell transplantation (allo-SCT) recipients (84). In Chapter 10, we investigated whether 
the number of CECs during allo-SCT was associated with conditioning regimen-
related endothelial damage, and allo-SCT-related complications. We observed that a 
myeloablative conditioning regimen, which is often given to younger patients, resulted 
in higher CEC counts for at least 12 months post-transplantation compared to CEC 
counts in patients receiving a reduced-intensity conditioning regimen. This suggests 
that patients receiving myeloablative conditioning have prolonged endothelial damage, 
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which might be related to long-term cardiovascular outcome, meaning that further 
studies on this association are warranted. In addition, we observed that CEC count were 
lower in patients who experienced graft-versus-host disease (GVHD), and that CECs 
express HLA class I and HLA class II antigens, leading to the hypothesis that the lower 
CEC numbers in patients who had GVHD may be caused by an alloreactive immune 
response against CECs. 
F U T U R E  P E R S P E C T I V E S
This thesis provided more insight into the technical aspects and possible clinical 
relevance of the liquid biopsies CTCs, cfDNA and CECs in cancer patients. Regarding 
CTC enumeration, we should keep in mind that although CTC enumeration by the 
CellSearch system has been thoroughly validated in almost every epithelial-type 
cancer and is already on the market for quite some time, its use is still limited to small 
groups of patients. If CTC enumeration is to reach its full potential, it is crucial that new 
studies evaluating CTC enumeration in PB of patients with epithelial tumors should be 
focused on the clinical applicability of CTC enumeration, preferably in the context of an 
interventional trial. An exception may be the enumeration of CTCs in bodily fluids other 
than PB, for example in PE as described above, or in cerebrospinal fluid (85), in which 
CTC enumeration is not validated as well as in PB and seems promising because CTC 
enumeration may be more sensitive as currently used methods by the pathologist. In 
addition, the enumeration of CTCs in patients with mesenchymal tumors is worth further 
investigation.
The characterization of CTCs, over just counting CTCs, is likely to significantly broaden 
the clinical utility of CTCs. The AR-V7 results, for example, are likely to be practice-
changing in due time, and underline the potential of CTC characterization to have 
real consequences for clinical decision-making. A recent cost-savings analysis of 
AR-V7 testing revealed that upfront testing of the AR-V7 status in mCRPC patients 
could potentially save $150 Million in the USA per year (86), also emphasizing the 
prospect of optimizing cost-effectiveness in cancer medicine by using liquid biopsies 
to personalize treatment. Unfortunately, the results obtained in this thesis regarding 
CTC characterization in MBC patients on the protein level (HER2), RNA level (ESR1 
expression and splice variants) and DNA level (ESR1 mutations) did not point towards 
direct clinical utility of CTC characterization in MBC patients; what is more, cfDNA 
analysis was superior to CTC characterization for detecting ESR1 mutations. For the 
ESR1 mutations, this certainly means that cfDNA should be used over CTCs. Does 
this mean that CTC characterization is futile? Certainly not. Still, CTCs remain the 
only substrate in which characterization can be performed at multiple dimensions. An 
extremely important marker for endocrine resistance such as the AR-V7 splice variant 
can never be measured at the (cf)DNA level (unless there is an associated mutational 
pattern), and the same goes for important targets for therapy that should be measured 
at the protein level, such as ER. In addition, at a more fundamental level, one could 
argue that a fragment from an apoptotic tumor cell, does not tell you anything about the 
biology of the living tumor (87). 
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Obtaining single and/or pure CTCs will, however, be necessary to conquer a lot of the 
problems now encountered with CTC characterization. When pure CTCs are obtained, 
without leukocyte characterization, this allows for more reliable RNA and DNA analysis. 
Furthermore, heterogeneity between single CTCs could be analyzed, as techniques 
sequencing DNA and mRNA from the same single cell have recently become feasible 
(88). These sorts of strategies will provide import insights into the biology and subclonal 
diversity of CTCs, and will especially be interesting to track during treatment with anti-
cancer agents. 
The characterization of cfDNA is likely to be complementary to single CTC analyses. 
First, not in every patient CTCs are detected, and while a correlation between higher 
CTC counts and cfDNA presence has been reported, cfDNA is still generally more often 
detected than CTCs (59). This will especially play a role in applications for early detection 
of relapse, a setting in which CTCs are rare. In this setting of minimal residual detection, 
cfDNA analyses are likely to offer more than CTCs, especially when techniques such as 
the described CNA assay to detect ctDNA are further optimized. In addition, these sorts 
of strategies provide opportunities in patients with mesenchymal or EpCAM-negative 
tumors. 
Second, it is now unknown if a single CTC resolution is always necessary, and whether 
that really adds to its clinical utility. If measuring a single mutation or mutational panel 
on cfDNA provides the clinician with enough information to direct a patient towards a 
certain treatment, or to evaluate drug response, this may just be enough. Single CTCs 
could then be used to analyze certain subclones in more detail. 
Third, while early studies on single CTCs suggested that most mutations from 
metastases are represented in the exome of CTCs (51), the question remains whether 
characterization of only a few CTCs, in particular in patients with low CTC counts, will 
represent the whole genomic landscape of the tumor.   
Lastly, we should keep in mind that the characterization of single CTCs will probably 
be more labor-intensive and in need of more specialized personnel and instruments 
than the characterization of cfDNA. For cfDNA characterization, blood collected in 
a CellSave tube can be sent to a diagnostics lab for processing of plasma within 96 
hours, and subsequently downstream analyses such as digital PCR or NGS can be 
performed swiftly, and these techniques are available in most research laboratories. 
For characterization of single CTCs, blood can similarly be collected, but then first an 
enrichment step will be needed, followed by staining for CTC markers, followed by 
the collection of the single CTCs, and if multiple single CTCs are then subsequently 
analyzed, lots of data will become available. For RNA analyses on single CTCs, the 
blood will have to shipped to the lab within 24 hours, as quick isolation of single CTCs 
will be necessary to obtain the highest quality of RNA. In addition, it should be realized 
that an apparatus especially for the isolation of these single CTCs is necessary, which 
is not readily available in most research labs. While all the work to obtain single CTCs 
will be feasible in a dedicated CTC research lab (such as the lab where the work for this 
thesis was performed), it can be imagined that the majority of other labs will go with 
cfDNA characterization, given the above mentioned advantages of its analysis.
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The overflow of data on CTCs and cfDNA raises the question if there is a place for CEC 
enumeration in clinical oncology. At this point, we do not know what its place will be. 
The small study on tCECs in mesothelioma patients as presented in this thesis is one 
of the first studies in which we were able to measure CECs coming from the tumor 
vasculature, and this is a big step forward. If there is a place for CECs, it will probably 
be in patients receiving anti-cancer agents targeting the vasculature or in patients with 
highly vascularized tumor types (such as mesothelioma), however, studies on the clinical 
relevance of tumor-associated CECs in these patients are urgently needed.  
In conclusion, the characterization of single CTCs along with complementary cfDNA 
analyses is likely to play an important role in clinical oncology in due time. For single CTC 
research, it will be vital to establish pipelines for optimal DNA and RNA characterization 
of single CTCs. Future research on cfDNA should focus on optimizing cfDNA detection 
methods to be able to overcome the current problem of being limited by gene panels 
or the detection of single mutations. This could be done by improving NGS techniques 
so that more genes (or even whole genomes) can be sequenced for detecting somatic 
mutations, or by measuring CNAs to detect ctDNA, depending on the research question. 
Eventually, it will be of utmost importance to establish the true clinical relevance of both 
single CTCs and cfDNA, to see in which cases one of these substrates will be superior 
to the other, and to see where these substrates can complement each other. Liquid 
biopsies will help us to an improved understanding of heterogeneity and plasticity of 
cancer, and ultimately this information along with its clinical use is going to strike a 
major blow in the war on cancer.  
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I N T R O D U C T I E
Kanker is de belangrijkste doodsoorzaak in Nederland. In de laatste decennia zijn 
belangrijke succesverhalen te vertellen wat betreft de behandeling van kanker, 
bijvoorbeeld de genezing van allerlei soorten kankers die voorkomen in kinderen, 
lymfeklierkanker en zaadbalkanker. Daarnaast is er ook sprake geweest van een 
verbeterde vroege detectie van kanker en behandeling na de operatie (adjuvante 
therapie), welke hebben geleid tot een verbetering in de 5-jaars overleving van patiënten 
met kanker. Echter, ondanks al deze verbeteringen, blijft kanker de belangrijkste 
doodsoorzaak in de westerse samenleving, en blijft verdere voortgang dus hard nodig. 
In de afgelopen decennia hebben we veel geleerd over de achterliggende oorzaken die 
het zo moeilijk maken om kanker te behandelen. Allereerst moet men zich realiseren 
dat patiënten met kanker niet zo zeer overlijden aan de tumor die het eerst aanwezig 
is (primaire tumor), maar aan het optreden van uitzaaiingen op afstand vanuit deze 
primaire tumor. De huidige behandeling van patiënten met kanker is over het algemeen 
gebaseerd op de karakteristieken van de primaire tumor. Jaren aan onderzoek heeft 
ons echter geleerd dat tumorcellen plastisch zijn: hun eigenschappen veranderen naar 
mate de tijd vordert en onder druk van anti-tumor behandelingen. Daarnaast hebben 
we geleerd dat tumorcellen niet allemaal hetzelfde zijn: als een tumor cel voor cel 
wordt bekeken, blijken er zelfs belangrijke verschillen te zijn (heterogeniteit) tussen elke 
individuele cel in een tumor. Dit betekent dat het erg onwaarschijnlijk is dat een enkel 
anti-kankermiddel een effect zal sorteren op álle kankercellen in een tumor, hetgeen 
genezing dus ook onwaarschijnlijker maakt, vooral in patiënten met uitgebreidere, 
uitgezaaide ziekte. 
Al deze inzichten laten zien dat er behoefte is aan manieren om de diagnosestelling, 
prognosebepaling en predictie van behandelsucces te verbeteren in patiënten met 
kanker, en dan het liefst voor, tijdens en na de therapie. Het biopteren van uitzaaiingen 
zou een optie kunnen zijn om naar de plasticiteit en heterogeniteit van kankercellen te 
kijken. Echter is dit een pijnlijke en soms moeilijke procedure, die realistisch gezien niet 
regelmatig uitgevoerd kan worden. Daarnaast krijgt men hiermee maar het beeld van 
één plek in één uitzaaiing. Daarom is er grote behoefte aan manieren om toch inzicht 
te krijgen in de eigenschappen van de kankercellen, die minder belastend zijn voor 
de patiënt. Zo’n manier is het nemen en karakteriseren van zogenaamde “vloeibare 
biopsies”.
V L O E I B A R E  B I O P S I E S
Met een ‘vloeibare biopsie’ wordt bedoeld dat door middel van een relatief simpele 
ingreep zoals een bloedafname, er een bron wordt verkregen waaruit we meer te weten 
kunnen komen over de eigenschappen van de tumor van een patiënt. Dit proefschrift 
heeft zich gericht op drie soorten vloeibare biopsies: circulerende tumorcellen (CTCs), 
circulerend tumor DNA (ctDNA) en circulerende endotheelcellen (CECs). De volgende 
paragrafen zullen deze vloeibare biopsies verder toelichten, en het werk zoals gedaan in 
dit proefschrift verder in perspectief zetten.
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C I R C U L E R E N D E  T U M O R C E L L E N
CTCs zijn kankercellen van een tumor die in het bloed terecht komen en vervolgens 
uitzaaiingen in andere organen kunnen vormen. Er bestaan allerlei technieken om 
deze tumorcellen uit het bloed of uit andere lichaamsvochten te isoleren, waarvan de 
meest gebruikte techniek de ‘CellSearch’ machine is. Deze machine maakt gebruikt 
van magnetische bolletjes die gekoppeld zijn aan een EpCAM antilichaam. EpCAM 
komt tot expressie op tumorcellen, hetgeen betekent dat die tumorcellen in bloed aan 
het EpCAM antilichaam gekoppeld aan een magnetisch bolletje binden, en zo met een 
magneet uit het bloed gehaald kunnen worden. Met behulp van deze techniek worden in 
ongeveer 60% van de patiënten met uitgezaaide kanker CTCs aangetroffen. Vervolgens 
zijn verschillende opties: 1) het aantal CTCs kan simpelweg geteld worden, waarvan 
we weten dat dit sterk gecorreleerd is met de prognose van patiënten met epitheliale 
uitgezaaide kanker zoals borstkanker, prostaatkanker en dikke darmkanker; of 2) de 
erfelijke (genetische) eigenschappen (eiwit, DNA en RNA) van de CTCs kunnen verder 
geanalyseerd worden. 
TELLEN VAN CTCS
Het tellen van CTCs is goedgekeurd door de Amerikaanse Food and Drug Administration 
voor diagnostisch gebruik in patiënten met uitgezaaide borstkanker, prostaatkanker 
en dikke darmkanker. Echter wordt het gebruik hiervan in de kliniek momenteel niet 
aangeraden in de ESMO (Europese Oncologie Organisatie) of ASCO (Amerikaanse 
Oncologie Organisatie) richtlijnen voor deze tumortypes. In hoofdstuk 2 van dit 
proefschrift werden aanbevelingen gedaan voor het gebruik van CTC tellingen in 
patiënten met borstkanker. In patiënten met borstkanker die niet is uitgezaaid, vonden 
we onvoldoende bewijs voor het gebruik van CTC tellingen. In patiënten met uitgezaaide 
borstkanker kunnen CTC tellingen echter toegepast worden in twee klinische situaties: 
1) in patiënten met slecht evalueerbare ziekte, zoals patiënten waarbij de uitzaaiingen 
en het effect van de behandeling op de uitzaaiingen slecht in kaart te brengen zijn met 
gebruikelijke technieken zoals CT-scans, en 2) als marker voor vroeg succes op anti-
kankertherapie, hetgeen kan leiden tot een snellere beoordeling van de efficiëntie van 
nieuwe anti-kankermedicijnen, al 3-4 weken na start van de behandeling.
Ondanks dat er dus toepassingen zijn van CTC tellingen, gelden deze toepassingen 
helaas maar voor kleine groepen patiënten. Daarnaast is een probleem dat de CellSearch 
techniek om CTCs te tellen niet werkt voor alle soorten tumoren. Dit is bijvoorbeeld 
het geval bij patiënten met asbestkanker (maligne pleuraal mesothelioom), waarbij 
de tumor nauwelijks EpCAM tot expressie brengt, waardoor deze tumorcellen niet 
gevangen worden met de CellSearch machine. Daarom heeft onze groep een andere 
techniek ontwikkelt, waarbij tumorcellen niet met EpCAM worden gevangen, maar met 
MCAM. In hoofdstuk 8 werd onderzocht of met deze techniek CTCs konden worden 
gedetecteerd in het bloed en het pleuravocht (‘vocht achter de longen’) van patiënten 
met asbestkanker. In 26% van de patiënten werden CTCs in het bloed gevonden, 
echter bleek het aanwezig zijn van deze CTCs niet van prognostische waarde. De 
detectie van CTCs in het pleuravocht was superieur aan de huidige klinische standaard 
(beoordeling door de patholoog van het pleuravocht). Dit betekent dat in de toekomst 
de diagnosestelling van asbestkanker mogelijk verbeterd kan worden met behulp van 
onze techniek.
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ANALYSE VAN GENETISCHE EIGENSCHAPPEN VAN CTCS
Het tellen van CTCs is een erg beperkt gebruik van CTCs. CTCs worden slechts geteld, 
terwijl zij ook allerlei informatie bezitten over de genetische eigenschappen van de 
tumorcellen. Daarom is in dit proefschrift tevens uitgebreid aandacht besteed aan het 
bepalen van de genetische eigenschappen van de CTCs.
In hoofdstuk 3 werd gekeken naar de HER2-status van de CTCs in patiënten met 
uitgezaaide borstkanker. HER2 is, indien uitgebreid aanwezig op de tumorcel, een 
receptor die betrokken is bij de groei van een tumorcel, en is een belangrijk doelwit voor 
therapie met de bestaande anti-HER2 therapieën. Zoals eerder gezegd, zijn tumoren 
plastisch, en kunnen eigenschappen zoals de HER2 status over de tijd of onder invloed 
van anti-kanker behandelingen veranderen. Wij onderzochten of HER2-positieve CTCs 
voorkwamen in patiënten met een HER2-negatieve primaire tumor, en in hoeverre dit 
van invloed was resistentie op hormonale therapie, aangezien patiënten met een HER2-
positieve primaire tumor een slechtere uitkomst hebben op hormonale therapie. We 
vonden dat HER2-positieve CTCs voorkwamen in 29% van alle patiënten (n=154) in 
deze studie. Het voorkomen van deze HER2-positieve CTCs bleek echter geen relatie 
te hebben met de uitkomst op hormonale therapie, en ook niet op de uitkomst op 
chemotherapie zoals geanalyseerd in een controlegroep. 
Het feit dat HER2-positieve CTCs voorkomen in zo’n grote groep patiënten met een 
HER2-negatieve primaire tumor, biedt opties om deze patiënten te behandelen met 
anti-HER2 therapie. Daarom zijn we recent een studie gestart waarin patiënten met 
HER2-positieve CTCs, maar een HER2-negatieve primaire tumor, behandeld worden 
met anti-HER2 therapie. Het doen van dit soort studies is van het grootste belang om 
uiteindelijk de vraag te beantwoorden of patiënten met HER2-positieve CTCs inderdaad 
baat hebben bij therapie met anti-HER2 middelen.
Naast HER2 is een ander belangrijk doelwit voor therapie in patiënten met uitgezaaide 
borstkanker de oestrogeen receptor. Patiënten met een oestrogeen receptor-positieve 
primaire tumor, krijgen hormonale therapie voorgeschreven. Dit is een behandeling 
waar een hoop patiënten baat bij hebben, met relatief milde bijwerkingen. In 40% 
van de patiënten met uitgezaaide borstkanker treedt echter direct resistentie tegen 
de behandeling op, en in de rest van de patiënten zal resistentie uiteindelijk ook 
altijd optreden. In dit proefschrift werd daarom onderzoek gedaan naar meerdere 
mechanismen die te maken hebben met resistentie op hormonale therapie.
Eén van de reden voor resistentie op hormonale therapie zou kunnen zijn het verlies van 
expressie van de oestrogeen receptor in de uitgezaaide tumorcellen. In hoofdstuk 3 
werd gekeken naar discrepanties tussen de oestrogeen receptor-status van de primaire 
tumor, en die van de CTCs. In 25% van de patiënten bleek de oestrogeen receptor-
status van de primaire tumor anders dan die van de CTCs, hetgeen overigens geen 
invloed had op de prognose van deze patiënten in exploratieve analyses. Interessant 
was de bevinding dat veel patiënten met een ER-negatieve primaire tumor, ER-positieve 
CTCs bleken te hebben. Dit zou kunnen betekenen dat deze patiënten baat zouden 
kunnen hebben bij hormonale therapie, hetgeen in nieuw onderzoek bewezen zal 
moeten worden.
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Een andere reden voor resistentie op hormonale therapie zou het optreden van mutaties 
in de oestrogeen receptor kunnen zijn. In hoofdstuk 4 werd verder uiteengezet wat we 
op dit moment weten van deze zogenaamde “ESR1 mutaties”. Deze ESR1 mutaties zijn 
nauwelijks aanwezig in de primaire tumor van patiënten met uitgezaaide borstkanker, 
maar treden vaak op in patiënten met uitgezaaide borstkanker die eerder hormonale 
therapie hebben gekregen. Dit betekent dat het voorkomen van deze mutaties onderzocht 
zal moeten worden in uitgezaaide tumorcellen, waarbij vloeibare biopsies natuurlijk 
interessant zijn. In hoofdstuk 5 onderzochten we of deze ESR1 mutaties te detecteren 
waren in CTCs. Deze mutaties bleken te detecteren in CTCs, echter bleek detectie in 
een andere vloeibaar biopsie, namelijk circulerend tumor DNA, veel gevoeliger dan in 
de CTCs (daarover meer in de paragraaf over circulerend tumor DNA). We denken dat 
dit komt doordat bij de manier van isoleren van CTCs ook witte bloedcellen worden 
geïsoleerd. Deze witte bloedcellen bevatten ook DNA en komen terecht in de CTC-
verrijkte fractie die geanalyseerd wordt. Omdat dit DNA geen tumor-afwijkingen bevat, 
wordt het tumor-specifieke DNA uitgedund door dit normale DNA, waardoor de detectie 
van tumormutaties bemoeilijkt wordt.
In hoofdstuk 5 werd ook een ander mechanisme van resistentie op hormonale therapie 
onderzocht. We keken of bepaalde splice varianten van de oestrogeen receptor, dit zijn 
RNA varianten die er mogelijk voor zorgen dat er een veranderde oestrogeen receptor 
tot expressie komt dan normaal, voorkomen in CTCs van patiënten met uitgezaaide 
borstkanker. We vonden dat één splice variant, de ∆5 splice variant, die eerder al 
geassocieerd werd met resistentie op hormonale therapie, vaker voorkomt in CTCs van 
patiënten dan in gezonde donoren. Er werd echter geen verrijking van deze splice variant 
gezien in patiënten die hormonale therapie hadden gekregen. Opvallend was dat alle 
gemeten splice varianten in onze studie ook tot expressie kwamen in de CTC-verrijkte 
fracties van gezonde donoren (terwijl zij geen CTCs hebben), hetgeen de complexiteit 
van het bepalen van genetische eigenschappen in CTCs nog eens weergeeft. 
C I R C U L E R E N D  T U M O R  D N A    
Eén van de problemen met CTCs, zoals ook hierboven toegelicht, is dat zij vrij zeldzaam 
zijn en dat het bepalen van de genetische eigenschappen van de CTCs erg complex is. Als 
CTCs of tumorcellen in de tumor zelf dood gaan (in apoptose gaan), kan dit in het bloed 
gevonden worden als circulerend tumor DNA (ctDNA). Als een buis bloed afgenomen 
wordt en wordt afgedraaid, wordt de bovenste laag gevormd door het plasma. Uit dit 
plasma kan DNA geïsoleerd worden, hetgeen we celvrij DNA (cfDNA) noemen. Iedereen 
heeft cfDNA, ook gezonde personen. Binnen dit cfDNA, is er in kankerpatiënten een 
fractie van DNA die afkomstig is van tumorcellen, het ctDNA. Vergeleken met CTCs, is 
de verwerking en analyse van cfDNA relatief eenvoudiger en lijkt ctDNA vaker voor te 
komen. Echter kan alleen het DNA geanalyseerd worden van het cfDNA en niet andere 
genetische eigenschappen (zoals eiwitten en RNA), hetgeen weer wel kan bij CTCs. 
Door de introductie van allerlei nieuwe technieken is het onderzoek naar cfDNA de 
laatste jaren snel toegenomen. Dit heeft te maken met het feit dat plasma makkelijk 
te verkrijgen is, en vervolgens te analyseren is met technieken die al veel laboratoria 
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in huis hebben. Echter is nog weinig inzicht in de optimale condities om het plasma 
te verzamelen en te verwerken. In hoofdstuk 6 werd daarom het effect van de tijd tot 
isolatie van het plasma bepaald en verschillende bloedbuizen om het plasma uit te 
isoleren vergeleken. Plasma uit CellSave of BCT buizen, dat binnen 96 uur geïsoleerd 
werd, bleek van even goede kwaliteit voor cfDNA analyses als plasma dat binnen 1 uur 
werd verwerkt. Dit betekent dat CellSave buizen, die ook gebruikt worden om bloed te 
verzamalen om CTCs te kunnen tellen, gebruikt kunnen worden om CTCs en cfDNA met 
optimale kwaliteit te bepalen tot 96 uur na afname.
Op het moment dat het plasma optimaal is verzameld, kunnen vervolgens mutaties in 
het cfDNA worden bepaald. Hoe de verschillende technieken om mutaties te detecteren 
zich verhouden tot elkaar, is echter nog maar weinig onderzocht. In hoofdstuk 7 werden 
verschillende technieken om mutaties in cfDNA te detecteren naast elkaar gezet in 
patiënten met leveruitzaaiingen van dikke darmkanker, waarbij de uitzaaiing in de lever 
operatief werd verwijderd. Het gebruik van next-generation sequencing (NGS) bleek 
zeer goed in staat om mutaties te detecteren in tumorweefsel van de dikke darm en de 
leveruitzaaiing. Het voordeel van deze techniek is dat meerdere mutaties van meerdere 
genen bekeken kunnen worden. NGS was echter minder goed in staat om mutaties te 
detecteren in het cfDNA, wegens een te lage sensitiviteit. De OnTarget techniek, die 
in staat is om 96 van tevoren gedefinieerde mutaties te meten, bleek wel erg gevoelig 
om mutaties te detecteren in cfDNA. Daarnaast bleek een digitale PCR techniek de 
meest gevoelige techniek om mutaties te detecteren in cfDNA. Dit onderzoek bood 
meer inzicht in de verschillende technieken voor detectie van mutaties in cfDNA, en hoe 
deze technieken zich verhouden tot elkaar. 
Uiteindelijk is de belangrijkste vraag in hoeverre deze technieken ingezet kunnen 
worden om de behandeling van patiënten met kanker te verbeteren. In hoofdstuk 4 
zetten wij, zoals al eerder genoemd, uiteen in hoeverre ESR1 mutaties gebruikt zou 
kunnen worden in de kliniek. Daarnaast raadden wij aan om ESR1 mutaties in cfDNA 
te meten en niet in biopsies van uitzaaiingen. In hoofdstuk 5 werd de digitale PCR 
techniek gebruikt om onderzoek te doen naar ESR1 mutaties in cfDNA. Hierin lieten we 
zien dat ESR1 mutaties nauwelijks voorkomen in patiënten die voor het eerst begonnen 
aan hormonale therapie voor uitgezaaide borstkanker, maar dat deze mutaties frequent 
voorkomen in patiënten die hormonale therapie hebben gekregen. Dit laat zien dat ESR1 
mutaties een belangrijke rol spelen in resistentie op hormonale therapie, en dit zal in de 
toekomst hoogstwaarschijnlijk invloed gaan hebben op de behandeling van patiënten 
met uitgezaaide borstkanker.
De bevindingen in hoofdstuk 4 en 5 zijn gerelateerd aan het gebruik van cfDNA voor 
het bepalen van resistentie op therapie. Vervolgens kan een patiënt op basis hiervan 
een andere therapie krijgen. Er zijn meer toepassingen van cfDNA die verder niet in 
dit proefschrift behandeld worden, namelijk 1) om patiënten te identificeren voor een 
bepaalde behandeling (bij een bepaalde mutatie of andere afwijking in het cfDNA hoort 
dan een bepaalde behandeling), 2) voor de vroege detectie van nieuwe tumoren of voor 
de detectie van terugkomende ziekte na een operatie, en 3) als een marker voor respons 
op therapie. Toekomstig onderzoek, mede door onze groep, zal belangrijke antwoorden 
gaan bieden over de potentiële toepasbaarheid van cfDNA in de kliniek. 
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C I R C U L E R E N D E  E N D O T H E E L C E L L E N
CTCs en cfDNA geven beiden belangrijke inzichten in de biologie van de tumorcel. Het 
is echter ook belangrijk om te kijken naar andere factoren die ook van invloed zijn op 
de tumor: bijvoorbeeld de aanwezigheid van bepaalde immuuncellen die belangrijk 
zijn in de eigen afweer tegen een tumor, of bloedvatcellen die de tumor zelf maakt 
en nodig zijn om de tumor van voedingsstoffen te voorzien. Deze bloedvatcellen, ook 
endotheelcellen genoemd, kunnen als ze loskomen van het vaatbed gemeten worden 
in het bloed. Ook gezonde mensen hebben deze circulerende endotheelcellen (CEC), 
ten gevolge van een normale vervanging van bloedvatcellen. In kankerpatiënten is het 
aantal CECs echter verhoogd, en er wordt gedacht dat het aantal CECs iets zegt over 
in hoeverre de tumorcel bloedvaten aanmaakt en afbreekt. Onze groep heeft eerder 
een techniek gepresenteerd waarin CECs betrouwbaar in het bloed van patiënten met 
kanker gemeten kunnen worden.
In hoofdstuk 9 hebben we onderzocht of CECs, gemeten met deze techniek vooraf en 
tijdens de behandeling, iets zeggen over de prognose en reactie op behandeling van 
patiënten met de hersentumor glioblastoom. Dit werd gedaan in patiënten uit de BELOB 
studie, waarin patiënten werden gerandomiseerd tussen 1) chemotherapie, 2) een 
medicijn dat nieuwe vaatgroei van de tumor remt (bevacizumab), of 3) chemotherapie 
en bevacizumab. Patiënten die een combinatie van beide middelen kregen, hadden 
tijdens de behandeling meer CECs, terwijl dit niet werd gezien in patiënten die maar 
één van beide middelen kregen. Dit suggereert dat de combinatie van middelen op een 
synergistische manier meer schade aan de bloedvaten geeft. Het stijgende aantal CECs 
hield echter geen verband met de overleving van deze patiënten. In patiënten behandeld 
met chemotherapie alleen, nog steeds de belangrijkste behandeling in patiënten met 
glioblastoom, hield een stijging van het aantal CECs wel verband met een betere 
prognose. Alhoewel dit mooie data was, relevant voor een grote groep glioblastoom 
patiënten die chemotherapie krijgen, werd juist verwacht dat CECs specifiek iets zouden 
zeggen over patiënten die therapie krijgen gericht tegen de bloedvatvorming. 
Het probleem is echter dat CECs van het gezonde vaatbed niet onderscheiden kunnen 
worden van CECs van het tumorvaatbed. Onze groep heeft recent een marker ontdekt, 
CD276, welke specifieker lijkt te zijn voor CECs afkomstig van tumorvaten, ook wel tumor-
CECs (tCECs) genoemd. In hoofdstuk 8 werd deze marker ingezet in patiënten met 
asbestkanker, en we zagen dat het aantal CECs geen verband hield met de overleving 
van patiënten, maar het aantal tCECs wel. Aangezien deze bevindingen werden gedaan 
in een vrij kleine patiëntengroep, is verder onderzoek hiernaar aangewezen, maar het 
laat wel zien dan dit een interessante marker voor de detectie van tCEC is.
CECs kunnen ook gebruikt worden buiten het vakgebied van de interne oncologie. 
In dat geval is er ook geen noodzaak om tumor-specifieke CECs aan te tonen. Als 
toepassingen buiten de interne oncologie kan gedacht worden aan de cardiologie en de 
transplantatiegeneeskunde. In hoofdstuk 10 onderzochten we in hoeverre het aantal 
CECs veranderde tijdens een allogene stamceltransplantatie (allo-SCT). Bij een allo-SCT 
krijgt een patiënt met een bloedziekte of bloedkanker (b.v. leukemie) een transplantatie 
met stamcellen van een familiedonor of een geschikte ongerelateerde donor. Hiertoe 
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krijgen de patiënten een zogenaamd ‘conditioneringsschema’, waarbij door middel van 
chemotherapie en bestralingen het eigen immuunsysteem kapot wordt gemaakt, om 
zo de stamcellen van de donor vrij spel te geven om de bloedziekte of bloedkanker 
te genezen. Wij lieten zien dat bij patiënten die een intensief conditioneringsschema 
kregen, het aantal CECs tot wel 12 maanden na transplantatie sterk verhoogd bleef, 
wijzend op langdurige vaatschade na de allo-SCT. Aangezien dit soort schema’s met 
name worden gegeven aan jonge patiënten, waarvan we weten dat die een verhoogde 
kans hebben op hart- en vaatziekten op de lange termijn, zou deze bevinding van lange 
vaatschade daar mogelijk meer te maken hebben, en dit verdient verder onderzoek. 
Daarnaast vonden we een verband tussen een daling van het aantal CECs en een 
belangrijke complicatie van allo-SCT, namelijk graft-versus-host ziekte. Dit zou kunnen 
betekenen dat T-cellen van de donor de endotheelcellen van de patiënt aanvallen, en dit 
wordt nu experimenteel onderzocht.
D E  T O E K O M S T  V A N  V L O E I B A R E  B I O P S I E S
Dit proefschrift heeft meer inzicht geboden in de technische aspecten en mogelijke 
klinische relevantie van de vloeibare biopsies CTCs, cfDNA en CECs in patiënten met 
kanker. Wat betreft het tellen van CTCs, moeten we ons realiseren dat na vele jaren van 
onderzoek het gebruik in de kliniek nog vrij beperkt is. Daarom moeten nieuwe studies 
zich ook richten op de klinische toepassing van CTC tellingen, het liefst in de vorm van 
een studie waarbij een bepaalde interventie wordt gedaan op basis van CTC tellingen. 
Zon studie wordt bijvoorbeeld momenteel door onze groep gedaan in patiënten met 
blaaskanker die door de spierlaag is heen gegroeid (CirGuidance studie). 
Het bepalen van de genetische eigenschappen van CTCs zal echter op de lange termijn 
de echte toekomst hebben. Een eerste voorbeeld van een klinische toepassing hiervan 
is bijvoorbeeld het bepalen van een splice variant V7 van de androgeen receptor (AR) in 
CTCs van patiënten met uitgezaaide prostaatkanker. Patiënten met deze AR-V7 splice 
variant in CTCs reageren nauwelijks op hormonale therapie, maar wel op chemotherapie. 
In de toekomst zullen patiënten dan ook zeer waarschijnlijk therapie krijgen op basis van 
hun AR-V7 status in CTCs. 
Voor patiënten met uitgezaaide borstkanker heeft dit proefschrift onderzoek gedaan 
naar allerlei klinische toepassingen van het bepalen van de genetische eigenschappen 
CTCs. Alhoewel dit voor enkele bevindingen aanleidingen heeft gegeven tot nieuw 
onderzoek, hebben de meeste bevindingen wat betreft CTCs in dit proefschrift nog geen 
klinische toepassing. In het onderzoek naar ESR1 mutaties, bleek dat deze mutaties 
veel beter te detecteren waren in het cfDNA dan in de CTCs. Dit betekent echter niet 
dat het onderzoek naar de genetische eigenschappen van CTCs niet zinvol is. Een zeer 
belangrijke marker als AR-V7 zal nooit in cfDNA gemeten kunnen worden, en hetzelfde 
geldt bijvoorbeeld voor eigenschappen op eiwitniveau zoals de oestrogeen receptor. 
De karakterisatie van CTCs zal echter sterk verbeterd moeten worden om uiteindelijk het 
optimale resultaat eruit te halen. Wanneer pure CTCs verkregen worden, zonder witte 
bloedcellen die de bepaling van de genetische eigenschappen van CTCs vertroebelen, 
zijn we een flinke stap verder. Dit is sinds kort mogelijk, en het lab waar het onderzoek 
voor dit proefschrift werd verricht krijgt binnenkort de beschikking over een machine 
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om deze zuivere en ‘single’/individuele CTCs in handen te krijgen. Het bepalen van 
genetische eigenschappen in cfDNA zal in de toekomst waarschijnlijk complementair 
zijn aan dit soort analyses op zuivere CTCs. Het is op dit moment de vraag hoe cfDNA 
en zuivere CTCs zich tot elkaar verhouden, en in welke situaties welke van de twee het 
beste ingezet kan gaan worden.
De grote hoeveelheid data over CTCs en cfDNA doet de vraag opkomen of er nog wel een 
plaats is voor CEC tellingen. Op dit moment weten we niet wat de plaats van CECs gaat 
zijn. Onze groep heeft belangrijk werk verricht met het opzetten van een techniek om 
betrouwbaar CECs te meten, om tumor-specifieke CECs te meten, en in dit proefschrift 
lieten we zien dat het meten van CECs en tCECs mogelijk ook klinisch interessant is. 
Dit laatste is een grote stap voorwaarts, maar nieuwe studies om de klinische relevantie 
van (t)CECs te onderzoeken zijn van cruciaal belang om vooruit te blijven gaan. Deze 
studies zullen zich dan vooral moeten richten op patiënten met tumoren die heel sterk 
doorbloed zijn en veel nieuwe bloedvaten aanmaken (zoals asbestkanker) of in patiënten 
die anti-kanker medicijnen krijgen die gericht zijn tegen de bloedvaten van de tumor.
Concluderend, zal het bepalen van de genetische eigenschappen van CTCs, 
gecombineerd met complementaire cfDNA analyses, te zijner tijd een belangrijke rol gaan 
spelen in de oncologie. Het is nu van het grootste belang om de technische aspecten van 
het onderzoek naar zuivere CTCs te optimaliseren, om vervolgens de klinische relevantie 
te testen. Voor cfDNA analyses zullen de technieken ook geoptimaliseerd worden, en 
de vraag is vervolgens welke techniek (cfDNA of CTCs of allebei) het meest bruikbaar 
is in de kliniek. Dit zal waarschijnlijk afhankelijk zijn van de klinische vraagstelling en het 
tumortype van de patiënten. Vloeibare biopten zullen ons informatie over kanker gaan 
verschaffen van onschatbare waarde, en uiteindelijk zal deze informatie, en het gebruik 
hiervan in de behandeling van kanker, een geweldige stap vooruit gaan betekenen voor 
patiënten met kanker. 
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C U R R I C U L U M  V I TA E
Nick Beije werd op 21 augustus 1987 geboren in Rotterdam. Hij groeide op in 
Spijkenisse, en haalde in 2005 zijn VWO diploma op het Penta Collega CSG Blaise 
Pascal in Spijkenisse. Vervolgens volgde hij één jaar de studie Bio-Farmaceutische 
Wetenschappen aan de Universiteit Leiden, hetgeen resulteerde in een propedeuse. In 
2006 begon hij aan de opleiding Geneeskunde aan de Erasmus Universiteit. Tijdens zijn 
opleiding werkte hij als afdelingsassistent op de afdeling maag-, darm- en leverziekten 
en de afdeling kindergeneeskunde van het Sint Franciscus Gasthuis. Daarnaast werkte 
hij als coördinator van het studententeam dat meehielp aan een gerandomiseerde 
studie betreffende het bevolkingsonderzoek naar dikke darmkanker in het Erasmus MC. 
Van 2010 tot 2012 liep hij coschappen, en nadat een groot deel van het coschap Interne 
Geneeskunde in het Vlietland Ziekenhuis werd gevolgd op de afdeling oncologie, 
werd zijn interesse in dit vakgebied gewekt. Zijn oudste coschap volgde hij bij de 
afdeling Interne Geneeskunde van het Ikazia Ziekenhuis (opleider: dr. Zandbergen). In 
2012 verrichte hij zijn wetenschappelijke stage op het laboratorium Medische Tumor 
Immunologie in de Daniël den Hoed Kliniek, onder supervisie van dr. Gratama, dr. 
Kraan en prof. dr. Cornelissen. De daaruit volgende thesis leidde vervolgens tot een 
promotieplek bij de Interne Oncologie in het Erasmus MC op het onderzoek naar “liquid 
biopsies”, onder supervisie van prof. dr. Sleijfer en dr. Martens, zoals in dit proefschrift 
verder beschreven. Tijdens zijn promotietraject gaf hij veelvuldig onderwijs aan allerlei 
groepen studenten, hetgeen in 2016 leidde tot het behalen van de Basiskwalificatie 
Onderwijs. Daarnaast presenteerde hij op meerdere (inter)nationale congressen, en 
was hij hoofdauteur van gehonoreerde subsidieaanvragen door de Stichting Coolsingel, 
de Daniel den Hoed Stichting, de Stichting Mitialto en Pink Ribbon. Vanaf september 
2016 was hij werkzaam als ANIOS in het Havenziekenhuis (opleider: dr. Wismans), 
en vanaf januari 2017 is hij aan de slag gegaan als AIOS Interne Geneeskunde in het 
Havenziekenhuis, met het uiteindelijke doel om internist-oncoloog te worden. 
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Year
Workload 
(ECTS)
1. PHD TRAINING
General academic and research skills
BROK course (GCP course) 2013 0.9
Research Integrity 2013 2
Biostatistical Methods I: Basic Principles (CC02) 2013 5.7
Photoshop and Illustrator CS6 workshop 2014 0.3
InDesign CS6 workshop 2014 0.15
Biomedical English Writing and Communication 2014 3
In-depth courses
Basic and Translational Oncology 2012 1.8
Medical Oncology Journal Club 2012-2016 1.5
Course on Molecular Diagnostics VIII 2013 1
NGS in DNA Diagnostics Course 2015 1
Teach The Teacher Course I 2015 0.7
Training on coaching medical students 2015-2016 0.4
Training on formulating exam questions 2016 0.2
Name PhD student: Nick Beije 
Erasmus MC Department: Medical Oncology 
Research School: Erasmus postgraduate school Molecular Medicine (MolMed) 
PhD period: November 2012 – September 2016 
Promotor: prof. dr. S. Sleijfer 
Copromotor: dr. J.W.M. Martens
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Oral presentations
Scientific JNI Lab Meeting, Erasmus MC, Rotterdam 2013-2016 1
Translational Cancer Genomics and Proteomics Meeting, Erasmus 
MC, Rotterdam
2014-2015 1
Ikazia Ziekenhuis Scientific Meeting, Ikazia, Rotterdam 2015 0.2
Pharmacokinetics Scientific Meeting, Erasmus MC, Rotterdam 2015 0.2
International Congress of Breast Disease Centers, ESMO Young 
Oncologist Meeting, Antwerp, Belgium
2015 0.2
Scientific Meeting Medical Oncology, Erasmus MC, Rotterdam 2015 0.2
European Cancer Congress, Vienna, Austria 2015 0.2
Bladder Cancer Research Day, Erasmus MC, Rotterdam 2015 0.2
Internal Medicine Clinical Demonstration, Erasmus MC, Rotterdam 2015 0.2
Medical Oncology Research Meeting, Erasmus MC, Rotterdam 2015 0.2
Dutch Uro-Oncology Studygroup Symposium, Utrecht 2015 0.2
Cancer Genomics Netherlands Annual Scientific Meeting, Utrecht 2016 0.2
Breast Cancer Research Meeting, Erasmus MC, Rotterdam 2016 0.2
EORTC Pathobioloy Group Meeting, Rotterdam 2016 0.2
Borstkanker Behandeling Beter Symposium, Rotterdam 2016 0.2
Year
Workload 
(ECTS)
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Poster presentations
European Cancer Congress, Vienna, Austria 2015 1
Cancer Genomics Netherlands Meeting: “Molecular and Cellular 
Aspects of Cancer”
2015 1
(Inter)national conferences
Center for Personalized Cancer Treatment (CPCT) Symposium, 
Utrecht
2014 0.2
Daniel 100 years Symposium, Rotterdam 2014 0.3
Cancer Genomics Netherlands Annual Meeting, Amsterdam 2014-2015 0.5
International Congress of Breast Disease Centers, Antwerp, 
Belgium
2015 0.2
European Cancer Congress, Vienna, Austria 2015 1
San Antonio Breast Cancer Meeting, San Antonio, USA 2015 1
2. TEACHING
Lecturing
Junior Med School Oncology Course, Erasmus MC, Rotterdam 2014-2016 1
Dell Inc. (on invitation from Pink Ribbon), Amsterdam 2014 0.3
Gezondheidsbeurs (on invitation from Pink Ribbon), Utrecht 2015 0.3
Supervising student theses
Co-supervising 21-week research project for 6th year medical 
school student (D. van Rappard)
2013 1
Supervising 21-week research project for 3th year higher 
laboratory education student (E. Bont)
2014-2015 2.5
Supervising 12-week research project for bachelor thesis Medical 
Natural Sciences student (C. Bersee)
2015 1.4
Year
Workload 
(ECTS)
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Medical school training-associated teaching and counselling
Tutorial class first-year medical students 2013-2015 4.5
Supervisor “clinical orientation on the medical profession” for first-
year medical students
2013-2015 1.5
Supervisor/coordinator 4-week Junior Med School Medical 
Oncology Research Program
2015 1
Medical School Bachelor Phase Coaching Program 2015-2017 1.5
Teaching certificates
University Teaching Qualification (“Basiskwalificatie onderwijs”/
BKO)
2016 2
3. Other
Grant allocation
Stichting Coolsingel (together with prof. Aerts): € 27,351 2014
Daniel den Hoed Foundation (principal author. PIs: dr. Martens, 
prof. Fodde, prof. Hendriks): € 267,140
2016
Mitialto Foundation (together with prof. Sleijfer): € 13,280 2016
Pink Ribbon (together with prof. Sleijfer, dr. Martens, dr. Onstenk 
and dr. Sieuwerts): € 59,491
2016
Peer review of manuscripts for international peer-reviewed journals
Current Cancer Drug Targets (IF 3.7)
Critical Reviews in Oncology/Hematology (IF 5.0)
Clinical Chemistry (IF 7.5)
Year
Workload 
(ECTS)
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L I S T  O F  P U B L I C AT I O N S
Beije N, Angus L, Jager A, Martens JWM, Sleijfer S
“ESR1 mutations: moving towards guiding treatment decision-making in metastatic 
breast cancer patients”
Cancer Treat Rev. 2016 in press
Beije N, Helmijr JC, Weerts MJA, Beaufort CM, Wiggin M, Mai L, Verhoef C, Sleijfer S, 
Jansen MPHM, Martens JWM
“Somatic mutation detection using various targeted detection assays in paired 
samples of circulating tumor DNA, primary tumor and metastases from patients 
undergoing resection of colorectal liver metastases”
Mol Oncol. 2016 in press
van Dessel LF, Beije N, Helmijr JCA, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, 
Jansen MPHM, Martens JWM, Lolkema MPJK 
“Application of circulating tumor DNA in prospective clinical oncology trials: 
standardization of pre-analytical conditions” 
Mol Oncol. 2016 in press
Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Peeters DJ, de 
Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S
“Prevalence and prognostic impact of HER2 and ER status of circulating tumor cells in 
metastatic breast cancer patients with a HER2-negative primary tumor”
Neoplasia. 2016 Oct 17;18(11):647-653
Beije N, Sleijfer S, Boormans JL
“De rol van circulerende tumorcellen bij het urotheelcelcarcinoom van de blaas”
Tijdschr Urol. 2015 Nov; 5:223-228
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Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot 
L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, 
van den Bent MJ 
“Prognostic value and kinetics of circulating endothelial cells in patients with recurrent 
glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or 
lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.”
Br J Cancer. 2015 Jul 14;113(2):226-31.
Beije N, Versluis J, Kraan J, Gratama JW, Sleijfer S, Cornelissen JJ
“Circulating endothelial cell enumeration demonstrates prolonged endothelial damage 
in recipients of myeloablative allogeneic stem cell transplantation”
Haematologica. 2015 Jun;100(6):e246-9.
Beije N, Jager A, Sleijfer S
“Circulating tumor cell enumeration by the CellSearch system: the clinician’s guide to 
breast cancer treatment?” 
Cancer Treat Rev. 2015 Feb;41(2):144-50.
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D A N K W O O R D
Uiteraard is dit proefschrift tot stand gekomen door de samenwerking met en de steun 
van vele andere mensen. Een aantal daarvan zou ik hier graag nog eruit willen lichten.
Allereerst natuurlijk veel dank aan mijn promotor, prof. dr. Sleijfer. Beste Stefan, ik kwam 
ooit binnen als student die bij Jan-Willem en Jaco zijn keuzeonderzoek deed op een 
alternatief project, en heb toen de kans gekregen om bij de CTC groep aan de slag te 
gaan. In de vier daarop volgende jaren heb ik verschrikkelijk veel opgestoken, niet in de 
laatste plaats door jouw begeleiding. Met name de besprekingen op dinsdagochtend 
waren van grote waarde, waarbij jij duidelijk het overzicht had over alle projecten die 
liepen, en altijd op duidelijke wijze de lijnen wist uit te zetten en de rode draad wist te 
bewaken. Ook je commentaren op manuscripten en andere stukken waren altijd nuttig, 
en ik blijf me verbazen over het feit dat commentaren ondanks je drukke bestaan altijd 
zo snel terugkwamen. Daarnaast ben ik dankbaar voor het feit dat ik van jou echt de 
kans heb gekregen om een belangrijk deel van mijn promotie zelf in te vullen. Ik kreeg 
veel vrijheid om behoorlijk wat projecten te exploreren en zelf op te starten. Ook de 
mogelijkheid die ik kreeg om een aantal grants (mee) te schrijven heb ik verschrikkelijk 
veel van geleerd, en gelukkig hebben we nog wat binnengehaald ook! Ik hoop dat ik 
ook na dit promotieonderzoek nog vele samenwerkingen met jou en de afdeling aan 
kan gaan.
Mijn copromotor, beste dr. Martens, beste John, na de verhuizing van onze groep naar 
het JNI zijn wij heel goed opgenomen in jouw club aldaar. Ik denk dat de verhuizing 
één van de beste dingen was die de CTC groep kon overkomen.  Er was natuurlijk al 
sprake van veel samenwerking, maar de verhuizing zorgde ervoor dat jij en de andere 
mensen van de 4e verdieping nog veel dichter bij het CTC onderzoek betrokken konden 
raken, met inmiddels heel wat mooie resultaten tot gevolg. Ook zorgde het voor een 
verbreding van mijn blikveld buiten de kliniek. Jouw kennis en input vanuit een moleculair 
biologische hoek hebben veel manuscripten beter gemaakt. Daarnaast ook aan jou veel 
dank voor alle dingen die ik naast het promoveren heb mogen doen, met het krijgen van 
de Daniel den Hoed Stichting grant voor het VyCAP systeem als hoogtepunt. Als laatste 
ook bedankt voor de gezelligheid, niet alleen op de afdeling, maar ook vaak als vaste 
gast op één van de vele borrels die we over de jaren hebben gehad.
Prof. dr. van den Bent,en prof. dr. Aerts, beste Martin en Joachim, hartelijk dank voor 
het plaatsnemen in mijn kleine commissie, en aan jullie bijdragen aan respectievelijk het 
hoofdstuk over CECs in de BELOB studie en de MESOPA studie. Deze hoofdstukken 
tonen aan dat uit multidisciplinaire samenwerking mooie resultaten kunnen komen, en 
ik kijk uit naar nieuwe samenwerkingen.
Prof. dr. Verheul wil ik graag danken voor het participeren in mijn kleine commissie, en 
prof. dr. van Laere en dr. Dinjens voor het plaatsnemen in mijn grote commissie. De tijd 
die jullie hebben geïnvesteerd in het lezen van het proefschrift wordt zeer gewaardeerd, 
en ik kijk uit naar de discussie. 
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Beste dr. Jager, beste Agnes, als co-auteur op vier van de manuscripten zoals in dit 
proefschrift beschreven vond ik het niet meer dan logisch om jou in mijn grote commissie 
plaats te laten nemen. Ik vind dat al deze manuscripten, alsmede ook meerdere 
klinische protocollen, door jouw scherpe input allemaal beter zijn geworden. Met name 
jouw pragmatische klinische blik (“wat is de échte klinische relevantie”) heb ik erg nuttig 
gevonden. Ik zie er naar uit om verder van gedachten te wisselen over het proefschrift.
Beste prof. dr. Cornelissen, beste Jan, als geneeskundestudent deed ik onderzoek 
naar allogene stamceltransplantaties, en ik vind het nog steeds een fascinerend gebied 
om me mee bezig te houden. Het stuk over CEC’s na allo-SCT hebben wij uiteindelijk 
voornamelijk door jouw input heel mooi weg kunnen zetten in Haematologica. Dank 
voor het plaatsnemen in mijn grote commissie.
Graag zou ik ook prof. dr. Foekens willen bedanken. Beste John, toen ik kwam had je 
de tent praktisch gezien al overgedragen aan de andere John, maar je bent toch bij veel 
projectplannen en manuscripten betrokken geweest. Jouw commentaar is altijd met 
verschrikkelijk veel oog voor detail, en heeft ervoor gezorgd dat manuscripten tot in de 
puntjes verzorgd zijn, tot aan de referenties aan toe. Ik vind het een goede zaak dat je 
met al jouw ervaring betrokken blijft bij al het onderzoek wat we doen, en hopelijk ga je 
dat nog lang volhouden.
Beste prof. dr. Berns, beste Els, jouw bijdrage aan dit proefschrift is relatief beperkt. Op 
het gebied van het onderwijs wat ik heb gegeven ben je echter wel degelijk belangrijk 
geweest. Ik heb zeer gewaardeerd dat je mij en ook andere PhD studenten de kans hebt 
gegeven om veel onderwijs te kunnen geven, bijvoorbeeld voor de Junior Med School. 
Daarnaast heeft jouw enthousiasme en passie voor het onderwijs er ook zeker aan 
bijgedragen dat ik uiteindelijk zelfs mijn BKO certificaat heb behaald, waarvoor dank.
Beste dr. Gratama, beste Jan-Willem, ik kwam binnen om onder jouw leiding mijn 
keuzeonderzoek als medisch student te doen. Nog voordat ik klaar was met mijn 
keuzeonderzoek, had ik al de toezegging om een PhD te mogen doen, waar jij je mede 
sterk voor hebt gemaakt. Ik ben erg dankbaar voor de kans die jij mij mede hebt gegeven 
om toentertijd van start te gaan met het promotieonderzoek. 
Dr. Sieuwerts, beste Anieta, jouw bijdrage aan een aantal hoofdstukken in dit proefschrift 
is heel belangrijk geweest. Jouw expertise omtrent (digital) PCR is ongekend, en heeft 
het moleculaire CTC werk naar een hoog niveau gedreven. De grotendeels door jou 
ontwikkelde karakterisatie van CellSearch CTCs op RNA niveau is in de wereld vrij uniek, 
en heeft onze groep en mij enorm veel mooie data en publicaties opgeleverd. Ik ben met 
name trots op het stuk over de ESR1 mutaties en splice varianten, waar van ons allebei 
heel veel uren inzitten, en wat uiteindelijk een prachtig stuk is geworden. Daarnaast ook 
zeker dank voor de gezelligheid, de trip naar San Antonio met jou, John en Marjolein 
was één van de hoogtepunten van mijn PhD tijd. Ik kijk uit naar de toekomst, waar we 
op single CTC niveau met het VyCAP systeem en jouw expertise nog veel mooie dingen 
kunnen gaan doen.
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Uiteraard wil ik hier ook dr. Kraan bedanken. Jaco, jij hebt de meeste begeleiding gedaan 
toen ik als geneeskundestudent mijn keuzeonderzoek kwam doen. We begonnen toen 
met een CEC project wat niet goed van de grond kon komen, en uiteindelijk eindigde 
ik met een mooi afstudeerproject over immuunreconstitutie na stamceltransplantatie. 
Jouw inbreng op het technische vlak is voor veel stukken in dit proefschrift van groot 
belang geweest. De expertise die je hebt o.a. wat betreft het optimaal verwerken van 
bloed, het correct verrijken van CTCs en flow cytometrie is voor de afdeling onmisbaar. 
Daarnaast lever je natuurlijk een belangrijke bijdrage aan de sfeer. Het koffie drinken na 
de lunch is een mooie traditie en af en toe vonden daar nog nuttige discussies plaats 
ook!
Dr. Jansen, beste Maurice, vooral de laatste anderhalf jaar hebben we veel samengewerkt 
op allerlei projecten omtrent cell-free DNA. Voor mij was dit een heel nieuw gebied 
om in te duiken, en mede met jouw hulp heb ik daar veel kennis in opgedaan. Door 
jouw ideeën omtrent het RMD paper en gelegde contacten met Boreal is dat bijna 
afgeschreven manuscript uiteindelijk nog een succes geworden en kan het nu in dit 
proefschrift opgenomen worden. Daarnaast heb ik ook onze discussies over de data, 
maar ook over het grote geheel (“waar gaan we uiteindelijk heen met de liquid biopsies”) 
gewaardeerd.    
Dr. Onstenk, beste Wendy, het was natuurlijk zeer pijnlijk om mij als kamergenoot te 
laten gaan na onze periode in de Daniël, en mij in te moeten ruilen voor Jaco. Gelukkig 
heb je dat goed opgepakt daarna, en kwam je af en toe nog eens in Be-414a buurten. 
Bedankt voor al je hulp als senior AIO bij het schrijven van de manuscripten, het omgaan 
met het promovendus zijn, en niet in de laatste plaats met de totstandkoming van dit 
boekje met o.a. alle offertes, adreslijsten en de totaal niet neurotische tijdsplanning! 
Ook de huidige bezetting dames in Be-414, die helaas niet als 4 paranimfen konden 
fungeren (in verband met een restrictie tot 2), ben ik natuurlijk dank verschuldigd. 
Er was altijd een goede sfeer op onze kamer, en alle borrels, etentjes en andere 
gezellige dingen waren echt top. Ook ben ik er heel erg trots op dat dit proefschrift 
maar liefst 3 hoofdstukken bevat waarbij wij als Be-414 promovendi met elkaar hebben 
samengewerkt, hetgeen maar aangeeft dat buiten alle gezelligheid er ook zeker hard 
werd gewerkt. 
Marjolein, jij bent niet alleen heel belangrijk geweest voor de sfeer op de kamer, maar 
zeker ook met al jouw technische en biologische kennis. Je hebt deze cliniclown steeds, 
en soms meerdere keren opnieuw, moeten uitleggen hoe nu precies zat met al die 
NGS technieken en nog veel meer andere technische zaken, en daardoor snapte ik 
er uiteindelijk oprecht een stuk meer van. Op een PhD kamer zijn juist mensen zoals 
jij met een andere invalshoek dan de arts-onderzoekers van belang om weer nieuwe 
ideeën te ontwikkelen en met sommige projecten verder te komen. Ik hoop echte van 
harte voor je dat de *onderwerp gecensureerd door Philips* het helemaal gaan worden. 
Ook natuurlijk dank voor de gezelligheid buiten het werk om: de verschillende etentjes, 
borrels, de trips naar verschillende binnen- en buitenlandse congressen en als kers op 
de taart de trip naar NYC.
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Inge, als mijn “raamgenoot” heb ik ook jouw positieve inbreng en humor op de kamer 
enorm gewaardeerd. Je hebt enorm veel projecten van mij mogen overnemen, waarvan 
ik weet dat ze in goede handen bij jou zijn. Jouw winst van de Pieter de Mulder award 
vond ik echt heel tof, de trip om jou op te zoeken in Stockholm was fantastisch, en ik 
hoop heel erg dat de PLP op CTC’s van de grond gaat komen. Ons gezamenlijke paper 
gaat er nog komen.
Lisanne, onze (zelfbenoemde) favoriete collega. Ook jij heel erg bedankt voor alle 
gezelligheid. Ik vond het echt heel tof dat wij toen te gast mochten zijn op jouw bruiloft, 
dat was echt een prachtige dag. Ik ben heel erg benieuwd wat jouw onderzoek gaat 
opleveren, met hele veelbelovende projecten zoals cfDNA in prostaatkanker, cfDNA in 
de urine en de gekweekte CTC’s na leukoferese.
Lindsay, ondanks dat je nog relatief nieuw bent heb je je wel snel thuis gemaakt in 
onze kamer (nadat we je van de kamer van Jaco en Wendy moesten kapen!) en de 
CTC groep. Je bent net een jaar bezig en hebt toch al mooie dingen bereikt, met alle 
nucleaire studies die nu uiteindelijk dankzij jou open zijn, het schrijven van de recente 
KWF aanvraag, en ook met de acceptatie van ons review. Ik ben echt heel erg benieuwd 
wat je in de komende jaren nog meer in petto hebt.
Daarnaast zou ik ook alle andere promovendi en oud-kamergenoten willen bedanken 
voor alle gezelligheid: Arjen, Diana, JingJing, Rene, Tommaso, Esther, en ook de mensen 
van de PK-groep Annemieke, Jacqueline, Lisette, Roelof, Bodien en Femke. Special 
shout-out voor Sander, jij bent vlak na mij begonnen, en was altijd in voor een goede 
kop koffie en een mooi gesprek over voetbal, of juist over de toekomst van de oncologie 
en het onderzoek. Ik kijk er naar uit om over een paar jaar als internist-oncologen i.o. de 
afdeling te gaan runnen.
Ook heel veel dank aan onze vaste analisten Mai, Zahra en Joan. Zonder al jullie werk 
op het lab hadden deze stukken er nooit kunnen komen. Ook bedankt voor alle hulp van 
de andere mensen op en rondom het lab: Jean, Corine, Silvia, Wendy, Vanja, Kirsten, 
Michelle, Mieke, Anita en Renee, de post-docs van de groep Jozien en Antoinette, en 
secretaresse Rosita.
Graag zou ik ook alle mensen willen bedanken waarmee ik heb samengewerkt door 
de jaren heen. Allereerst alle nog niet genoemde oncologen in het Erasmus MC. Dr. 
Seynaeve, beste Caroline, dank voor alle nuttige en kritische input die je hebt geleverd 
op mijn stukken. Dr. Homs, Marjolein, bedankt voor je hulp bij het indienen en van de 
grond laten komen van de CareMore-Trastuzumab studie. Prof. dr. Mathijssen, beste 
Ron, bedankt voor alle adviezen door de jaren heen over het vak en professionele 
ontwikkeling. Dr. Lolkema, beste Martijn, bedankt voor de discussies die we hebben 
gehad over cell-free DNA en nieuwe studievoorstellen. Ook alle andere oncologen 
uit het Erasmus MC die ik niet heb genoemd bedankt voor alle hulp die ik van jullie 
heb gekregen bij alle studies die we hadden lopen, en de inclusies in de verschillende 
studies.
272
Een belangrijke samenwerking in huis was met dr. Boormans van de afdeling urologie. 
Beste Joost, mede door jouw enorme inzet voor de studie is de CirGuidance studie 
een succes geworden, en mogen we zeer binnenkort de laatste patiënt, nummer 300, 
gaan begroeten. Ook al komt het betreffende stuk uiteindelijk niet in mijn boekje, wel 
hebben we een mooi Nederlands review geschreven, ben ik dankbaar voor de kans 
om op een aantal symposia zoals de DUOS meeting te hebben mogen presenteren op 
voorspraak van jou, en gaan we hopelijk in de toekomst nog verder samenwerken op 
andere blaaskanker-gerelateerde projecten.
Ook belangrijke was de samenwerking met de ziekenhuizen in de regio Rotterdam. 
Dr. Hamberg, beste Paul, het Franciscus Gasthuis heeft enorm bijgedragen aan de 
inclusie in verschillende studies die inmiddels zijn gepubliceerd of nog lopen. Bijna in 
elke studie is het Franciscus Gasthuis één van de top includerende centra, en dat is 
niet in de laatste plaats door jouw inzet voor al deze studies. Daar wil ik je graag voor 
bedanken, en ook zeker voor jouw altijd kritische input op nieuwe studievoorstellen en 
manuscripten.
Dr. de Jongh, beste Felix, ook in het Ikazia kunnen wij altijd terecht om nieuwe studies 
op te starten. Ik weet vanuit mijn oudste coschap wat ik ooit in het Ikazia heb gelopen 
hoe bezeten je bent van het vak, en dat enthousiasme zag ik altijd terug bij onze 
besprekingen over nieuw te starten studies, en je commentaren op stukken. Hopelijk 
kunnen we samenwerking met het Ikazia nog lang voortzetten. 
Ook zou ik graag de researchverpleegkundigen uit deze centra willen bedanken, met 
name Karin Wensing en Corry Leunis, die altijd scherp zijn geweest op het verzamelen 
van materialen voor onze studies, wat van enorm belang is voor de kwaliteit en 
volledigheid van de data van onze studies.
Buiten Nederland hebben we ook samengewerkt. Met name wil ik de mensen van de 
Translational Cancer Research Unit in Antwerpen bedanken. Onder leiding van dr. Dirix 
en prof. dr. van Laere hebben we vele mooie onderzoeksvragen mogen beantwoorden, 
en de interlab-meetings waren nuttig en ook gezellig. Ook dank aan Dieter en Anja voor 
de samenwerking omtrent verschillende studies en het uitwisselen van data.
Also thanks to Matthew, David and Andre from Boreal Genomics, who were kind 
enough to collaborate on our manuscript on cfDNA in colorectal cancer with their 
OnTarget assay. The addition of the OnTarget data really strengthened our manuscript 
and resulted in a nice publication in Molecular Oncology.
Dank ook aan al mijn collega’s in het Havenziekenhuis. Ik ben daar hartstikke goed 
opgevangen. In vrije korte tijd ben ik me mede door jullie in het team thuis gaan voelen, 
en ook in mijn (nieuwe) rol als clinicus. Ik zie er naar uit om me in het Havenziekenhuis 
verder te ontwikkelen als dokter. 
Graag wil ik ook al mijn Ardennengroep buddies Weeda, Mariska, Polder, Do, JP, Nicole, 
VDV, Ellen, Lost, Fab, Leonie, Vos, Lé, Melda, Marjolein, Niels, Suus en Joe bedanken. 
Niet zozeer omdat jullie nu een weergaloze bijdrage hebben geleverd aan dit boekje, 
maar wel vanwege alle mooie dingen die we afgelopen jaren hebben gedaan en zeker 
vol gaan houden.
273
Ook natuurlijk dank voor alle gezellige etentjes met mijn oude studiegroep-genoten 
Mariëtte, Line en Aimee. Aimee, je bent niet voor niets mijn paranimf, we kennen elkaar 
nu al echt weer lang (alweer 10+ jaar), en ik word er altijd blij van om met je af te spreken, 
wat te gaan eten (/koken te vermijden), en het dan te hebben over serieuze en (vaak ook) 
minder serieuze zaken. Je merkt het, ook in dit proefschrift stoppen de complimenten 
aan jouw adres niet. Bedankt dat je mijn paranimf wil zijn!
Graag wil ik ook al mijn familie bedanken. Opa en oma van der Schee voor alle lieve 
berichten en belangstelling. Opa en oma Beije voor alle support door de jaren heen. 
Ilona en Suus voor alle positiviteit en aanmoedigingen. 
Britt, ik vind het leuk dat jij mijn paranimf wil zijn. Ben trots op wat jij allemaal in korte tijd 
al hebt bereikt met je studie en werk, en wie weet sta jij ooit ook nog eens op mijn positie 
als promovendus. De Giuliano lunches gaan we zeker volhouden!
Mijn ouders wil ik ook graag bedanken. Pap, mam, van kleins af aan ben ik nooit iets 
tekort gekomen, en hebben jullie eigenlijk elke beslissing gesteund die ik ooit gemaakt 
heb. Ik ben enorm trots dat ik dit boekje heb kunnen maken, en jullie hebben daar zeker 
in geholpen.
Als laatste wil ik graag alle patiënten bedanken die hebben deelgenomen aan de 
verschillende onderzoeken die in dit proefschrift zijn beschreven. Ondanks dat zij 
vaak niets hadden aan het afstaan van bloed en/of weefsels, wilden zij graag met hun 
deelname voor de patiënten na hen iets betekenen. Vele van de patiënten die hebben 
geparticipeerd in onze onderzoeken zijn inmiddels overleden, maar ik weet zeker dat we 
mede door hun deelname ervoor kunnen zorgen dat de zorg en kwaliteit van leven van 
toekomstige kankerpatiënten verder zal verbeteren.
